JCIM JOURNAL OF CHEMICAL INFORMATION AND MODELING
Cite This: J. Chem. Inf. Model. XXXX, XXX, XXX−XXX
Article
pubs.acs.org/jcim

Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules

Andrei L. Lomize*,† and Irina D. Pogozheva†

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church Street, Ann Arbor, Michigan 48109-1065, United States

Supporting Information



ABSTRACT: Assessment of permeability is a critical step in the drug development process for selection of drug candidates with favorable ADME properties. We have developed a novel physics-based method for fast computational modeling of passive permeation of diverse classes of molecules across lipid membranes. The method is based on heterogeneous solubility−diffusion theory and operates with all-atom 3D structures of solutes and the anisotropic solvent model of the lipid bilayer characterized by transbilayer profiles of dielectric and hydrogen bonding capacity parameters. The optimal translocation pathway of a solute is determined by moving an ensemble of representative conformations of the molecule through the dioleoyl-phosphatidylcholine (DOPC) bilayer and optimizing their rotational orientations in every point of the transmembrane trajectory. The method calculates (1) the membrane-bound state of the solute molecule; (2) free energy profile of the solute along the permeation pathway; and (3) the permeability coefficient obtained by integration over the transbilayer energy profile and assuming a constant size-dependent diffusivity along the membrane normal. The accuracy of the predictions was evaluated against experimental permeability coefficients measured in pure lipid membranes (for 78 compounds, R^2 was 0.88 and rmse was 1.15 log units), PAMPA-DS (for 280 compounds, R^2 was 0.75 and rmse was 1.59 log units), BBB (for 182 compounds, R^2 was 0.69 and rmse was 0.87 log units), and Caco-2/MDCK assays (for 165 compounds, R^2 was 0.52 and rmse was 0.89 log units).

INTRODUCTION

A variety of organic molecules, including metabolites, drugs, and xenobiotics, interact with cellular membranes and modulate their properties. Many of them translocate across the lipid bilayer using diverse mechanisms of active and passive membrane transport.[1] The quantification and analysis of direct physical interactions of organic molecules with the lipid bilayer is required to understand, model, and predict many of these processes.

There is strong experimental evidence that small lipophilic molecules, including many marketed drugs, are able to traverse artificial lipid bilayers by passive diffusion driven by the concentration gradient between the solutions on the opposite sides of the bilayer.[1] Spontaneous membrane permeation is often described in terms of a solubility−diffusion model or the so-called "Overton's rule" stating that the permeability coefficient is proportional to the solute partition in water−oil systems.[2] Indeed, fair correlations were obtained between measured permeability coefficients of organic molecules and their partition coefficients in water/organic solvent systems (e.g., octanol, hexadecane, etc.).[3,4] To rationalize permeation of solutes through the lipid bilayer, solubility−diffusion models were applied, where permeability coefficients were assessed using solute diffusion coefficients in the membrane, their partitioning between water and the nonpolar solvent, and the width of the barrier domain.[4−6]

In natural membranes, mechanisms of selective permeability are more complex: in addition to passive transbilayer diffusion and diffusion through aqueous boundary layer, there are compound-specific transporter- and carrier-mediated influx and efflux, adsorptive transcytosis of cationic compounds, receptor-mediated endocytosis, micropinocytosis, and other mechanisms.[2,7−9] The relevance of the passive diffusion and

Received: March 14, 2019

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

transport-mediated influx and efflux of drug-related compounds has been extensively discussed,[1,8,10−13] and it was concluded that both mechanisms coexist and contribute to translocation across biological membranes.[1,10] However, rigorous evaluation of the contribution of passive diffusion *in vivo* is a challenging task, as the measurable permeation of drugs across biological membranes depends on many factors, such as physicochemical properties of drugs (molecular weight, polarity, lipophilicity, hydrogen bonding capacity, charge, etc.) and specific properties of biological membranes, including the presence of particular transporters.

The prediction of membrane permeability is also required for the development and optimization of new drugs. The primary goal of drug development is to enhance drug efficiency, bioavailability, and delivery to the intended target while reducing its toxicity and side effects. During the design of promising drug candidates, optimization of their pharmacological efficiency is usually performed in parallel with selection of leads with favorable pharmacokinetics, i.e. absorption, distribution, metabolism, and excretion (ADME). Properties that influence drug delivery and distribution, include water solubility, metabolic stability, absorption, and the permeability coefficient. The latter determines the rate at which drugs cross permeability barriers, such as epithelial cell membranes from the intestinal mucosal barrier or endothelial cell membranes of the blood−brain barrier (BBB). Several *in vitro* experimental systems have been developed to predict drug permeation across the BBB or the intestinal barrier: black lipid membranes (BLM), liposomes, parallel artificial membrane permeability assay (PAMPA), cell-based Caco-2 (colon adenocarcinoma cell line), or MDCK (Madin−Darby canine kidney cell line) assays, as well as *in situ* rodent brain perfusion experiments.[14−17]

As an alternative, diverse computational methods have been proposed. These methods have an advantage over experimental approaches for conducting high-throughput permeability analysis. At the early stages of drug discovery, the filtering of candidates that more likely exhibit poor permeation is routinely based on the violation of two or more physicochemical criteria of drug-likeness, known as Lipinski's "rule-of-five" (MW < 500, calculated octanol−water partition coefficient < 5, number of H-bond donors ≤ 5; number of H-bond acceptors ≤ 10).[18] However, this rule is not quantitative; it focuses mainly on the oral drug space and does not apply to natural products (NP) or substrates of transporters. Besides, up to 6% of FDA-approved oral drugs that are not NPs violate two or more of these criteria.[19] To refine this rule, quantitative estimates of drug-likeness were proposed.[19]

Quantitative structure−activity relationship (QSAR) and structure−permeability relationship (QSPR) models are regarded as primary quantitative tools for ADME optimization.[20−23] Statistically based QSPR models of drug absorption use correlations between the experimental cell permeability and physicochemical descriptors related to experimentally derived molecular properties. Improved multidimensional QSAR models have been developed that use addition levels of chemical structure representation, including molecular topology (2D-QSAR), information from 3D-structures (3D-QSAR), combination of 3D-coordinates and sampling of conformations (4D-QSAR), or mutual orientation and dynamics (4D-6D QSAR).[20−24] Some models, such as the MI-QSAR models developed by Hopfinger, complement properties of solutes by descriptors for membrane interactions calculated by MD simulations.[25] More general QSPR models[26−28] predict partition and permeability coefficients of solutes using a set of five Abraham solvation parameters.

The QSPR models are usually trained on limited sets of compounds and show good performance for classes of similar molecules but have poor transferability to compounds with different molecular skeletons.[21] The statistical relationships derived from limited training sets of chemicals do not encompass numerous newly approved drugs, including orally available NP-inspired compounds which lay outside the traditional drug property space but can passively penetrate through membranes.[18,29,30] Importantly, the QSPR models for drug transport do not allow deriving a physically accurate picture of the permeation process through the lipid bilayers.

Optimization of permeability coefficients of structurally diverse and complex leads, including large permeants violating Lipinski's rules, requires a theoretical model that adequately describes different aspects of drug−membrane interactions, such as the anisotropic lipid environment, membrane binding and dissociation, rotational and translational diffusion, and conformational changes.[31] For relatively large and structurally flexible molecules, it is important to address the existence of multiple conformations[32,33] and their spatial positioning in membranes that may influence calculated partitioning and permeability coefficients.[5]

Several general physics-based computational methods have been applied to overcome these problems. All-atom molecular dynamics (MD) simulations,[31,34−41] multiscale (CG/MD) simulations,[42,43] Monte Carlo simulations,[44] and simulations with milestoning algorithms[45,46] were used to obtain detailed information on the dynamics of small molecules in phospholipid bilayers. MD simulations in explicit lipid bilayers were used to calculate free-energy profiles of small molecules in membranes and their permeability coefficients,[35−43] evaluate their optimal orientations in the bilayer,[47] and predict BBB-permeable drugs.[48,49] However, high computational cost hampers application of MD simulations with explicit solvent models for high-throughput drug screening.

Simulations of molecules in the membrane treated as a low-dielectric continuum[50−53] are less computationally extensive. Such an approach was applied in the SMx-based[54,55] and COSMO-based methods.[56−61] The anisotropic complexity of the lipid bilayer was approximated by a low-dielectric slab with either isotropic or anisotropic properties along the normal.[62,63] Implicit solvent models have been successfully applied for prediction of transfer free energies and partition coefficients of neutral and ionic solutes from water to organic solvents, micelles, and lipid bilayers.[57,60,62−65] More recently, physical models of passive membrane permeation based on solubility−diffusion and barrier domain approaches were developed by Leung et al.,[32,33] Swift and Amaro,[66,67] and Brocke et al.[68] These models assume that the passive membrane permeability primarily depends on the free energy change of barrier crossing, ΔG. The value of ΔG can be calculated as the solvation energy difference between global minimum conformations evaluated in water and in implicit nonpolar organic solvent[32,33] or by integration of transbilayer profiles of the free energy of membrane insertion using heterogeneous dielectric generalized Born (HDGB) or dynamic HDGB (DHGDB) implicit membrane models.[68] An extended solubility-diffusion model was proposed by Ferrarini et al.[69] to describe translocation across membrane using complex free energy landscapes, multiple permeation paths, and the mechanical

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

properties of membranes, such as lateral pressure and acyl chain ordering. Despite rigorous treatment of conformational distributions of permeants[32] or advanced models for lipid membranes,[68] the performance of these methods against PAMPA permeability coefficients for sufficiently large data sets (≥70 compounds) was unremarkable, with correlation coefficients (R^2) below 0.60 and highly variable slopes (ranging from 0.5 to 5) and intercepts (from −9 to 15) of correlation plots for different data sets.[32,68]

Here we present a novel physics-based computational method, PerMM, that calculates the passive transmembrane translocation pathways and permeability coefficients of structurally diverse molecules (first reported as a conference abstract[70]). It is based on the solubility−diffusion model[5] and our computational method PPM (positioning of proteins in membranes) that was developed for analysis of interactions of arbitrary organic molecules with the lipid bilayer.[63,71] The PPM method was parametrized to reproduce free energies of transfer for a large set of small molecules from water to various isotropic organic solvents or anisotropic solvent environments, such as the lipid bilayer. Unlike most other implicit solvent models, it accounts not only for the hydrophobic interactions and electrostatic solvation energy, but also for the solute−solvent hydrogen bonding. The corresponding dielectric and hydrogen bonding polarity profiles were derived from the distributions of different lipid groups that were experimentally determined for DOPC and other bilayers by X-ray and neutron scattering. PPM has been successfully applied to predict membrane binding affinities and spatial positions in membranes of small molecules, peptides, and proteins.[63,71,72] The PerMM method calculates (1) the spatial arrangement of solutes in membranes, including the selective accumulation of amphiphilic molecules on the membrane/water interface; (2) the solvation free energy changes of compounds as they move along the translocation pathway in the fluid DOPC bilayer; and (3) the permeability coefficient across the artificial (BLM, PAMPA) and natural (Caco-2/MDCK and BBB) lipid membranes. The method was not trained using any data sets but relies on a general approach to calculating the energy of atomic solvation and electrostatic interactions of solutes translocated across the implicit membrane with anisotropic properties. It successfully reproduced the experimental permeability coefficients of large sets of compounds across different membrane systems with R^2 ranging from 0.52 (Caco-2/MDCK cells) to 0.88 (BLM) and root-mean-square errors (rmses) ranging from 0.69 (BBB) to 1.59 (PAMPA-DS) log units. The method has been implemented into an open-access PerMM web server (https://permm.phar.umich.edu/server).

METHODS

Calculation of Membrane Permeability Coefficients. The overall membrane resistance (R), which is inverse to the permeability coefficient (P_m), was calculated based on the inhomogeneous solubility-diffusion model[5] as the integral of the local resistance across the membrane:

$$R = \frac{1}{P_m} = \int_{-d/2}^{d/2} \frac{dz}{K(z)D(z)} \quad (1)$$

where $K(z)$ and $D(z)$ are partition and diffusion coefficients, respectively, which depend on the z position of the solute along the bilayer normal and d is the membrane thickness.

The $K(z)$ value was calculated from the Gibbs free energy of a solute in membrane:

$$K(z) = e^{-\Delta G_{transf}(z)/RT} \quad (2)$$

where $\Delta G_{transf}(z)$ is the transfer free energy of the molecule from water to the position z along the bilayer normal (the energy was averaged for a set of conformers). The profile $\Delta G_{transf}(z)$ reflects the solute affinity to the different membrane regions and determines the lowest free energy translocation pathway.

Diffusion coefficients of molecules in membranes cannot be measured experimentally but can be approximated by their diffusion coefficients in water or organic solvents[73] or assessed from MD simulations.[35−43,74] According to MD simulations, the diffusion coefficient profiles, $D(z)$, are relatively flat along the bilayer normal, with values that are several times lower than in water or at the water−lipid interface.[35,36,42] A notable exception includes small molecules (e.g., water, ammonia, oxygen) that demonstrate an increased diffusivity at the center of the membrane.[74] Hence, we assumed that the diffusion coefficient D_i for an organic molecule i can be considered invariable along the lipid bilayer but dependent on the permeant size. The dependence of diffusion coefficient D_i on the volume of a permeant molecule, V_i, is frequently described as in the publication by Xiang and Anderson:[6]

$$D_i = \frac{D_0(\eta)}{V_i^n} \quad (3)$$

where D_0 is a constant for a particular membrane type characterized by its microviscosity η. The parameter n was suggested to be ∼2/3 because the diffusion coefficient depends mainly on the cross-sectional area of the permeant.[75] However, fitting to experimental permeability data for bilayers suggested a slightly higher value of $n \sim 0.8$.[6]

To simplify the calculations, we used the total accessible surface area of the molecule (ASA), instead of molecular volume, as another parameter related to the cross-section area:

$$D_i = k\frac{D_0(\eta)}{ASA_i^n} \quad (4)$$

Based on eqs 1−4, the log of calculated membrane permeability coefficient for compound i, can be written as

$$\log P_{m,i} = a + b\log P_{\Sigma i} \quad (5)$$

where $a = \log kD_0(\eta)$ and

$$\log P_{\Sigma i} = -\log\left(ASA_i^n \int_{-d/2}^{d/2} \frac{dz}{K_i(z)}\right) \quad (6)$$

Parameters "a" and "b" can be empirically determined by a linear fit of experimental permeability coefficients for N compounds and the corresponding calculated log $P_{\Sigma i}$ values.

We also tested a simplified version of the model, without molecular size correction, where $D(z)$ was considered constant and independent of molecular size. We found that including the cross-section area-dependent contribution ASA^n leads to only a minor improvement of the fit, and the results are not sensitive to the value of n in (4). Hence, we used $n = 1$.

The calculation of the free energy profiles, $\Delta G_{transf}(z)$, was performed in the interval from −30 to +30 Å distance from the lipid bilayer center. The permeability barriers (positive values of ΔG_{transf} relative to the aqueous solution) were observed only

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

in the hydrophobic lipid core but not in the headgroup regions for all compounds, hydrophilic and hydrophobic. Therefore, the integral in eq 6 was calculated through the hydrocarbon core of the lipid bilayer, i.e. in the interval from −15 to +15 Å distance relative to the bilayer center with a step of 1 Å. This part of the lipid bilayer includes the acyl chains and lipid carbonyls with some residual water (Figure S1). Extending the integration interval did not lead to significant changes in the calculated permeability coefficients or to a better agreement with experimental data. We did not include the unstirred water layers outside membrane boundaries, also known as aqueous boundary layer (ABL). While calculating the permeability coefficients of highly hydrophobic compounds, we focused on their intrinsic permeability coefficients, omitting ABL-effects.

Free Energy of Transfer from Water to the Lipid Bilayer. The energy of transfer of a molecule from water to different positions (z) in membrane, $\Delta G_{transf}(z)$, was calculated by the PPM 2.0 method, as previously described.[63] Calculations were based on our version of the universal solvation model[65] and the anisotropic solvent model of the lipid bilayer,[63] which account for contributions of ionizable groups and the dependence of atomic solvation parameters σ and η on the atom position along the bilayer normal (z). The energy was represented as a sum of a short-range ASA-dependent term (hydrogen bonding, van der Waals, and hydrophobic interactions), long-range electrostatic contributions of dipole moments (μ), and energy of deionization of ionizable groups in the nonpolar environment:

$$\Delta G_{transf}(d, \varphi, \tau) = \sum_{i=1}^{N} \sigma_i^{wat\rightarrow bil}(z_i)ASA_i + \sum_{j=1}^{M} \eta_j^{wat\rightarrow bil}(z_j)\mu_j + \sum_{k=1}^{L} \min\{\Delta E_k^{ion}, \Delta E_k^{neutr}\} \quad (7)$$

where $\sigma_i(z_i)$ is an atomic solvation parameter describing transfer energy (per squared angstrom) of atom i from water to the point z_i along the bilayer normal, ASA_i is a solvent-accessible surface area of atom i, $\eta(z_j)$ is an energy penalty of transferring the dipole moment of 1D from water to point z_j, μ_j is a dipole moment of group j, E_k^{ion} and E_k^{neutr} are energies of ionizable group k in ionized and neutral states, respectively, N is the number of atoms in the molecule, M is the number of group dipoles, L is the number of ionizable groups, and parameters d, φ, and τ define spatial position of the molecule with respect to the lipid bilayer, as previously described.[71] Thus, for each ionizable group, the lowest energy ionization state (charged or uncharged one) was automatically selected at the given position in the membrane. The transfer energy of an ionizable group k in neutral state was calculated as a sum of the deionization energy of the group and ASA-dependent transfer energies of the corresponding atoms (L_k is the number of atoms in ionizable group k):

$$\Delta E_k^{neutr} = \Delta G_k^{deionization} + \sum_{l=1}^{L_k} \sigma_l^{wat\rightarrow bil}(z_l)ASA_l \quad (8)$$

The energy cost of deionization during transfer from water to the nonpolar environment was defined by the Henderson–Hasselbalch equation:

$$\Delta G_k^{deionization} = 2.3RT(pH - pK_{ak}) \quad (9)$$

The transfer energy in the ionized state was described by the following equation:

$$\Delta E_k^{ion} = \frac{166e_{Born}}{r_k}F_{Abe}^{wat} - F_{Abe}(z_k) + \sum_{l=1}^{L_k} \sigma_{l,ion}^{wat\rightarrow bil}(z_l)ASA_l \quad (10)$$

where $\sigma_{l,ion}$ is solvation parameter of O or N atoms in a charged state; e_{Born} is a weight factor of long-range electrostatic contribution to transfer energy; r_k is an ionic radius. The dielectric function for ions was described by the Born equation modified by Abe:[76]

$$F_{Abe}(z) = \left(\frac{1}{\ln \varepsilon(z)} - \frac{1}{\varepsilon(z)\ln \varepsilon(z)} - 1\right) \quad (11)$$

Dipolar contribution was calculated using the Block–Walker dielectric function of the media, $F_{BW}(\varepsilon)$:[77]

$$\eta^{wat\rightarrow bil}(z) = e_{dip,BW}(F_{BW}^{bil}(z) - F_{BW}^{wat}) \quad (12)$$

$$F_{BW} = \frac{3\varepsilon\ln \varepsilon}{(\varepsilon\ln \varepsilon - \varepsilon + 1)} - \frac{6}{\ln \varepsilon} - 2 \quad (13)$$

All types of atoms (26 types) with their solvation parameters and atomic radii were chosen as described previously.[65] We assumed that all charged and dipolar groups with ASA > 0.1 Å are in contact with the surrounding solvent and, therefore, their electrostatic contributions to solvation energy should be included.

The atomic solvation parameters σ_i depend on the polarity parameters of the lipid bilayer:

$$\sigma_i^{wat\rightarrow bil}(z) = \sigma_i^0 - e_i\left(\frac{1}{\varepsilon_{bil}(z)} - \frac{1}{\varepsilon_{wat}}\right) + a_i(\alpha_{bil}(z) - \alpha_{wat}) + b_i(\beta_{bil}(z) - \beta_{wat}) \quad (14)$$

where $\alpha_{bil}(z)$, $\beta_{bil}(z)$, and $\varepsilon_{bil}(z)$ are transbilayer profiles of hydrogen bonding donor and acceptor capacities and dielectric constant, respectively, and α_{wat}, β_{wat}, and ε_{wat} are the corresponding values in water. The values of coefficients e_{Born}, σ^0, e_i, a_i, b_i, $e_{dip,\pi}$, and $e_{dip,BW}$ (from eqs 10, 12, and 14) were defined previously.[63]

The profiles of hydrogen bonding donor and acceptor capacities ($\alpha_{bil}(z)$, $\beta_{bil}(z)$), dielectric constant ($\varepsilon_{bil}(z)$), and dipolarity/polarizability parameter ($\pi^*_{bil}(z)$) were calculated for several artificial membranes from distributions of groups in lipids and membrane protein structures along the bilayer normal.[78] In this work, we used profiles obtained for the fluid DOPC bilayer based on the distributions of lipid segments determined by X-ray and neutron scattering[78,79] (Figure S1).

Here, we modified the original PPM method to work with small molecules. The adapted PPM version automatically defines atom types and assigns dipole moments to all polar groups. The program uses a library of dipole moments for different standard functional groups, taken from the previously published tabulations of group dipole moments.[80,81] In addition, the pK_a values of ionizable groups should be included in the coordinate file. The experimental pK_a values were taken from the compilation by Avdeef[82] and from the literature.[83−85] In a few cases, the values were not experimentally determined and, therefore, they were calculated using Marvin Suite (ChemAxon). All pK_a values for compounds used in this

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

work can be found in the PerMM database (https://permm.phar.umich.edu/).

Calculation of Transmembrane Translocation Pathway. To determine the lowest energy pathway of a molecule across the lipid bilayer, we used two options. The first option was the "drag" method for finding saddle points.[86] The transfer energy was locally minimized with respect to rotational variables of the molecule in every $z + \Delta z$ point of the transmembrane pathway, starting from the optimal rotational orientation calculated in the previous point z. Hence, the rotational position of a molecule was gradually changing during its movement along the membrane normal. This method produced an asymmetric energy curve.

As an alternative approach, we tested an option of "global rotational optimization" of transfer energy with respect to rotational variables of the molecule at every point (z) along the membrane normal. Step Δz was taken as 1 Å. To sample different orientations, the permeant was rotated using 2° steps in the intervals [0°, 360°] and [0°, 180°] in the rotational (φ) and tilt (τ) angles relative to the membrane normal, and the solvation energy was locally minimized with respect to the φ and τ variables starting from each rotational position. The lowest energy orientation was selected automatically for each z value. This approach produced a symmetric energy curves, but it nullified the energy barrier for flip-flop of the molecule in the middle of the membrane. Therefore, the "drag" optimization is preferable for calculation of permeability coefficients.

The location of a molecule along membrane normal was defined by the coordinate z of a "reference atom" representing the atom closest to the center of mass of polar groups of the molecule. To simultaneously move an ensemble of multiple conformations through the membrane, we superimposed conformations through four common atoms that are the closest to the "reference atom". The local rotational optimization was accomplished for each conformer, and the Boltzmann average value of $\Delta G_{transf}(z)$ was calculated for the set of conformers. For local energy minimization, we used the Davidon−Fletcher−Powell method with analytically calculated partial derivatives of the transfer energy (as implemented in the original PPM method[63]), where each conformer was considered as a rigid body.

The free energy profiles for 506 compounds that were used in this work can be obtained by running the PerMM web server with source coordinate files provided in the PerMM database. The web server and the database are described in more detail in the accompanying paper.[97] The PerMM source code will be provided by the authors upon request, after receiving permission from the owners of the program NACCESS used for ASA calculations.

Generating Structures of Molecules. The 3D structures of compounds used in this study were downloaded from the PubChem databases in the structure data format (sdf), converted into the pdb format using PyMol (https://pymol.org/2/). The PubChem structures were already energetically optimized.[87] Only in a few cases, the 3D structures were taken from the Protein Data Bank (PDB)[88] or the Cambridge Structural Database (CSD).[89] For example, 3D structures of the 11-residue cyclic peptide cyclosporine A were downloaded from PDB (PDB IDs 2mrc, 1ikf) and CSD (CSD ID KERNAU). The coordinates of several molecules not found in public databases were generated using molecular modeling modules of QUANTA software package for molecular mechanics simulations (BIOVIA-Accerlys Inc.).

The analysis of flexible molecules requires conformational sampling.[33,90] To increase the speed of calculations, a set of low-energy conformers was precalculated for every conformationally flexible molecule, and each conformer was considered as a rigid body. As described above, the multiple conformers were superimposed and moved through the membrane to calculate their average transfer energy from water. We found that it is sufficient to include only 6 to 15 significantly dissimilar conformers for medium-size flexible molecules. Further increasing the conformational ensemble did not affect the values of calculated permeability coefficients. For compounds used in this study, we selected conformers that were the lowest energy representatives of different structural clusters identified using the Conformational Search module of QUANTA. A grid scan in the space of torsion angles was followed by ABNR local energy minimization was conducted with CHARMm27 (100 steps, $\varepsilon = 10$) and cluster analysis. Multiple conformers of a molecule were included into an input coordinate file (in pdb format) as multiple models, using MODEL records.

Experimental Permeability Coefficients. Using reliable experimental data from publications is critical for development and testing of a new permeability model. Our work is focused on modeling of passive permeability across the fluid DOPC bilayer. Thus, to verify our method, we compared our calculations with permeability coefficients measured *in vitro* through artificial lipid bilayers. After collecting available data from publications and a critical assessment of the data quality, we obtained 132 permeability coefficients through BLM and liposomes: 111 intrinsic permeability coefficients (log P_{0exp}^{BLM} in Table S1) and 21 membrane permeability coefficients for ionized compounds (log P_{mexp}^{BLM} in Table S1). These data originated from many reputable research groups (e.g., those of Xiang and Anderson, Finkelstein, Walter and Gutknecht, Pohl, Antonenko, and others; see the Supporting Information for references). The main data set included 58 log P_{0exp}^{BLM} values for the un-ionized species and 20 log P_{mexp}^{BLM} values for the ionized in water species obtained in comparable experimental conditions (eggPC and DOPC, 25 °C). Data obtained in slightly modified experimental conditions were included in the additional data set.

Data for more complex membrane systems were taken from a compilation by Avdeef[15−17] who provided the intrinsic permeability, P_0, which refers to the membrane permeability of the neutral form of ionized molecules, i.e., the maximum possible value that the membrane permeability can reach. Overall, we used ∼700 intrinsic permeability coefficients through PAMPA-DS, BBB, and Caco-2/MDCK cells that Avdeef collected from reliable publications and processed using the pCEL-X computer program (http://www.in-adme.com/pcel_x.html).

Hence the intrinsic permeability data obtained *in vivo* for BBB (log P_{0exp}^{BBB}) (Table S3) were taken from Avdeef's compilation.[16] Most data were obtained from *in situ* rodent brain perfusion studies and referred to permeation from saline at pH 7.4 and corrected for ionization, while some were based on *in vivo* intravenous injections (i.v.). The i.v. data were not used for lipophilic compounds that are known to bind plasma proteins. The *in situ* brain perfusion technique is used for the *in vivo* measurement of the initial rate of brain penetration at the luminal BBB membrane.[16] The permeability−surface area product, PS, is the product of the luminal permeability, P_c (cm s^{-1}), and the endothelial surface area, S (cm^2 g^{-1}). PS is the

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX



Figure 1. Spatial positions, optimized orientations (A), and transfer energy profiles (B) calculated for several drug molecules as they move through the DOPC bilayer. Calculations of transbilayer energy profiles were performed by the publicly available PerMM web server (https://permm.phar.umich.edu/server) using the "global rotational optimization" option. The locations of hydrocarbon core boundaries between the acyl chains and head groups of lipids (at ±15 Å distances from the membrane center) are approximated by planes and shown as dummy atoms (A).

transfer constant for the initial brain transport of a drug corrected for the velocity of the perfusion flow. Data were selected for efflux-minimized conditions, in which PS values were measured during inhibition of carrier- or transporter-mediated permeability or in knockout mouse models.

Intrinsic permeability data for intestinal cellular membranes (log $P_{0exp}^{Caco\text{-}2/MDCK}$) (Table S4) were taken from Avdeef's database[17] that collects high-quality P_{app} values measured in Caco-2 and MDCK epithelial cell lines. These data were collected by Avdeef from 55 reliable publications and corrected for all non-trans-cellular effects using the *p*CEL-X computer program (http://www.in-adme.com/pcel_x.html). To cancel contributions from active or facilitated transport, the average was taken between apical-to-basolateral and basolateral-to-apical measurements for compounds that are known as substrates for efflux/uptake carrier-mediated transport.

The parallel artificial membrane permeability assay (PAMPA) is another experimental assay quantifying the passive diffusive permeability of artificial membrane systems (log $P_{0exp}^{PAMPA\text{-}DS}$). Here we used values obtained by Avdeef in PAMPA-DS assay using the lecithin-based double sink model (with 0.5% DMSO in donor chamber, surfactant in acceptor chamber), where the membrane retention of hydrophobic compounds is greatly reduced (Table S5).[15] These experimentally obtained permeability coefficients were additionally corrected by Avdeef for permeability through the ABL adjacent at both sides of the membrane.

Experimental permeability coefficients for 506 compounds measured in different membrane systems can be found in our PerMM database (https://permm.phar.umich.edu/, see the accompanying paper[97]).

RESULTS

We assessed the performance of the PerMM method using large sets of organic compounds, FDA-approved drugs, and similar molecules, for which permeability coefficients were experimentally determined in artificial (BLM/liposomes and PAMPA-DS) and natural (BBB and Caco-2/MDCK cells) membrane systems (Tables S1−S9). For each molecule studied, the program calculated a series of its optimized spatial arrangements as a permeant moves along the membrane normal. The free energy profile ($\Delta G_{transf}(z)$) along the permeation pathways was produced by optimizing the free energy of transfer of the molecule from water to each position within the lipid bilayer combined with the search for its optimal conformer from precalculated variants. Integration of the obtained transfer energy profile along the membrane normal (eqs 5 and 6) allows calculating the permeability coefficient.

Such energy profiles were calculated for more than 500 permeants, most of which were included in this work. The representative examples of transbilayer energy profiles obtained for five BBB-penetrating drugs, a cyclic peptide, and 17 organic molecules from the initial testing set are shown in the Figures 1, S2, and S3, respectively. For hydrophilic molecules, the free energy profile has a maximum at the bilayer center, which constitutes the main barrier for their permeation (Figure 1B). For hydrophobic molecules, the transbilayer profiles of ΔG_{transf} are negative at all depths, with a minimum at the membrane center, so that the partition is more favored in the hydrophobic core of the lipid bilayer than at the lipid−water interface. In contrast, all amphiphilic molecules have two minima with negative ΔG_{transf} values at the water−lipid interfaces and a maximum in the membrane center. Similar free energy profiles for small organic molecules and drugs were obtained in MD simulations,[35,41,43,47,48,91] except that small energy barriers were found in the lipid headgroup region for some hydrophobic compounds in a number of studies.[35,38,42,92,93] During the movement, the permeant molecule rotates to place its nonpolar groups deeper to the lipid acyl chain region and to orient the most polar atoms toward the membrane boundaries (see Figure 1A). The predicted changes in spatial orientations along the translocation pathway of 506 permeants can be inspected using the interactive GL mol viewer included in the PerMM database.

Performance of PerMM for Model Lipid Bilayers. The current version of PerMM was developed using polarity parameters of the DOPC bilayer. Therefore, the performance of the method was initially assessed using data for similar lipid bilayer systems, such as BLM or liposomes primarily composed of phosphatidylcholine (PC), rather than data for more complex PAMPA, Caco-2/MDCK, and BBB membranes.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX



Figure 2. Prediction of the permeability of artificial lipid bilayers to organic molecules. (A) Comparison of experimental (log P_{exp}^{BLM}) and calculated (log P_{Σ}^{BLM}) permeability coefficients across unilamellar lipid bilayers of 58 un-ionized (black circles) and 20 ionized in water (open circles) organic molecules. The corresponding data values are from Tables S1 and S2. (B) Plot of experimental BLM permeability coefficients (log P_{exp}^{BLM}) vs the calculated ones (log P_{calc}^{BLM}) for 78 organic molecules. Dashed lines indicate ideal line and residual line limits (using a cutoff of |3.1| that corresponds to 2.0 rmse for ionized molecules). Predicted permeability coefficients, log P_{calc}^{BLM}, in B were calculated using eq 15. The log P_{Σ}^{BLM} values were calculated using eq 6. For ionized species, the integral log $P_{m\Sigma}^{BLM}$ accounted for the deionization penalty of ionizable groups at the specified pH. The number of molecules "*n*" is indicated in parentheses.

Hence, we compared the permeability coefficients calculated by PerMM with the corresponding experimental data measured in PC-based BLM or liposomes (Tables S1 and S2). First, we used a main set of the most frequently cited data determined by Anderson and co-workers, Walter and Gutknecht, and several other groups. It included 58 intrinsic permeability coefficients published for uncharged forms of permeants (log P_{0exp}^{BLM} for 42 acids, 3 bases, and 13 neutral molecules) and 20 membrane permeability coefficients for molecules ionized in water (log P_{mexp}^{BLM} for 11 acids, 5 bases, and 4 zwitterions). The PPM solvation model considers the equilibrium between charged and neutral states of ionizable groups, depending on their pK_a and pH values (eqs 7−13),[63] thus allowing ionizable groups to diffuse through the membrane in the neutral state. The ionized species can still be present in the membrane region at 10−15 Å distance from the membrane center, where the protonation or deprotonation takes place. The deionization energy cost was estimated using the Henderson−Hasselbalch equation. This energy was not included in calculation of permeability coefficients for the neutral states of acids, bases, and zwitterions.

We found a good correlation (R^2 = 0.88) between integrals (log P_{Σ}^{BLM}) calculated according to eq 6 and experimental permeability coefficients (log P_{0exp}^{BLM}) of 58 un-ionized and 20 ionized compounds combined, which covered a wide range of experimental permeability values, from −13 to +1 log units (Figure 2A). The linear fitting of the scatter plot allowed us to find parameters "*a*" (intercept) and "*b*" (slope) in eq 5. Importantly, the slope *b* was found to be close to 1, as expected. The intercept value *a* represents a constant related to the diffusion coefficient in membrane with the viscosity η that depends on the lipid composition. The following linear regression model (eq 15) was included into the PerMM method for the prediction of permeability coefficients of molecules crossing lecithin-based bilayers (e.g., BLM):

$$\log P_{calc}^{BLM} = 1.063 \log P_{\Sigma}^{BLM} + 3.669 \quad (15)$$

Equation 15 was applied for scaling the log P_{Σ}^{BLM} values to experimental BLM data so that *a* and *b* became 0 and 1, respectively. This transformation resulted in rmse value of 1.15 log units between experimental and estimated permeability coefficients (Figure 2B).

We found that it was important to have a sufficiently large set of compounds (>50) to obtain a reliable calibration curve (Figure 2A). For example, two separate linear regression fits for 58 un-ionized and 20 ionized molecules were described by the equations: log P_{0calc}^{BLM} = 1.03 log P_{Σ}^{BLM} + 3.71 (n = 58, R^2 = 0.88) and log P_{mcalc}^{BLM} = 0.83 log $P_{m\Sigma}^{BLM}$ + 0.58 (n = 20, R^2 = 0.79), respectively (Figure S4). The regression function for the first data set of 58 compounds was similar to that for the larger set of 78 compounds (Figure 2A) but different for the data set of 20 molecules. The parameters of regression varied for small data sets from individual publications.

To validate the linear model described by eq 15, we increased the main data set by including 54 additional compounds that were studied in BLM and liposomes under more variable experimental conditions. The linear regression fit for the extended set of 132 compounds was described by equation log P_{calc}^{BLM} = 0.86 log P_{Σ}^{BLM} + 1.91 (n = 132, R^2 = 0.82) (Figure S5A). After excluding three outliers (represented using green triangles in Figure S5A), the equation did not change significantly, but the correlation improved: log P_{calc}^{BLM} = 0.90 log P_{Σ}^{BLM} + 2.24 (n = 129, R^2 = 0.85). Thus, after addition of 51 experimental data points obtained in slightly altered experimental conditions, R^2 only slightly decreased, but the slope remained close to 1. The estimated rmse for sets of 129 and 132 compounds were of 1.40 and 1.56 log units, respectively. Thus, we defined as outliers three additional compounds (nitric acid, hydrofluoric acid, and lysine), which significantly increased the rmse.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX



Figure 3. Comparison of experimental permeability data for natural and artificial membrane systems. (A) Correlation between intrinsic permeability coefficients obtained *in situ* rodent brain perfusion experiments (log P_{0exp}^{BBB}) vs Caco-2/MDCK assays (log $P_{0exp}^{Caco\text{-}2/MDCK}$). (B) Correlation between intrinsic BBB or Caco-2/MDCK permeability coefficients vs intrinsic permeability coefficients through BLM/liposomes (log P_{0exp}^{BLM}). Colors indicate different types of molecules: red for acids, blue for bases, gray for neutral molecules, and yellow for zwitterions. The number of molecules "*n*" is indicated in parentheses. Experimental BLM, BBB, and Caco-2/MDCK permeability coefficients are from Tables S7 and S8.

Importantly, our model was able to evaluate the intrinsic permeability coefficients for highly hydrophobic compounds with $P_0 \gg P_{ABL}$, whose measurable permeability coefficients are limited by diffusion through ABL (P_{ABL} of $15-30 \times 10^{-6}$ cm/s).[15] For example, PerMM-calculated permeability coefficients through the DOPC bilayer (log P_{0calc}^{BLM}) for imipramine, desipramine, and chlorpromazine were 2.70, 2.63, and 1.39, respectively, whereas experimental values through the DOPC bilayer (log P_{0exp}^{BLM}) provided by Avdeef (Figures 7.26 and 7.30 in ref 15) were 5.1, 1.74, and 1.62, respectively.

We also tested the influence of the conformational flexibility of molecules with multiple rotating bonds on the results of our calculations. We found that the use of multiple precalculated conformations of compounds slightly changed the permeability coefficients of some conformationally flexible compounds (Figure S2). For example, the optimal membrane-bound conformation of the cyclic peptide cyclosporine A was oval-shaped and stabilized by four intramolecular hydrogen bonds (CSD ID KERNAU), while the optimal conformations in water and at the water−membrane interface were more round-shaped (PDB IDs 2rmc, 1ikf) with one intramolecular hydrogen bond. The application of three dissimilar conformations of cyclosporine A in our PerMM calculation decreased the BLM permeability coefficient by ∼0.6 log units as compared to calculations with just one round-shaped conformation. For the whole data set, the use of a conformational ensemble instead of a single conformation did not significantly improve the accuracy of calculations (Figure S4). Nevertheless, we opted to use multiple conformations for flexible compounds in all subsequent calculations.

Comparison of Experimental Permeability Coefficients in Different Membrane Systems. To investigate how permeability data depend on the experimental method applied, we compared experimental permeability coefficients of the same compounds measured in different artificial (BLM and PAMPA-DS) and natural (BBB and Caco-2/MDCK) membranes. To simplify the analysis, we considered only intrinsic permeability coefficients with log P_{0exp} values ranging from −7 to 0 (Tables S7−S9).

Such comparisons lead to several important conclusions. First, we found a sufficiently good correlation between the intrinsic permeability coefficients obtained using *in situ* BBB assay and *in vitro* cell-based Caco-2/MDCK assays (73 compounds, Figure 3A). The linear regression curve had a slope *b* close to 1, the intercept *a* close to zero, and R^2 of 0.78 This is consistent with the general expectation that Caco-2 or MDCK cell-based assays can be used as models for predicting BBB permeability of drugs.[94]

Second, we found a good correlation (R^2 of 0.82 and slope *b* of 0.81) between experimental permeability coefficients measured in BLM and in "efflux minimized" BBB assay or Caco-2/MDCK assays after correction for nontrancellular effects (set of 32 compounds, Figure 3B). The regression function was

$$\log P_{0calc}^{PM} = 0.81 \log P_{0calc}^{BLM} - 1.88 \quad (16)$$

The significant intercept value ($a = -1.88$) in the linear regression line can be explained by the difference in lipid composition between epithelial membranes and BLM. The presence of cholesterol and sphingomyelin in epithelial membranes could be a cause of the much lower permeability (by 1.88 log units) of natural membranes as compared to lecithin-based BLM. Indeed, the addition of cholesterol (CHOL) to BLM formed by PC in experiments performed by Finkelstein[95] and Xiang et al.,[96] reduced the experimental permeability coefficients by ∼0.6 log units, while addition of both cholesterol and sphingomyelin (CHOL+SM) decreased these coefficients by ∼1.9 log units, which appeared as a decrease of the intercept values in corresponding plots (Figure

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX



Figure 4. Experimental and calculated permeability data for PAMPA-DS. (A) Correlation between intrinsic permeability coefficients obtained in PAMPA-DS assays and using BLM or liposomes (log P_{0exp}^{BLM}). Experimental PAMPA-DS and BLM data were taken from Table S9. (B) Correlation between permeability coefficients through the plasma membrane and PAMPA-DS. Intrinsic permeability coefficients of molecules through the plasma membrane (log P_{0calc}^{PM}) were calculated using eq 17. Experimental data for PAMPA-DS (log $P_{0calc}^{PAMPA-DS}$) were taken from Table S5. Colors indicate different types of molecules: red for acids, blue for bases, gray for neutral molecules, and yellow for zwitterions. The number of molecules "*n*" is indicated in parentheses.



Figure 5. Correlation between calculated intrinsic permeability coefficients through the plasma membrane (PM) and experimental intrinsic permeability coefficients through BBB (A) and Caco-2/MDCK cells (B). Intrinsic permeability coefficients of molecules through the plasma membrane (log P_{0calc}^{PM}) were calculated using eq 16. Experimental data were taken from Tables S3 for BBB (log P_{0exp}^{BBB}) and Table S4 for Caco-2/MDCK assays (log $P_{0exp}^{Caco-2/MDCK}$). Colors indicate different types of molecules: red for acids, blue for bases, gray for neutral molecules, and yellow for zwitterions. The number of molecules "*n*" is indicated in parentheses.

S5B). The PM-correction in accordance with eq 16 was included to predict the permeability coefficients through the plasma membranes.

Finally, we compared permeability coefficients measured in PAMPA-DS vs BLM assays for the set of 24 compounds (Figure 4A). We found a slightly lower correlation between experimental data obtained in both assays (R^2 = 0.62, slope *b* of 0.94). The regression function, based on PAMPA-DS data, was

$$\log P_{0calc}^{PM} = 0.94 \log P_{0calc}^{BLM} - 1.75 \quad (17)$$

The value of the intercept *a* indicated the lower permeability coefficients (by 1.75 log units) through PAMPA-DS membranes as compared to BLM, which is reminiscent of the decreased permeability of cholesterol- and SM-rich epithelial membranes of Caco-2/MDCK cells and the BBB. Such a permeability difference could be attributed to a larger width and different lipid composition (20% lipid mixture of PC, PE, PI, PA, and triglycerides)[15] of a hydrophobic barrier in PAMPA-DS relative to that in BLM. Equation 17 was used instead of eq 16 for PM-correction, while calculating data for the PAMPA-DS assay.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX



Figure 6. Prediction of intrinsic permeability coefficients through different membrane systems. Plot of experimental vs calculated permeability coefficients through BLM (A), PAMPA-DS (B), BBB (C), and Caco-2/MDCK cells (D). The formula above each panel relates the calculated intrinsic log P_{0calc} values for each systems and the integral log P^{BLM}_{Σ} values of molecules in the neutral state determined by integration of eq 6. Dashed lines indicate the ideal line and residual line limits with cutoffs of |3.2| (A and B) and |2.0| (C and D). Colored circles indicate different charge classes of molecules: red for acids, blue for bases, gray for neutral molecules, and yellow for zwitterions. The number of molecules "*n*" is indicated in parentheses.

Prediction of Permeability Coefficients for BBB, Caco-2/MDCK, and PAMPA-DS Assays. In this work, we used three sets of experimental intrinsic permeability coefficients (log P_{0exp}) that were compiled by Avdeef for PAMPA-DS, BBB, and Caco-2/MDCK assays.[15−17] They included 322, 199, and 185 data points, respectively. The intrinsic permeability coefficients of these compounds ranged from −12 to +2 for PAMPA-DS, from −9 to +1 for BBB, and from −7 to −2 for Caco-2/MDCK assays.

To reproduce these data, log P^{BLM}_{Σ} values were calculated for all compounds in the neutral form using eq 6. For each of three data sets, we then compared experimental log P_{0exp} values with calculated integrals (log P^{BLM}_{Σ}) in three subsets: (1) the whole data set; (2) the core set, excluding outliers; and (3) the reduced set, excluding outliers and zwitterions (Figure S6). We considered data points as outliers if they deviated by more than 2 rmse from the value predicted by the linear regression line (i.e., the cutoff of 2 in absolute value for standardized residuals) and their one-by-one exclusion significantly improved the correlation coefficient and decreased the rmse. Such an approach allowed us to exclude 42 compounds from the PAMPA-DS data set (13% outliers), 17 compounds from the BBB data set (8.5% outliers), and 20 compounds from the Caco-2/MDCK data set (10.8% outliers) (shown as green triangles on Figures S6 and S7). Interestingly, excluding zwitterions from these sets did not significantly improve the R^2 for BBB data and even decreased the R^2 for PAMPA-DS and Caco-2/MDCK data. Therefore, during subsequent calculations, we used the core sets of 280, 182, and 165 compounds for PAMPA-DS, BBB, and Caco-2/MDCK data, respectively.

As follows from the experimental data (Figures 3B and 4A), the permeability of plasma membranes (PM) of the BBB and Caco-2/MDCK cells and of PAMPA membranes is lower by ∼1.8 log units as compared to permeability of the lecithin-based BLM. Therefore, we used corrected log P^{PM}_{0calc} values for PM in all subsequent comparisons. The calculation of log P^{PM}_{0calc} values can be viewed as a two-step linear transformation. First, the permeability coefficients through BLM (log P^{BLM}_{0calc}) were estimated using eq 15. Then, we applied eq 16 to obtain PM-

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

corrected log P^{PM}_{0calc} values for BBB and Caco-2/MDCK or eq 17 for PAMPA-DS data.

The scatter plots for experimental permeability coefficients for PAMPA-DS, BBB, and Caco-2/MDCK assays versus log P^{PM}_{0calc} are shown in Figures 4B and 5. We found a sufficiently good correlation (R^2 = 0.75, $b \sim 1$, $a \sim 0$) between experimental intrinsic PAMPA-DS permeability coefficients (log $P^{PAMPA-DS}_{0exp}$) for 280 diverse molecules (50 acids, 122 base, 72 neutral molecules, and 36 zwitterions) and the corresponding PM-corrected permeability values (log P^{PM}_{0calc}) (Figure 4 B). The linear regression model for PAMPA-DS was

$$\log P^{PAMPA-DS}_{0exp} = 0.98\log P^{PM}_{0calc} + 0.49 \quad (18)$$

Using this model for scaling calculated data produced the rmse value of 1.59 log units (Figures 6B and S6B).

The relationships between experimental and PM-corrected permeability coefficients of 182 compounds (18 acids, 80 bases, 60 neutral molecules, and 24 zwitterions) studied in the BBB assay and 165 compounds (10 acids, 69 bases, 53 neutral molecules, and 33 zwitterions) studied in Caco-2/MDCK assays can be described by the linear regression lines with R^2 of 0.69 and 0.52, respectively, and slopes b of 0.43 and 0.32, respectively (Figure 5A, B). The observed deviation of slopes from 1 can be attributed to the presence of diverse transporters in natural membranes, which, despite experimental efforts to minimize their contribution, may not be completely eliminated. The presence of influx and efflux transporters would increase the uptake of low-permeable polar molecules and decrease the inward translocation (by promoting the outward efflux) of highly permeable hydrophobic molecules. The linear regression models for BBB and Caco-2/MDCK data were the following:

$$\log P^{BBB}_{0exp} = 0.43\log P^{PM}_{calc} - 2.08 \quad (19)$$

$$\log P^{Caco-2/MDCK}_{0exp} = 0.32\log P^{PM}_{0calc} - 2.89 \quad (20)$$

Using eqs 19 and 20 for scaling calculated data to experimental data to get linear regression line with a = 0 and b = 1 produced the rmse values of 0.87 log units for BBB data and 0.89 log units for Caco-2/MCDK data (Figures 6C, D and S6C, D).

Hence, the resulting equations to relate the integrals over transfer energy profiles (log P^{BLM}_{Σ}) for the neutral forms and calculated intrinsic permeability coefficients (log P_{0calc}) through PAMPA-DS, BBB, and Caco-2/MDCK membranes were the following (Figures 6 and S6):

$$\log P^{PAMPA-DS}_{0calc} = 0.981\log P^{BLM}_{\Sigma} + 2.159 \quad (21)$$

$$\log P^{BBB}_{0calc} = 0.375\log P^{BLM}_{\Sigma} - 1.600 \quad (22)$$

$$\log P^{Caco-2/MDCK}_{0calc} = 0.272\log P^{BLM}_{\Sigma} - 2.541 \quad (23)$$

Equations 15 and 21 can be also applied to predict membrane permeability coefficients through artificial membranes of compounds ionized in water. In this case, the corresponding integrals of transbilayer energy profiles (log $P^{BLM}_{m\Sigma}$) will account for contribution from deionization penalty for ionizable group(s) with specified pK_a at indicated pH. Indeed, membrane permeability coefficients for ionized compounds were satisfactory reproduced for artificial bilayers, BLM and liposomes (Figures 2, S4, and S5), and the PAMPA-DS system (Figure S8). In the latter case, a reasonably good prediction of PAMPA-DS log P_{mexp} values at pH 6.5 and 7.4 (with rmse of 1.77 and 1.69 log units; R^2 of 0.58 and 0.69, respectively) was obtained for weak acids and bases from Avdeef's data set[15] (Table S6), excluding zwitterions.

To predict membrane permeability coefficients of ionized compounds through the BBB membranes, the following equation was obtained:

$$\log P^{BBB}_{m-7.4calc} = 0.229\log P^{BLM}_{m} - 0.830 \quad (24)$$

The accuracy of the prediction of BBB membrane permeability coefficients (log P^{BBB}_{PSexp}) using eq 24 was moderate (rmse of 0.65 log units; R^2 of 0.60) for the set of 79 bases and 23 acids from the Avdeef's database.[16]

Finally, we assessed the ability of PerMM to distinguish compounds able to cross BBB by passive diffusion (BBB+) from BBB-impermeable molecules (BBB−). We analyzed the range of permeability coefficients for both types of compounds (Figure S9) and found that the predicted intrinsic permeability coefficients of BBB-impermeable compounds were less than −4.35 log units.

Thus, the compounds with higher permeability coefficients (log $P^{BBB}_{0calc} \geq -4.35$) are expected to cross the BBB and serve as central nervous system-active agents, unless they are substrates for efflux transporters, such as P-glycoprotein or other ABC transporters.

Equations 7 and 13−15 were included in our PerMM program and the web server for prediction of permeability coefficients of organic chemicals and drug-like molecules through different membrane systems based on integration of transfer energy profiles over the permeation pathway. Using these equations, PerMM reproduced experimental permeability coefficients in different systems well: BLM and liposomes (78 compounds, R^2 = 0.88, rmse = 1.15 log units), PAMPA-DS assay (280 compounds, R^2 = 0.75, rmse = 1.59 log units), Caco-2/MDCK assays (165 compounds, R^2 = 0.52, rmse = 0.89 log units), and *in situ* brain perfusion experiments (182 compounds, R^2 = 0.69, rmse = 0.87 log units) (Figure 6).

Comparison of PerMM with Other Computational Methods. To assess the utility and the predictive power of the PerMM method, we compared it with other computational methods, in particular, with the physics-based methods recently developed by Leung et al.[32] and Brocke et al. (implemented in the MemDrugPerm web server).[68] These methods were applied for the relatively large and structurally diverse sets of compounds, many of which were also calculated by PerMM. We also compared results of calculations by PerMM, with predictions by the QSPR-based QikProp method (Schrödinger) and by the machine learning algorithm developed by Brocke et al.[68] as an alternative approach to MemDrugPerm. Comparison of performances of these methods is shown in Figures S10 and S11. We evaluated the intrinsic permeability coefficients of compounds that were common for our and other data sets against the experimental intrinsic log P_{0exp} values compiled for PAMPA-DS and Caco-2 assays by Avdeef,[15,17] rather than against diverse data sets obtained by various authors in dissimilar experimental conditions.

We founds that PerMM outperformed both physics-based methods with respect to R^2 and rmse values and demonstrated better accuracy than the statistically based QikProt method and the machine learning algorithm. For the set of 58 common compounds, PerMM predicted PAMPA-DS permeability coefficients with R^2 of 0.67 and rmse of 1.51 log units, while the HDGB and DHDGB models of Brocke et al. demonstrated

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

rmse of 1.99 and 1.73 log units and R^2 of 0.50 and 0.49, respectively (Figure S10A, C, D). Results of the machine learning algorithm were less impressive with R^2 of 0.40 and rmse of 2.28 log units, though rmse decreased to 1.68 log units after scaling the calculated values to the experimental values to get a linear regression line with $a = 0$, $b = 1$ (Figure S10B). Importantly, the slopes (b) of the regression lines were rather close to 1 for PerMM and the HDGB model but smaller for the DHDGB model ($b = 0.66$) and much smaller for the machine learning algorithm ($b = 0.23$), while intercepts increased from 0 for PerMM to ~0.5 for both HDGB and DHDGB models and to ~4 for the machine learning approach. Scaling the calculated values to experimental values for HDGB and DHGB models did not improve rsme values (Figure S10C and D).

The performance of the method by Leung et al. for the prediction of PAMPA-DS permeability was also moderate. The scatter plot of predicted vs experimental data for 73 compounds was fitted by the regression line with R^2 of 0.38, b of 1.31, and a of −9.12. The significant intercept value was likely due to the extremely low permeability coefficients predicted by Leung's model (in the range from −28 to −4 log units) (Figure S11C). For the same set of compounds, the accuracy of PerMM predictions was much better: the linear regression line had R^2 of 0.68, b close to 1, and a close to 0 (Figure S10A). The accuracy of the Leung's and QikProp methods for prediction of Caco-2 permeability for 44 compounds was also lower than that of PerMM: R^2 values were of 0.30, 0.27, and 0.59, respectively (Figure S11B, D, and F).

DISCUSSION

In this study, we developed a novel physics-based computational method PerMM for predicting passive membrane permeation of structurally diverse molecules through the phospholipid bilayer. In addition to estimating the permeability coefficients, this method provides visualization of the transmembrane translocation pathway for a compound of interest. By describing the thermodynamics of membrane-solute interactions, such an approach helps to understand the mechanisms of permeability of drug candidates, which may assist in optimization of their ADME properties.

Our data set included nonpolar and polar nonelectrolytes and weak electrolytes. According to results of our calculations, the ionized species of weak acids and bases become uncharged in the lipid carbonyl region and cross the lipid bilayer in the neutral form. Consistent with experimental studies,[4] we found that the permeability barriers are located in the hydrophobic domain of the lipid bilayer but not outside this region.

To verify the method, we compared the results of our calculations for the DOPC bilayer with permeability coefficients measured in unilamellar phospholipid bilayers (Figures 2 and S4). This comparison covered a wide range of log P_0 values (from −12 to +2) and produced R^2 of 0.88 and the slope b close to 1 (Figure 2 A), as expected. A comparison of experimental and calculated permeability coefficient through BBB and Caco-2/MDCK cells demonstrated a smaller slope (b of 0.43 and 0.32, respectively) and lower R^2 values (0.69 and 0.52, respectively) (Figure 5). Although these correlations can be used for evaluation of permeability of BBB and Caco-2/MDCK systems, the prediction accuracy is lower than that for model phospholipid bilayers (Figures 2 and 6C, D).

We assume that the observed permeability differences between artificial and natural membrane systems could be due to the presence of the facilitated molecular transport in biological membranes. To reduce the effect of transporters, a significant effort was made by Avdeef in collecting "efflux-minimized" BBB permeability data[16] and including Caco-2/MDCK data that represent the averages of apical-to-basolateral and basolateral-to-apical measurements canceling out some of carrier-mediated contributions.[17] Nevertheless, the efflux and influx effects can still be present or not completely eliminated for a number of permeants due to the presence of multiple transporters. In fact, the vast majority of drugs included in our data set can interact with a variety of influx and efflux transporters[8] (see pages for individual molecules in the PerMM database). The possible effect of influx transporters is expected to result in a higher permeability of polar permeants than that predicted from passive diffusion. The possible effect of efflux transporters would decrease the measured permeability of highly hydrophobic permeants relative to predictions based on passive diffusion. Thus, both effects would results in the observed slope $b < 1$ of the linear regression fits for BBB and Caco-2/MDCK data (in addition to possible scattering), as we actually observed (Figure 5).

Similar to other physics-based methods, PerMM operates with atomic structures of molecules moving across the lipid bilayer and uses the solubility-diffusion framework for estimating the molecular permeability. However, our and other methods employ different approaches for calculating the free energy change of barrier crossing and the corresponding permeability coefficients of permeants. For example, Leung et al.[32] represent the lipid bilayer as an implicit organic solvent and calculate the solvation energy difference between global minimum conformations evaluated in water and chloroform. Brocke et al.[68] describe the implicit membrane by varying dielectric profiles along the membrane normal, based on either standard HDGB or dynamic (D)HDGB models, and calculates membrane insertion energy profiles and their integrals to derive permeability coefficients. The PerMM method uses a general anisotropic solvent representation of the lipid bilayer that has been previously developed and extensively tested to study spatial positioning in membranes of peptides, proteins, and small molecules.[63,71,72] Furthermore, similar to Brocke's method, PerMM calculates permeability coefficients by integration over transfer energy profiles instead of using a simple barrier approximation as in the Leung method.

There are other methodological differences between these methods, including treatment of conformational flexibility of permeants and calculation of their diffusivity in membranes. For better computational efficiency, PerMM utilizes precalculated structures of permeants, similar to that in Brocke's method.[68] To account for the conformational dynamics, we use a limited set of structurally diverse conformations for flexible molecules, instead of performing the more exhaustive conformational sampling proposed by Leung et al.[32] We found that including conformational flexibility only slightly improves the permeability coefficients of conformationally flexible molecules but does not significantly affect the overall accuracy of permeability predictions (Figures S2 and S4). Similar to other methods, we consider the size-dependence of permeant diffusion in membranes. However, instead of diffusivity profiles along the membrane normal, we assume a constant diffusivity of a solute throughout the membrane. This is a reasonable

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

approximation, because the exact shape of $D(z)$ was shown not to be important for permeability prediction.[68]

As described in Results, PerMM demonstrated better performance than two other recently developed physics-based methods, as well as the machine learning algorithm by Brocke et al. and the regression-based QikProp method. We found that PerMM outperformed these methods in terms of R^2 and rmse for prediction of PAMPA or Caco-2 permeability coefficients for relatively large data sets (Figures S10 and S11). The MemDrugPerm method[68] showed the closest accuracy to PerMM against PAMPA data.

The advantages of our approach are likely due to the better parametrization of atomic solvation (σ) and dipolar (η) parameters for different chemical groups in our universal solvation model, as described in our previous publication[65] and to the use of dielectric and hydrogen bonding parameter profiles for the DOPC bilayer in the PPM method.[63] The correct evaluation of the solvation energy in the heterogeneous environment is critical, because permeability depends exponentially of this energy.

It is of note that PerMM has broad applicability: it allows quantitative calculation of permeability coefficients in different membrane systems, including BLM, PAMPA, Caco-2/MDCK cells, and the BBB. It demonstrated the best accuracy (R^2 = 0.88, rmse of 1.15 log units) for pure lecithin-based unilamellar membranes. This was expected because the method implements the dielectric and polarity parameters of the DOPC bilayer. PerMM also showed a reasonably good performance in predicting BBB and Caco-2/MDCK permeability coefficients with accuracy within 1 log unit (rmse of 0.87 and 0.87 log units, respectively), even though the permeability of a number of compounds in such systems could be affected by the active efflux and influx and carrier-facilitated transport, in addition to passive diffusion. Our results suggest that plasma membranes of Caco-2/MDCK and the BBB cellular systems are less permeable than the lecithin-based bilayers or DOPC by ~1.8 log P_0 units, probably due to the presence of cholesterol and sphingomyelin.

The PerMM method properly reproduced experimental permeability coefficients for a large set of 506 compounds, which differed in sizes, structural scaffolds, and chemical classes. This demonstrates the transferability of our approach, similar to other physics-based methods. Importantly, the PerMM allows predicting the absolute values of intrinsic permeability coefficients, especially for the phospholipid bilayers, rather than the relative permeability data for a series of compounds, as is customary in other methods. We also found that correlations between calculated and experimental permeability coefficients for molecules from different charge classes (acids, bases, neutral molecules) can be described by the same regression line, as should be expected for calculations with any physics-based model.

In summary, the PerMM method can be useful for prediction of intrinsic permeability coefficients through lipid membranes of a wide spectrum of drug candidates, including natural product-derived compounds with large molecular weight. However, our method is still approximate, as it employs the flat diffusion coefficient profiles across the membrane, does not account for the mechanical properties and the lipid composition of membranes, especially in the headgroup region, and does not include effects of dipole and surface membrane potentials, as well as the influence of permeants on properties of the lipid bilayer. We envision addressing these issues in the future, which may improve the method's accuracy. To facilitate practical use of our method by the scientific community, we have implemented it as a publicly available web server with a supplementary database, as described in the accompanying paper.[97]

■ ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website at DOI: 10.1021/acs.jcim.9b00224.

Experimental data sets, results of PerMM calculations, illustrations of technical details, Figures S1−S10, and Tables S1−S9 (PDF)

■ AUTHOR INFORMATION

Corresponding Author

*Email: almz@umich.edu. Phone: +1(734) 615-7194.

ORCID

Andrei L. Lomize: 0000-0002-3044-7597

Author Contributions

†These authors contributed equally.

Funding

NIH R21DA040752 and NSF DBI-1458002 (to A.L.L. and I.D.P.).

Notes

The authors declare no competing financial interest.

■ ACKNOWLEDGMENTS

We are grateful to Dr. Avdeef for the provided sets of membrane binding and permeability data of drugs and numerous organic molecules that were experimentally obtained in PAMPA, BBB, and Caco-2/MDCK assays. We are thankful to Dr. Mosberg for helpful discussions and comments.

■ ABBREVIATIONS

ADME, absorption, distribution, metabolism, and excretion; ABNR, adopted basis Newton−Raphson; ASA, accessible surface area; BBB, blood−brain barrier; BLM, black lipid membranes; Caco-2, colon adenocarcinoma cell line; CG/MD, coarse-grained molecular dynamics; CHARMm, chemistry at Harvard molecular mechanics; DHDGB, dynamic heterogeneous dielectric generalized Born; DOPC, dioleoylphosphatidylcholine; FDA, Food and Drug Administration; HDGB, heterogeneous dielectric generalized Born; MD, molecular dynamics; MDCK, Madin−Darby canine kidney cell line; NP, natural product; PAMPA, parallel artificial membrane permeability assay; PAMPA-DS, PAMPA double-sink; PC, phosphatidylcholine; PDB, Protein Data Bank; PPM, positioning of proteins in membranes; QSAR, quantitative structure−activity relationship; QSPR, quantitative structure−permeability relationship; rmse, root-mean-square error.

■ REFERENCES

(1) Smith, D.; Artursson, P.; Avdeef, A.; Di, L.; Ecker, G. F.; Faller, B.; Houston, J. B.; Kansy, M.; Kerns, E. H.; Kramer, S. D.; Lennernas, H.; van de Waterbeemd, H.; Sugano, K.; Testa, B. Passive Lipoidal Diffusion and Carrier-Mediated Cell Uptake are Both Important Mechanisms of Membrane Permeation in Drug Disposition. *Mol. Pharmaceutics* **2014**, *11*, 1727−1738.

(2) Al-Awqati, Q. One Hundred Years of Membrane Permeability: Does Overton Still Rule? *Nat. Cell Biol.* **1999**, *1*, E201.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

(3) Missner, A.; Pohl, P. 110 Years of the Meyer-Overton Rule: Predicting Membrane Permeability of Gases and Other Small Compounds. *ChemPhysChem* **2009**, *10*, 1405−1414.
(4) Xiang, T. X.; Xu, Y. H.; Anderson, B. D. The Barrier Domain for Solute Permeation Varies with Lipid Bilayer Phase Structure. *J. Membr. Biol.* **1998**, *165*, 77−90.
(5) Diamond, J. M.; Katz, Y. Interpretation of Nonelectrolyte Partition Coefficients Between Dimyristoyl Lecithin and Water. *J. Membr. Biol.* **1974**, *17*, 121−154.
(6) Xiang, T. X.; Anderson, B. D. The Relationship Between Permeant Size and Permeability in Lipid Bilayer Membranes. *J. Membr. Biol.* **1994**, *140*, 111−122.
(7) Kramer, S. D.; Aschmann, H. E.; Hatibovic, M.; Hermann, K. F.; Neuhaus, C. S.; Brunner, C.; Belli, S. When Barriers Ignore the "Rule-of-Five". *Adv. Drug Delivery Rev.* **2016**, *101*, 62−74.
(8) Kell, D. B.; Oliver, S. G. How Drugs Get Into Cells: Tested and Testable Predictions to Help Discriminate Between Transporter-Mediated Uptake and Lipoidal Bilayer Diffusion. *Front. Pharmacol.* **2014**, *5*, 231.
(9) Mikitsh, J. L.; Chacko, A.-M. Pathways for Small Molecule Delivery to the Central Nervous System Across the Blood-Brain Barrier. *Perspect. Medicin. Chem.* **2014**, *6*, 11−24.
(10) Sugano, K.; Kansy, M.; Artursson, P.; Avdeef, A.; Bendels, S.; Di, L.; Ecker, G. F.; Faller, B.; Fischer, H.; Gerebtzoff, G.; Lennernaes, H.; Senner, F. Coexistence of Passive and Carrier-Mediated Processes in Drug Transport. *Nat. Rev. Drug Discovery* **2010**, *9*, 597−614.
(11) Di, L.; Artursson, P.; Avdeef, A.; Ecker, G. F.; Faller, B.; Fischer, H.; Houston, J. B.; Kansy, M.; Kerns, E. H.; Kramer, S. D.; Lennernas, H.; Sugano, K. Evidence-Based Approach to Assess Passive Diffusion and Carrier-Mediated Drug Transport. *Drug Discovery Today* **2012**, *17*, 905−912.
(12) Kell, D. B.; Dobson, P. D.; Oliver, S. G. Pharmaceutical Drug Transport: the Issues and the Implications That It Is Essentially Carrier-Mediated Only. *Drug Discovery Today* **2011**, *16*, 704−714.
(13) Kell, D. B. What Would Be the Observable Consequences if Phospholipid Bilayer Diffusion of Drugs into Cells is Negligible? *Trends Pharmacol. Sci.* **2015**, *36*, 15−21.
(14) Kramer, S. D. Quantitative Aspects of Drug Permeation Across in Vitro and in Vivo Barriers. *Eur. J. Pharm. Sci.* **2016**, *87*, 30−46.
(15) Avdeef, A. Permeability—PAMPA. In *Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 319−498.
(16) Avdeef, A. Permeability: Blood−Brain Barrier. *In Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 575−680.
(17) Avdeef, A. Permeability: Caco-2/MDCK. *In Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 499−574.
(18) Lipinski, C. A. Rule of Five in 2015 and Beyond: Target and Ligand Structural Limitations, Ligand Chemistry Structure and Drug Discovery Project Decisions. *Adv. Drug Delivery Rev.* **2016**, *101*, 34−41.
(19) Bickerton, G. R.; Paolini, G. V.; Besnard, J.; Muresan, S.; Hopkins, A. L. Quantifying the Chemical Beauty of Drugs. *Nat. Chem.* **2012**, *4*, 90−98.
(20) Andrade, C. H.; Pasqualoto, K. F.; Ferreira, E. I.; Hopfinger, A. J. 4D-QSAR: Perspectives in Drug Design. *Molecules* **2010**, *15*, 3281−3294.
(21) Cherkasov, A.; Muratov, E. N.; Fourches, D.; Varnek, A.; Baskin, I. I.; Cronin, M.; Dearden, J.; Gramatica, P.; Martin, Y. C.; Todeschini, R.; Consonni, V.; Kuz'min, V. E.; Cramer, R.; Benigni, R.; Yang, C.; Rathman, J.; Terfloth, L.; Gasteiger, J.; Richard, A.; Tropsha, A. QSAR Modeling: Where Have You Been? Where Are You Going To? *J. Med. Chem.* **2014**, *57*, 4977−5010.
(22) Damale, M. G.; Harke, S. N.; Kalam Khan, F. A.; Shinde, D. B.; Sangshetti, J. N. Recent Advances in Multidimensional QSAR (4D-6D): a Critical Review. *Mini-Rev. Med. Chem.* **2014**, *14*, 35−55.
(23) Tropsha, A. Best Practices for QSAR Model Development, Validation, and Exploitation. *Mol. Inf.* **2010**, *29*, 476−488.
(24) Fujikawa, M.; Ano, R.; Nakao, K.; Shimizu, R.; Akamatsu, M. Relationships Between Structure and High-Throughput Screening Permeability of Diverse Drugs with Artificial Membranes: Application to Prediction of Caco-2 Cell Permeability. *Bioorg. Med. Chem.* **2005**, *13*, 4721−4732.
(25) Liu, J.; Li, Y.; Pan, D.; Hopfinger, A. J. Predicting Permeability Coefficient in ADMET Evaluation by Using Different Membranes-Interaction QSAR. *Int. J. Pharm.* **2005**, *304*, 115−123.
(26) Nitsche, J. M.; Kasting, G. B. A Correlation for 1,9-Decadiene/Water Partition Coefficients. *J. Pharm. Sci.* **2013**, *102*, 136−144.
(27) Nitsche, J. M.; Kasting, G. B. Permeability of Fluid-Phase Phospholipid Bilayers: Assessment and Useful Correlations for Permeability Screening and Other Applications. *J. Pharm. Sci.* **2013**, *102*, 2005−2032.
(28) Nitsche, J. M.; Kasting, G. B. A Universal Correlation Predicts Permeability Coefficients of Fluid- and Gel-Phase Phospholipid and Phospholipid-Cholesterol Bilayers for Arbitrary Solutes. *J. Pharm. Sci.* **2016**, *105*, 1762−1771.
(29) Stratton, C. F.; Newman, D. J.; Tan, D. S. Cheminformatic Comparison of Approved Drugs from Natural Product Versus Synthetic Origins. *Bioorg. Med. Chem. Lett.* **2015**, *25*, 4802−4807.
(30) Faller, B.; Ottaviani, G.; Ertl, P.; Berellini, G.; Collis, A. Evolution of the Physicochemical Properties of Marketed Drugs: Can History Foretell the Future? *Drug Discovery Today* **2011**, *16*, 976−984.
(31) Shinoda, W. Permeability Across Lipid Membranes. *Biochim. Biophys. Acta, Biomembr.* **2016**, *1858*, 2254−2265.
(32) Leung, S. S.; Mijalkovic, J.; Borrelli, K.; Jacobson, M. P. Testing Physical Models of Passive Membrane Permeation. *J. Chem. Inf. Model.* **2012**, *52*, 1621−1636.
(33) Rezai, T.; Bock, J. E.; Zhou, M. V.; Kalyanaraman, C.; Lokey, R. S.; Jacobson, M. P. Conformational Flexibility, Internal Hydrogen Bonding, and Passive Membrane Permeability: Successful in Silico Prediction of the Relative Permeabilities of Cyclic Peptides. *J. Am. Chem. Soc.* **2006**, *128*, 14073−14080.
(34) Awoonor-Williams, E.; Rowley, C. N. Molecular Simulation of Nonfacilitated Membrane Permeation. *Biochim. Biophys. Acta, Biomembr.* **2016**, *1858*, 1672−1687.
(35) Bemporad, D.; Essex, J. W.; Luttmann, C. Permeation of Small Molecules Through a Lipid Bilayer: a Computer Simulation Study. *J. Phys. Chem. B* **2004**, *108*, 4875−4884.
(36) Xiang, T. X.; Anderson, B. D. Liposomal Drug Transport: a Molecular Perspective from Molecular Dynamics Simulations in Lipid Bilayers. *Adv. Drug Delivery Rev.* **2006**, *58*, 1357−1378.
(37) Lee, C. T.; Comer, J.; Herndon, C.; Leung, N.; Pavlova, A.; Swift, R. V.; Tung, C.; Rowley, C. N.; Amaro, R. E.; Chipot, C.; Wang, Y.; Gumbart, J. C. Simulation-Based Approaches for Determining Membrane Permeability of Small Compounds. *J. Chem. Inf. Model.* **2016**, *56*, 721−733.
(38) Comer, J.; Schulten, K.; Chipot, C. Permeability of a Fluid Lipid Bilayer to Short-Chain Alcohols from First Principles. *J. Chem. Theory Comput.* **2017**, *13*, 2523−2532.
(39) Zocher, F.; van der Spoel, D.; Pohl, P.; Hub, J. S. Local Partition Coefficients Govern Solute Permeability of Cholesterol-Containing Membranes. *Biophys. J.* **2013**, *105*, 2760−2770.
(40) Sun, R.; Han, Y.; Swanson, J. M. J.; Tan, J. S.; Rose, J. P.; Voth, G. A. Molecular Transport Through Membranes: Accurate Permeability Coefficients from Multidimensional Potentials of Mean Force and Local Diffusion Constants. *J. Chem. Phys.* **2018**, *149*, 072310.
(41) Palaiokostas, M.; Ding, W.; Shahane, G.; Orsi, M. Effects of Lipid Composition on Membrane Permeation. *Soft Matter* **2018**, *14*, 8496−8508.
(42) Orsi, M.; Sanderson, W. E.; Essex, J. W. Permeability of Small Molecules Through a Lipid Bilayer: a Multiscale Simulation Study. *J. Phys. Chem. B* **2009**, *113*, 12019−12029.
(43) Dickson, C. J.; Hornak, V.; Pearlstein, R. A.; Duca, J. S. Structure-Kinetic Relationships of Passive Membrane Permeation from Multiscale Modeling. *J. Am. Chem. Soc.* **2017**, *139*, 442−452.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

(44) Ghaemi, Z.; Minozzi, M.; Carloni, P.; Laio, A. A Novel Approach to the Investigation of Passive Molecular Permeation Through Lipid Bilayers from Atomistic Simulations. *J. Phys. Chem. B* **2012**, *116*, 8714−8721.
(45) Votapka, L. W.; Lee, C. T.; Amaro, R. E. Two Telations to Estimate Membrane Permeability Using Milestoning. *J. Phys. Chem. B* **2016**, *120*, 8606−8616.
(46) Cardenas, A. E.; Jas, G. S.; DeLeon, K. Y.; Hegefeld, W. A.; Kuczera, K.; Elber, R. Unassisted Transport of N-Acetyl-L-Tryptophanamide Through Membrane: Experiment and Simulation of Kinetics. *J. Phys. Chem. B* **2012**, *116*, 2739−2750.
(47) Tejwani, R. W.; Davis, M. E.; Anderson, B. D.; Stouch, T. R. An Atomic and Molecular View of the Depth Dependence of the Free Energies of Solute Transfer from Water into Lipid Bilayers. *Mol. Pharmaceutics* **2011**, *8*, 2204−2215.
(48) Carpenter, T. S.; Kirshner, D. A.; Lau, E. Y.; Wong, S. E.; Nilmeier, J. P.; Lightstone, F. C. A Method to Predict Blood-Brain Barrier Permeability of Drug-Like Compounds Using Molecular Dynamics Simulations. *Biophys. J.* **2014**, *107*, 630−641.
(49) Wang, Y.; Gallagher, E.; Jorgensen, C.; Troendle, E. P.; Hu, D.; Searson, P. C.; Ulmschneider, M. B. An Experimentally Validated Approach to Calculate the Blood-Brain Barrier Permeability of Small Molecules. *Sci. Rep.* **2019**, *9*, 6117.
(50) Shivakumar, D.; Deng, Y.; Roux, B. Computations of Absolute Solvation Free Energies of Small Molecules Using Explicit and Implicit Solvent Model. *J. Chem. Theory Comput.* **2009**, *5*, 919−930.
(51) Roux, B.; Simonson, T. Implicit Solvent Models. *Biophys. Chem.* **1999**, *78*, 1−20.
(52) Feig, M.; Brooks, C. L., 3rd Recent Advances In the Development and Application of Implicit Solvent Models in Biomolecule Simulations. *Curr. Opin. Struct. Biol.* **2004**, *14*, 217−224.
(53) Oren, I.; Fleishman, S. J.; Kessel, A.; Ben-Tal, N. Free Diffusion of Steroid Hormones Across Biomembranes: a Simplex Search with Implicit Solvent Model Calculations. *Biophys. J.* **2004**, *87*, 768−779.
(54) Cramer, C. J.; Truhlar, D. G. Implicit Solvation Models: Equilibria, Structure, Spectra, and Dynamics. *Chem. Rev.* **1999**, *99*, 2161−2200.
(55) Cramer, C. J.; Truhlar, D. G. A Universal Approach to Solvation Modeling. *Acc. Chem. Res.* **2008**, *41*, 760−768.
(56) Hornig, M.; Klamt, A. COSMOfrag: a Novel Tool for High-Throughput ADME Property Prediction and Similarity Screening Based on Quantum Chemistry. *J. Chem. Inf. Model.* **2005**, *45*, 1169−1177.
(57) Klamt, A.; Huniar, U.; Spycher, S.; Keldenich, J. COSMOmic: a Mechanistic Approach to the Calculation of Membrane-Water Partition Coefficients and Internal Distributions within Membranes and Micelles. *J. Phys. Chem. B* **2008**, *112*, 12148−12157.
(58) Wittekindt, C.; Klamt, A. COSMO-RS as a Predictive Tool for Lipophilicity. *QSAR Comb. Sci.* **2009**, *28*, 874−877.
(59) Klamt, A.; Eckert, F.; Arlt, W. COSMO-RS: an Alternative to Simulation for Calculating Thermodynamic Properties of Liquid Mixtures. *Annu. Rev. Chem. Biomol. Eng.* **2010**, *1*, 101−122.
(60) Jakobtorweihen, S.; Zuniga, A. C.; Ingram, T.; Gerlach, T.; Keil, F. J.; Smirnova, I. Predicting Solute Partitioning in Lipid Bilayers: Free Energies and Partition Coefficients from Molecular Dynamics Simulations and COSMOmic. *J. Chem. Phys.* **2014**, *141*, 045102.
(61) Ebert, A.; Hannesschlaeger, C.; Goss, K. U.; Pohl, P. Passive Permeability of Planar Lipid Bilayers to Organic Anions. *Biophys. J.* **2018**, *115*, 1931−1941.
(62) Parisio, G.; Ferrarini, A. Solute Partitioning into Lipid Bilayers: an Implicit Model for Nonuniform and Ordered Environment. *J. Chem. Theory Comput.* **2010**, *6*, 2267−2280.
(63) Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. Anisotropic Solvent Model of the Lipid Bilayer. 2. Energetics of Insertion of Small Molecules, Peptides, and Proteins in Membranes. *J. Chem. Inf. Model.* **2011**, *51*, 930−946.
(64) Chambers, C. C.; Giesen, D. J.; Hawkins, G. D.; Cramer, C. J.; Truhlar, D. G.; Vaes, W. H. J. Modeling the Effect of Solvation on Structure, Reactivity, and Partitioning of Organic Solutes: Utility in Drug Design. In *Rational Drug Design*; Truhlar, D. G., Howe, W. J., Hopfinger, A. J., Blaney, J., Dammkoehler, R. A., Eds.; Springer: New York, NY, 1999; Vol. *108*, pp 51−72.
(65) Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. Anisotropic Solvent Model of the Lipid Bilayer. 1. Parameterization of Long-Range Electrostatics and First Solvation Shell Effects. *J. Chem. Inf. Model.* **2011**, *51*, 918−929.
(66) Swift, R. V.; Amaro, R. E. Modeling the Pharmacodynamics of Passive Membrane Permeability. *J. Comput.-Aided Mol. Des.* **2011**, *25*, 1007−1017.
(67) Swift, R. V.; Amaro, R. E. Back to the Future: Can Physical Models of Passive Membrane Permeability Help Reduce Drug Candidate Attrition and Move Us Beyond QSPR? *Chem. Biol. Drug Des.* **2013**, *81*, 61−71.
(68) Brocke, S. A.; Degen, A.; MacKerell, A. D.; Dutagaci, B.; Feig, M. Prediction of Membrane Permeation of Drug Molecules by Combining an Implicit Membrane Model with Machine Learning. *J. Chem. Inf. Model.* **2019**, *59*, 1147−1162.
(69) Parisio, G.; Stocchero, M.; Ferrarini, A. Passive Membrane Permeability: Beyond the Standard Solubility-Diffusion Model. *J. Chem. Theory Comput.* **2013**, *9*, 5236−5246.
(70) Lomize, A. L.; Pogozheva, I. D. Prediction of Passive Membrane Permeability and Translocation Pathways of Biologically Active Molecules. *Biophys. J.* **2017**, *112*, 525a.
(71) Lomize, A. L.; Pogozheva, I. D.; Lomize, M. A.; Mosberg, H. I. Positioning of Proteins in Membranes: a Computational Approach. *Protein Sci.* **2006**, *15*, 1318−1333.
(72) Lomize, A. L.; Pogozheva, I. D.; Lomize, M. A.; Mosberg, H. I. The Role of Hydrophobic Interactions in Positioning of Peripheral Proteins in Membranes. *BMC Struct. Biol.* **2007**, *7*, 44.
(73) Xiang, T. X.; Anderson, B. D. Influence of Chain Ordering on the Selectivity of Dipalmitoylphosphatidylcholine Bilayer Membranes for Permeant Size and Shape. *Biophys. J.* **1998**, *75*, 2658−2671.
(74) Marrink, S. J.; Berendsen, H. J. C. Permeation Process of Small Molecules Across Lipid Membranes Studied by Molecular Dynamics Simulations. *J. Phys. Chem.* **1996**, *100*, 16729−16738.
(75) Bemporad, D.; Luttmann, C.; Essex, J. W. Computer Simulation of Small Molecule Permeation Across a Lipid Bilayer: Dependence on Bilayer Properties and Solute Volume, Size, and Cross-Sectional Area. *Biophys. J.* **2004**, *87*, 1−13.
(76) Abe, T. A Modification of the Born Equation. *J. Phys. Chem.* **1986**, *90*, 713−715.
(77) Block, H.; Walker, S. M. Modification of Onsager Theory for a Dielectric. *Chem. Phys. Lett.* **1973**, *19*, 363−364.
(78) Pogozheva, I. D.; Tristram-Nagle, S.; Mosberg, H. I.; Lomize, A. L. Structural Adaptations of Proteins to Different Biological Membranes. *Biochim. Biophys. Acta, Biomembr.* **2013**, *1828*, 2592−2608.
(79) Kučerka, N.; Nagle, J. F.; Sachs, J. N.; Feller, S. E.; Pencer, J.; Jackson, A.; Katsaras, J. Lipid Bilayer Structure Determined by the Simultaneous Analysis of Neutron and X-Ray Scattering Data. *Biophys. J.* **2008**, *95*, 2356−2367.
(80) Lien, E. J.; Guo, Z. R.; Li, R. L.; Su, C. T. Use of Dipole-Moment as a Parameter in Drug Receptor Interaction and Quantitative Structure Activity Relationship Studies. *J. Pharm. Sci.* **1982**, *71*, 641−655.
(81) Li, W. Y.; Guo, Z. R.; Lien, E. J. Examination of the Interrelationship Between Aliphatic Group Dipole-Moment and Polar Substituent Constants. *J. Pharm. Sci.* **1984**, *73*, 553−558.
(82) Avdeef, A. pKa Determination. *In Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ., 2012; pp 31−173.
(83) Manchester, J.; Walkup, G.; Rivin, O.; You, Z. Evaluation of pKa Estimation Methods on 211 Druglike Compounds. *J. Chem. Inf. Model.* **2010**, *50*, 565−571.
(84) Hickey, A. L.; Rowley, C. N. Benchmarking Quantum Chemical Methods for the Calculation of Molecular Dipole Moments and Polarizabilities. *J. Phys. Chem. A* **2014**, *118*, 3678−3687.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

(85) Hermone, A. R.; Gussio, R. Calculation Methods for the Enhancement of Pharmaceutical Properties in Small Molecules: Estimating the Cationic pKa. *Curr. Pharm. Des.* **2013**, *19*, 4310−4315.
(86) Henkelman, G.; Jóhannesson, G.; Jónsson, H. Methods for Finding Saddle Points and Minimum Energy Paths. In *Theoretical Methods in Condensed Phase Chemistry*; Schwartz, S. D., Ed., Springer Netherlands: Dordrecht, 2002; pp 269−302.
(87) Bolton, E. E.; Chen, J.; Kim, S.; Han, L.; He, S.; Shi, W.; Simonyan, V.; Sun, Y.; Thiessen, P. A.; Wang, J.; Yu, B.; Zhang, J.; Bryant, S. H. PubChem3D: a New Resource for Scientists. *J. Cheminform.* **2011**, *3*, 32.
(88) Burley, S. K.; Berman, H. M.; Kleywegt, G. J.; Markley, J. L.; Nakamura, H.; Velankar, S. Protein Data Bank (PDB): the Single Global Macromolecular Structure Archive. *Methods Mol. Biol.* **2017**, *1607*, 627−641.
(89) Groom, C. R.; Bruno, I. J.; Lightfoot, M. P.; Ward, S. C. The Cambridge Structural Database. *Acta Crystallogr., Sect. B: Struct. Sci., Cryst. Eng. Mater.* **2016**, *72*, 171−179.
(90) Kalyanaraman, C.; Jacobson, M. P. An Atomistic Model of Passive Membrane Permeability: Application to a Series of FDA Approved Drugs. *J. Comput.-Aided Mol. Des.* **2007**, *21*, 675−679.
(91) Cardenas, A. E.; Shrestha, R.; Webb, L. J.; Elber, R. Membrane Permeation of a Peptide: It Is Better to Be Positive. *J. Phys. Chem. B* **2015**, *119*, 6412−6420.
(92) MacCallum, J. L.; Tieleman, D. P. Computer Simulation of the Distribution of Hexane in a Lipid Bilayer: Spatially Resolved Free Energy, Entropy, and Enthalpy Profiles. *J. Am. Chem. Soc.* **2006**, *128*, 125−130.
(93) Tse, C. H.; Comer, J.; Wang, Y.; Chipot, C. Link between Membrane Composition and Permeability to Drugs. *J. Chem. Theory Comput.* **2018**, *14*, 2895−2909.
(94) Hellinger, E.; Veszelka, S.; Toth, A. E.; Walter, F.; Kittel, A.; Bakk, M. L.; Tihanyi, K.; Hada, V.; Nakagawa, S.; Duy, T. D.; Niwa, M.; Deli, M. A.; Vastag, M. Comparison of Brain Capillary Endothelial Cell-Based and Epithelial (MDCK-MDR1, Caco-2, and VB-Caco-2) Cell-Based Surrogate Blood-Brain Barrier Penetration Models. *Eur. J. Pharm. Biopharm.* **2012**, *82*, 340−351.
(95) Finkelstein, A. Water and Nonelectrolyte Permeability of Lipid Bilayer Membranes. *J. Gen. Physiol.* **1976**, *68*, 127−135.
(96) Xiang, T. X.; Chen, J.; Anderson, B. D. A Quantitative Model for the Dependence of Solute Permeability on Peptide and Cholesterol Content in Biomembranes. *J. Membr. Biol.* **2000**, *177*, 137−148.
(97) Lomize, A.; Hage, J. M.; Schnitzer, K.; Golobokov, K.; Lafaive, M. B.; Forsyth, A. C.; Pogozheva, I. D. PerMM: A Web Tool and Database for Analysis of Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules. *J. Chem. Inf. Model.* **2019**, DOI: 10.1021/acs.jcim.9b00225.

DOI: 10.1021/acs.jcim.9b00224
J. Chem. Inf. Model. XXXX, XXX, XXX−XXX

Supporting Information

A Physics-Based Method for Modeling Passive Membrane Permeability and Translocation Pathways of Bioactive Molecules

Andrei L. Lomize‡ and Irina D. Pogozheva‡*

Department of Medicinal Chemistry, College of Pharmacy, University of Michigan, 428 Church St., Ann Arbor, MI 48109-1065

*Corresponding Author: Andrei L. Lomize. Email: almz@umich.edu.

Table of Contents:

FIGURES



Figure S1. **Distributions of chemical groups and polarity profiles in artificial lipid bilayers**. (A) Volume fractions of lipid segments determined by X-ray and neutron scattering for fluid DOPC membrane [1]. (B) Profiles of hydrogen-bonding donor (α) and acceptor (β) capacities, and dipolarity/polarizability parameter (π*) calculated for DOPC bilayers [2]. Abbreviations: "PC", phosphate groups; "CG", carbonyl-glycerol groups; "CH", double-bond region. The acyl chain core region is colored brown; midpolar regin is colored light brown.



Figure S2. Influence of conformational flexibility of cyclosporine A on calculated permeability coefficients and energy profiles. The use of multiple conformers and averaging of their transfer energies improves the calculated permeability coefficient ($\log P^{\mathrm{BLM}}_{0\ calc}$) from -2.26 to -1.63. The program automatically selects the conformer with the lowest energy in every point of the transmembrane trajectory. Left panel illustrates the process of selection of the optimal conformation of a permeant, and right panel shows its translocation pathway across membrane. The conformation "1" (PDB ID: 2rmc) with round shape has the lowest solvation energy in water and at water/membrane interface. The conformation "2" (CSD ID: KERNAU) with elongated ovale shape and four intramolecular H-bonds is energetically preferred in the middle of membrane. The conformation "3" (PDB ID: 1ikf) with round shape is optimal at the distance of 10 to 20 Å from the membrane center. The locations of hydrocarbon core boundaries between acyl chains and head groups of lipids (at ±15 Å-distance from the membrane center) are approximated by planes and shown by dummy atoms.



Figure S3. **Transfer energy profiles along the DOPC bilayer for organic chemicals (A-C) and correlation curve between their experimental and calculated permeability coefficients (D)**. Intrinsic permeability coefficients ($\log P_{0\ exp}^{\mathrm{BLM}}$) for 17 unionized permeants studied in BLM were taken from publication by Walter and Gutknecht (1986). Calculation of intrinsic permeability coefficients ($\log P_{0\ calc}^{\mathrm{BLM}}$) was based on equation (15). Calculations of transbilayer energy profiles were performed by the PerMM web server (https://permm.phar.umich.edu/server) using the "drag" option.



Figure S4. Weak Influence of multiple conformations of flexible compounds on calculated permeability across the lipid bilayer. Correlation between experimental and calculated permeability coefficients across the artificial lipid bilayer (BLM or liposomes): (A) intrinsic permability coefficients for 58 unionized ($\log P_{0\,exp}^{\mathrm{BLM}}$ *vs* $\log P_{\Sigma}^{\mathrm{BLM}}$) and (B) membrane permability coefficients for 20 ionized permeants ($\log P_{\mathrm{m}\,exp}^{\mathrm{BLM}}$ *vs* $\log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}}$). The permeability coefficients were calculated using single (colored black) or multiple (colored red) conformations. The integral $\log P_{\Sigma}^{\mathrm{BLM}}$ values were calculated using equation (6). For the ionized species, the integral $\log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}}$ included deionization penalty of ionizable groups at specified pH.



Figure S5. Prediction of permeability of pure phospholipid bilayers. (**A**) Correlation between calculated and experimental permeability coefficients through BLM and liposomes. The $\log P_{\Sigma}^{\mathrm{BLM}}$ values were calculated using equation (6). For the ionized species, the integral $\log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}}$ accounted for the deionization penalty of ionizable groups at specified pH. Black solid regression line corresponds to the initial set of 78 compounds, purple dashed line corresponds to the extended set of 129 compounds (76 acids shown by red circles, 19 bases shown by blue circles, 26 neutral molecules shown by gray circles, and 8 zwitterions shown by yellow circles), green dashed line corresponds to the extended set 132 compounds with 3 outliers shown by green triangles. Number of molecules "n" is indicated in parenthesis. (**B**) Influence of cholesterol and sphingomyelin on BLM permeability. Experimental permeability coefficients decrease by ~1.9 log units upon addition of cholesterol and sphingomyelin in the lipid bilayer, as follows from measurements by Finkelstein [3] and Xiang et al. [4].



Figure S6. Selection of data sets for permeability calculations. (A) Correlation between experimental intrinsic PAMPA-DS (A), BBB (B) and Caco-2/MDCK (C) permeability coefficients *vs* calculated integral $\log P_{\Sigma}^{\mathrm{BLM}}$ values (eq. 6) for different sets of compounds (*n* is the number of compounds). Colored circles indicate different charge classes of molecules: red for acids, blue for bases, and gray for neutral molecules, yellow for zwitterions; green triangles represent outliers. Number of molecules "n" is indicated in parenthesis. Black solid linear regression lines in all panels indicate models for all compounds without outliers, green dashed lines in panels (A, C, E) corresponds to extended sets of compounds with outliers, but in panels (B, D, F) they correspond to decreased sets of compounds that exclude outliers and zwitterions. The complete data sets without outliers were chosen for testing the PerMM method.



Figure S7. Prediction of permeability coefficients through different membranes. Plot of experimental *vs* calculated permeability coefficients through BLM (A), PAMPA-DS (B), BBB (C), and Caco-2/MDCK cells (D). For BLM, intrinsic permeability coefficeins ($\log P^{\mathrm{BLM}}_{0\ calc}$) were calculated for 108 unionized compounds and membrane permeability coefficients ($\log P^{\mathrm{BLM}}_{\mathrm{m}\ calc}$) for 21 ionized compounds. Intrinsic permeability coefficeins ($\log P_{0\ calc}$) were compared with 322, 199, and 185 experimenat data obtained in PAMPA-DS, BBB, and Caco-2/MDCK assays, respectively. Dashed lines indicate the ideal line and residual line limits with cutoff of |3.2| (A and B) and |2| (C and D). Colored circles indicate different charge classes of molecules: red for acids, blue for bases, gray for neutral molecules, and yellow for zwitterions; green triangles are for outliers. Numbers of molecules of each class are indicated in parenthesis.



Figure S8. Prediction of intrinsic (A) and membrane (B, C) permeability coefficients of organic molecules through PAMPA-DS system. Plots of experimental *vs* calculated PAMPA-DS permeability coefficients of organic molecules in the unionized state ($\log P^{\mathrm{PAMPA-DS}}_{0\,exp}$ *vs* $\log P^{\mathrm{PAMPA-DS}}_{0\,calc}$) (A) and the ionized states at pH 6.5 ($\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-6.5}\,exp}$ *vs* $\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-6.5}\,calc}$) (B) and pH=7.4 ($\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-7.4}\,exp}$ *vs* $\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-7.4}\,calc}$) (C). Dashed lines indicate ideal line and residual line limits with cutoff of |3.2|. Colored circles indicate different charge classes of molecules: red for acids and blue for bases. Numbers of molecules "n" is shown in parenthesis. Experimental intrinsic ($\log P^{\mathrm{PAMPA-DS}}_{0\,exp}$) and membrane permeability coefficients ($\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-pH}\,exp}$) for PAMPA-DS at pH 6.5 and 7.4 were compiled by Avdeef[5].



Figure S9. Prediction of intrinsic BBB permeability of organic molecules. (A) Plot of experimental ($\log P^{\mathrm{BBB}}_{0\ exp}$) *vs* calculated ($\log P^{\mathrm{BBB}}_{0\ calc}$) permeability coefficients of 56 BBB-permeable (BBB+, red circles) and 16 BBB-impermeable (BBB-, blue circles) compounds, excluding zwitterions. BBB-permeable compounds demonstrate permeability higher than the threshold, $\log P^{\mathrm{BBB}}_{0\ calc} = -4.35$. Dashed lines indicate ideal line and residual line limits (cutoff = |1.76|). "Efflux minimized" data for intrinsic BBB permeability coefficients corrected for ionization ($\log P^{\mathrm{BBB}}_{0\ exp}$) obtained by *in situ* rodent brain perfusion, were taken from Table S3, where (+) and (-) symbols indicated BBB+ and BBB- compounds, respectively. Number of molecules "n" is indicated in parenthesis.



Figure S10. Comparison of the accuracy of prediction of PAMPA permebility coefficents by PerMM (A), Machine Learning algorythm (B) and MemDrugPerm (C, D). The predicted permeability coefficients were evaluated against the experimental intrinsic $\log P_{0\,exp}^{\mathrm{PAMPA-DS}}$ values for PAMPA-DS assays compiled by Avdeef[5]. Permeability data for 58 compounds calculated by MemDrugPerm and Machine Learing Algorithm were taken from Table S7 in reference[6]. The rmse* values in parenthesis for panels B, C, and D were obtained after scaling the calculated values to the experimental values to get linear regression line with "*a*"=0, "*b*"=1. Number of molecules "n" is indicated in parenthesis.



Figure S11. Comparison of the accuracy of prediction of PAMPA and Caco-2 permebility coefficents by different computational methods: PerMM (A, B), Leung's model (B, C), and QikProp (E, F). The predicted permeability coefficients were evaluated against the experimental intrinsic permeability coefficients obtained in PAMPA-DS ($\log P_{0\ exp}^{\mathrm{PAMPA-DS}}$) and Caco-2/MDCK ($\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$) assays and compiled by Avdeef [5, 7]. Results of caclulation by Leung's model and QikProp for 73 and 44 compounds, which were also analysed in this study by PerMM, were taken from Table S2 in reference[8]. Number of molecules "n" is indicated in parenthesis.

TABLES

Table S1. Experimental ($\log P_{0\ exp}^{\mathrm{BLM}}$) and calculated ($\log P_{0\ calc}^{\mathrm{BLM}}$) intrinsic permeability coefficients of unionized molecules through artificial lipid membranes (BLM and liposomes).

Compound Name	Group	$\log P_{0\ exp}^{\mathrm{BLM}}$	$\log P_{\Sigma}^{\mathrm{BLM}}$	$\log P_{0\ calc}^{\mathrm{BLM}}$*	Ref.	Experimental Conditions
Main set (58 compounds: 42 acids, 3 bases, 13 neutrals)						
1-Naphthoic acid	Acids	0.36	-3.10	0.37	[9]	BLM, eggPC, 25°C
2-Naphthoic acid	Acids	1.23	-3.07	0.40	[9]	BLM, eggPC, 25°C
4-Carboxymethylphenyl acetyl_NHMe	Acids	-4.47	-6.60	-3.35	[10]	LUV, DOPC:DOPA=96:4, 25°C
4-Carboxymethylphenyl acetyl-Gly-NMe2	Acids	-5.80	-7.74	-4.56	[10]	LUV, DOPC:DOPA=96:4, 25°C
4-Carboxymethylphenyl acetyl-NMe2	Acids	-3.48	-6.44	-3.18	[10]	LUV, DOPC:DOPA=96:4, 25°C
4-Hydroxybenzoic acid	Acids	-3.08	-6.53	-3.27	[11]	BLM, eggPC, 25°C
4-Methylbenzoic acid	Acids	0.04	-3.53	-0.08	[9, 12]	BLM, eggPC, 25°C
4-Methylphenyl acetic acid	Acids	-0.15	-3.19	0.28	[10]	LUV, DOPC:DOPA=96:4, 25°C
9-Anthroic acid	Acids	0.51	-2.02	1.52	[9]	BLM, eggPC, 25°C
Acetic acid	Acids	-2.30(-2.16)	-5.37	-2.04	[9 (13)]	BLM, eggPC, 25°C
alpha-Carbamoyl-methylhippuric acid	Acids	-8.00	-10.40	-7.39	[10]	LUV, DOPC:DOPA=96:4, 25°C
alpha-Carbamoyl-p-Toluic acid	Acids	-4.39	-7.86	-4.69	[9, 12]	BLM, eggPC, 25°C
alpha-Carboxy-p-methylhippuric acid	Acids	-6.77	-9.46	-6.39	[10]	LUV, DOPC:DOPA=96:4, 25°C
alpha-Carboxy-p-Toluic acid	Acids	-3.74	-6.79	-3.55	[9, 12]	BLM, eggPC, 25°C
alpha-Chloro-p-methylhippuric acid	Acids	-3.46	-7.05	-3.83	[10]	LUV DOPC:DOPA=96:4
alpha-Chloro-p-Toluic acid	Acids	-0.19	-4.19	-0.79	[9, 12]	BLM, eggPC, 25°C
alpha-Cyano-p-methylhippuric acid	Acids	-5.04	-8.72	-5.60	[10]	LUV, DOPC:DOPA=96:4, 25°C
alpha-Cyano-p-Toluic acid	Acids	-1.57	-6.21	-2.93	[9, 12]	BLM, eggPC, 25°C
alpha-Hydroxy-p-methylhippuric acid	Acids	-6.26	-9.37	-6.29	[10]	LUV, DOPC:DOPA=96:4, 25°C
alpha-Hydroxy-p-Toluic acid	Acids	-2.80	-6.77	-3.53	[9, 12]	BLM, eggPC, 25°C
alpha-Methoxy-methylhippuric_acid	Acids	-4.00	-8.34	-5.20	[10]	LUV, DOPC:DOPA=96:4, 25°C
alpha-Methoxy-p-Toluic acid	Acids	-0.46	-5.40	-2.07	[9, 12]	BLM, eggPC, 25°C
Benzoic acid	Acids	-0.24(-0.26)	-3.85	-0.43	[9 (13)]	BLM, eggPC, 25°C
Butyric acid	Acids	-1.02	-4.55	-1.17	[13]	BLM, eggPC, 25°C

Caproic (hexanoic) acid	Acids	0.04	-3.83	-0.40	[13]	BLM, eggPC, 25°C
L-Lactic acid	Acids	-4.30	-7.54	-4.35	[13]	BLM, eggPC, 25°C
Propionic acid	Acids	-1.46	-4.86	-1.50	[13]	BLM, eggPC, 25°C
Salicylic acid	Acids	-0.11	-4.99	-1.64	[13]	BLM, eggPC, 25°C
Thiocyanic acid	Acids	0.41	-4.35	-0.96	[13]	BLM, eggPC, 25°C
Tol-Ala	Acids	-2.64	-5.34	-2.01	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Ala-Ala	Acids	-4.96	-6.95	-3.72	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Ala-Ala-Ala	Acids	-7.02	-8.65	-5.53	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly	Acids	-3.19	-6.39	-3.13	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly-Gly	Acids	-6.38	-7.84	-4.67	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly-Gly-Gly	Acids	-8.77	-10.92	-7.94	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly-Gly-Sar	Acids	-7.31	-9.60	-6.54	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly-Sar	Acids	-4.72	-8.05	-4.89	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Gly-Sar-Gly	Acids	-7.32	-9.39	-6.32	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Sar	Acids	-2.82	-6.36	-3.09	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Sar-Gly	Acids	-5.49	-7.87	-4.70	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Sar-Gly-Gly	Acids	-7.85	-9.77	-6.72	[10]	LUV, DOPC:DOPA=96:4, 25°C
Tol-Sar-Sar-Gly	Acids	-7.12	-9.71	-6.66	[10]	LUV, DOPC:DOPA=96:4, 25°C
Codeine	Bases	-0.85	-4.62	-1.24	[13, 14]	BLM, eggPC, 25°C
Ethylamine	Bases	-0.92	-4.43	-1.04	[13]	BLM, eggPC, 25°C
Methylamine	Bases	-1.10	-5.62	-2.31	[13]	BLM, eggPC, 25°C
1,4-Butanediol	Neutral	-3.57	-7.24	-4.03	[13]	BLM, eggPC, 25°C
2,3-Dideoxyadenosine	Neutral	-4.20	-9.34	-6.26	[9]	BLM, eggPC, 25°C
2-Deoxyadenosine	Neutral	-6.03	-11.71	-8.78	[9]	BLM, eggPC, 25°C
Acetamide	Neutral	-3.54(-3.77)	-6.37	-3.10	[9 (13)]	BLM, eggPC, 25°C
Adenine	Neutral	-4.86	-7.86	-4.69	[9]	BLM, eggPC, 25°C
Ethylene glycol	Neutral	-4.06	-7.94	-4.77	[13, 14]	BLM, eggPC, 25°C
Formamide	Neutral	-4.00	-7.36	-4.16	[13]	BLM, eggPC, 25°C
Glycerol	Neutral	-5.27	-10.05	-7.02	[13]	BLM, eggPC, 25°C
Hydrocortisone	Neutral	-3.25	-8.24	-5.09	[9]	BLM, eggPC, 25°C
Prednisolone	Neutral	-3.82	-8.37	-5.23	[9]	BLM, eggPC, 25°C
Propylene glycol	Neutral	-3.55	-6.76	-3.52	[13, 14]	BLM, eggPC, 25°C
Urea	Neutral	-5.40	-9.62	-6.56	[13]	BLM, eggPC, 25°C

Water	Neutral	-2.72(-2.47)	-7.51	-4.32	9 (13)	BLM, eggPC, 25°C
Additional set (51 compounds: 23 acids, 11 bases, 13 neutrals, 4 zwitterions)						
2,4-Dihydroxybenzoic acid	Acids	-3.33	-7.76	-4.58	11	BLM, eggPC, 25°C
2-Hydroxybutyric acid	Acids	-3.91	-6.97	-3.74	11	BLM, eggPC, 25°C
2-Hydroxycaproic acid	Acids	-3.67	-6.23	-2.96	11	BLM, eggPC, 25°C
2-Hydroxyvaleric acid	Acids	-3.53	-6.59	-3.34	11	BLM, eggPC, 25°C
Acetylsalicylic acid	Acids	-0.82	-3.32	0.14	15	BLM, eggPC, 24°C
Bromoacetic acid	Acids	-2.91	-4.67	-1.30	11	BLM, eggPC, 25°C
Chloroacetic acid	Acids	-2.94	-5.91	-2.62	11	BLM, eggPC, 25°C
Citric acid	Acids	-10.51	-12.97	-10.12	16	MLV, eggPC:PA=9:1,25°C,pH7
Epinephrine	Acids	-5.57	-8.60	-5.48	17	Liposomes, eggPC, pH7
Formic acid	Acids	-2.54(-2.14)	-6.07	-2.79	9 (13)	BLM 2%eggPC
Hydrochloric acid	Acids	0.46	-2.57	0.94	13	BLM, eggPC, 25°C
Iodoacetic acid	Acids	-2.96	-5.52	-2.20	11	BLM, eggPC, 25°C
Isobutyric acid	Acids	-3.03	-4.32	-0.92	11	BLM, eggPC, 25°C
Isovaleric acid	Acids	-2.88	-4.10	-0.69	11	BLM, eggPC, 25°C
Malic acid	Acids	-7.92	-11.20	-8.24	16	MLV, eggPC:PA=9:1,25°C,pH7
n-Octylmalonic acid	Acids	-3.00	-5.38	-2.05	18	BLM, DPhPC, pH6, 21-23°C
Phenylacetic acid	Acids	-3.09	-3.61	-0.17	11	BLM, eggPC, 25°C
Pivalic acid	Acids	-3.62	-3.82	-0.39	11	BLM, eggPC, 25°C
Sebacic acid	Acids	-3.00	-5.76	-2.46	18	BLM, DPhPC, pH6, 21-23°C
Tiglic acid	Acids	-2.87	-3.90	-0.48	11	BLM, eggPC, 25°C
Valeric acid	Acids	-1.10	-4.18	-0.78	19	GUV,DPPC:DOPC:CH=1:1:1,pH7
Vanillic acid	Acids	-3.58	-7.75	-4.57	11	BLM, eggPC, 25°C
Phloretin	Acids	-3.62	-9.00	-5.90	20	BLM, DPhPC
Ammonia	Bases	-1.28(-0.89)	-6.75	-3.51	21 (13)	BLM, soyPC
Chlorpromazine	Bases	0.59	-2.14	1.39	22	LUV, POPC, pH5.9
Desipramine	Bases	0.65	-0.98	2.63	22	LUV, POPC, pH5.9
Domperidone	Bases	-2.60	-6.49	-3.23	22	LUV, POPC, pH5.9
Ethanolamine	Bases	-4.89	-7.82	-4.65	23	renal lisosomes
Histamine	Bases	-4.46	-6.57	-3.32	24	BLM, eggPC:CHOL=2:1, 24°C, pH9.8-10.6
Labetalol	Bases	-2.10	-4.91	-1.55	22	LUV, POPC, pH5.9
Loperamide	Bases	-0.42	-1.22	2.37	22	LUV, POPC, pH5.9
Propranolol	Bases	0.19	-0.23	3.42	22	LUV, POPC, pH5.9
Tryptamine	Bases	-0.76	-4.34	-0.95	24	BLM, eggPC:CHOL=2:1, 24°C, pH7.5-10
Verapamil	Bases	0.01	-5.88	-2.58	22	LUV, POPC, pH5.9

1,6-Hexanediol	Neutral	-3.65	-5.22	-1.88	[3]	BLM, eggPC:CHOL=1:2,24°C, pH5.6
D-Fructose	Neutral	-9.40	-13.29	-10.46	[25]	LUV, eggPC, 25°C, pH7.5
D-Glucose	Neutral	-10.52	-14.87	-12.14	[25]	LUV, eggPC, 25°C, pH7.5
Butanol	Neutral	-2.92	-3.91	-0.49	[26]	GUV, SOPC:SOPS=99.5:0.5
Ethanol	Neutral	-4.42	-4.68	-1.31	[26]	GUV, SOPC:SOPS=99.5:0.5
Isobutyramide	Neutral	-3.70	-5.40	-2.07	[3]	BLM, eggPC:CHOL=1:2,24°C, pH5.6
n-Butyramide	Neutral	-3.52	-5.49	-2.17	[3]	BLM, eggPC:CHOL=1:2,24°C, pH5.6
Pentanamide	Neutral	-3.74	-5.30	-1.97	[27]	Liposomes, eggPC,
Propanol	Neutral	-3.55	-4.24	-0.84	[26]	GUV, SOPC:SOPS=99.5:0.5
Propionamide	Neutral	-4.21	-5.81	-2.51	[27]	Liposomes, eggPC, 24°C
Erythritol	Neutral	-6.40	-11.99	-9.08	[28]	LUV, POPC:CH:PA=20:15:2, 23°C
Sucrose	Neutral	-13.10	-18.41	-15.91	[25]	LUV, eggPC, 25°C, pH7.5
Theophylline	Neutral	-3.53	-8.99	-5.89	[24]	BLM, eggPC:CHOL=2:1, , pH7.7-9.4
Enrofloxacin	Zwitterions	-3.91	-6.49	-3.23	[29]	GUV, DPhPC, pH=7
Fleroxacin	Zwitterions	-4.96	-9.25	-6.17	[29]	GUV, DPhPC, pH=7
Norfloxacin	Zwitterions	-6.23	-8.06	-4.90	[29]	GUV, DPhPC, pH=7
Pefloxacin	Zwitterions	-4.28	-7.68	-4.50	[29]	GUV, DPhPC, pH=7
Outliers (2 compounds)						
Hydrofluoric acid	Acids	-3.51	-3.24	0.22	[13]	BLM, eggPC, 25°C
Nitric acid	Acids	-3.04	-2.07	1.47	[13]	BLM, eggPC, 25°C

***** - Calulation of intrinsic permeability coefficients through BLM/liposomes of the inionized species was performed using the equation $\log P_{0\,calc}^{\mathrm{BLM}} = 1.063 \log P_{\Sigma}^{\mathrm{BLM}} + 3.669.$

Notes:

1. Selecting the main set, we combined data obtained under similar experimental conditions. Data obtained in slightly different experimental conditions were included in the additional set. We also took into account that very small solutes (hydrochloric acid, hydrofluoric acid, ammonia, formic acid) permeate 2 to 15 times faster than predicted based on their partition coefficients, as found by Walter and Gutknecht.[13] Therefore, these data were also placed to the additional set, except the hydrofluoric and nitric acids that were considered as outliers. The outliners were selected using the cutoff of 2 for standardized residuals.
2. For references included in parenthesis, the experimental permeability coefficients are indicated in parenthesis.

Table S2. Experimental ($\log P_{\mathrm{m}\,exp}^{\mathrm{BLM}}$) and calculated ($\log P_{\mathrm{m}\,calc}^{\mathrm{BLM}}$) membrane permeability coefficients of ionized molecules through artificial lipid membranes (BLM and liposomes) at specified pH.

Compound Name	Group	$\log P_{\mathrm{m}\,exp}^{\mathrm{BLM}}$	$\log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}}$	$\log P_{\mathrm{m}\,calc}^{\mathrm{BLM}}$*	Ref.	Experimental Conditions
Parameterization set (20 compounds: 11 acids, 5 bases, 4 zwitterions)						
12-Hydroxydodecanoic acid	Acids	-4.70	-6.42	-3.16	[30]	BLM, DphPC, 37°C, pH7.2
2-Aminobenzoic acid	Acids	-8.73	-11.00	-8.03	[31]	LUV,eggPC, 25°C,pH7
2-Hydroxynicotinic acid	Acids	-6.78	-11.13	-8.17	[31]	LUV,eggPC, 25°C,pH7
3,5-Dichlorobenzoic acid	Acids	-7.17	-8.61	-5.49	[31]	LUV,eggPC, 25°C,pH7
alpha-Carbamoyl-methylhippuric acid	Acids	-12.70	-13.82	-11.03	[32]	LUV, eggPC, 25°C,10%gA,pH>9
alpha-Carboxy-p-methylhippuric acid	Acids	-12.52	-12.65	-9.78	[32]	LUV, eggPC, 25°C,10%gA,pH>9
alpha-Cyano-p-methylhippuric acid	Acids	-10.02	-12.13	-9.23	[32]	LUV, eggPC, 25°C,10%gA,pH>9
alpha-Hydroxy-p-methylhippuric acid	Acids	-11.66	-12.77	-9.91	[32]	LUV, eggPC, 25°C,10%gA,pH>9
alpha-Methoxy-methylhippuric acid	Acids	-9.82	-11.62	-8.69	[32]	LUV, eggPC, 25°C,10%gA,pH>9
Salicylic acid	Acids	-6.94**	-10.23	-7.21	[31]	LUV,eggPC, 25°C,pH7
Tol-Gly	Acids	-9.36	-9.71	-6.66	[32]	LUV, eggPC, 25°C,10%gA,pH>9
Methylamine	Bases	-6.00	-7.91	-4.74	[33]	MLV,eggPC,25°C, pH7.1
Ethylamine	Bases	-6.15	-8.22	-5.07	[33]	MLV,eggPC,25°C, pH7.1
1-Butylamine	Bases	-4.28	-7.04	-3.82	[33]	MLV,eggPC,25°C, pH7.1
1-Propylamine	Bases	-5.37	-7.28	-4.07	[33]	MLV,eggPC,25°C, pH7.1
Pentylamine	Bases	-3.40	-6.40	-3.14	[33]	MLV,eggPC,25°C, pH7.1
Glycine	Zwitterions	-11.24	-15.22	-12.51	[34]	MLV,eggPC, 20-22°C, pH7
L-Tryptophan	Zwitterions	-9.39	-13.30	-10.47	[34]	MLV,eggPC, 20-22°C, pH7
L-Phenylalanine	Zwitterions	-9.60	-12.91	-10.06	[34]	MLV,eggPC, 20-22°C, pH7
L-Serine	Zwitterions	-11.26	-17.05	-14.46	[34]	MLV,eggPC, 20-22°C, pH7
Outlier						
L-Lysine	Zwitterions	-11.29	-8.68	-5.56	[34]	MLV,eggPC, 20-22°C, pH7

*** -** Calulation of *actual* membrane permeability coefficients through BLM/liposomes ($\log P_{\mathrm{m}\,calc}^{\mathrm{BLM}}$) of ionized species in water was performed using the equation $\log P_{\mathrm{m}\,calc}^{\mathrm{BLM}} = 1.063 \log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}} + 3.669$, where the integral of transbilayer energy profile, $\log P_{\mathrm{m}\,\Sigma}^{\mathrm{BLM}}$, included deionization penalties of ionizable compounds at pH 7 or 9.

** -The experimental value $\log P_{exp}^{\mathrm{BLM}} = -6.94$ for salicylic acid was reported by Thomae et al.[31] as being valid for the neutral form. This became a matter of criticism[35] and controversy as compared to the intrinsic premability coefficient of salicylic acid that was previously reported by Walter and Gutknecht[13] ($\log P_{0\,exp}^{\mathrm{BLM}} = -0.11$, Table S1). We believe this controversy can be resolved by assuming that Thomae et al. actually measured the membrane permeability coefficient ($\log P_{m\,exp}^{\mathrm{BLM}}$), which depends on both solvation and deionization energy terms.

Table S3. Experimental ($\log P_{0\ exp}^{\mathrm{BBB}}$) and calculated ($\log P_{0\ calc}^{\mathrm{BBB}}$) intrinsic permeability coefficients of unionized molecules through BBB membranes.

Compound Name	Group	$\log P_{0\ exp}^{\mathrm{BBB}}$ *	$\log P_{\Sigma}^{\mathrm{BLM}}$	$\log P_{0\ calc}^{\mathrm{PM}}$ **	$\log P_{0\ calc}^{\mathrm{BBB}}$ ***
Main set (158 compounds: 18 acids, 80 bases, 60 neutral, 24 zwitterions)					
2-Aminobenzoic acid	Acids	-4.91	-4.97	-3.19	-3.46
Butyric acid	Acids	-2.15	-4.55	-2.83	-3.31
Caproic acid	Acids	-1.31	-3.83	-2.21	-3.04
Flurbiprofen	Acids	-0.58	-2.48	-1.04	-2.53
Fluvastatin (+)	Acids	-2.28	-4.85	-3.09	-3.42
Glyburide	Acids	-3.74	-9.05	-6.70	-4.99
Ibuprofen (+)	Acids	-1.22	-1.91	-0.55	-2.32
Kynurenic acid	Acids	-5.42	-7.35	-5.24	-4.36
Naringenin	Acids	-3.96	-8.08	-5.87	-4.63
Octanoic (caprylic) acid	Acids	-1.14	-3.13	-1.60	-2.77
Probenecid (+)	Acids	-2.55	-5.42	-3.58	-3.63
Quercetin (-)	Acids	-4.03	-10.26	-7.75	-5.45
Quinolinic acid	Acids	-6.26	-8.82	-6.50	-4.91
Taurocholic acid	Acids	-6.10	-11.11	-8.48	-5.77
Thiothixene	Acids	-2.35	-6.04	-4.11	-3.87
Tolbutamide	Acids	-3.53	-6.09	-4.15	-3.88
Valproic acid	Acids	-2.00	-2.62	-1.16	-2.58
Warfarin (+)	Acids	-1.56	-3.31	-1.76	-2.84
Alfentanil	Bases	-2.98	-4.73	-2.98	-3.37
Amantadine	Bases	-0.86	-1.99	-0.62	-2.35
Aminoguanidine	Bases	-5.85	-6.48	-4.49	-4.03
Amitriptyline (+)	Bases	-1.13	0.11	1.19	-1.56
Amoxapine (+)	Bases	-2.75	-3.59	-2.00	-2.95
Astemizole (+)	Bases	-2.61	-1.87	-0.52	-2.30
Atomoxetine	Bases	-1.27	-0.69	0.50	-1.86
Bremazocine (+)	Bases	-2.76	-2.64	-1.18	-2.59
Brompheniramine	Bases	-1.58	-1.81	-0.47	-2.28
Bupropion	Bases	-2.09	-1.73	-0.40	-2.25
Buspirone (+)	Bases	-2.53	-4.75	-3.00	-3.38
Chlorpheniramine (+)	Bases	-1.84	-2.05	-0.67	-2.37
Chlorpromazine (+)	Bases	-1.23	-2.14	-0.75	-2.40
Cimetidine (+)	Bases	-5.61	-6.89	-4.84	-4.18
Citalopram (+)	Bases	-2.07	-4.57	-2.84	-3.31
Clemastine (+)	Bases	-0.95	0.15	1.22	-1.54
Clozapine	Bases	-3.11	-3.70	-2.10	-2.99
Codeine (+)	Bases	-3.80	-4.62	-2.89	-3.33

CP-141938	Bases	-3.98	-5.25	-3.43	-3.57
Diltiazem (+)	Bases	-2.81	-4.46	-2.75	-3.27
Diphenhydramine (+)	Bases	-1.90	-0.65	0.53	-1.84
Dipyridamole	Bases	-4.59	-10.91	-8.30	-5.69
Domperidone (+)	Bases	-4.45	-6.49	-4.50	-4.03
Donepezil	Bases	-1.68	-3.43	-1.86	-2.89
Dopamine	Bases	-2.68	-6.91	-4.86	-4.19
Doxepin	Bases	-1.24	-1.45	-0.16	-2.14
Ergotamine	Bases	-3.82	-7.20	-5.11	-4.30
Fentanyl (+)	Bases	-2.24	0.29	1.34	-1.49
Fluoxetine (+)	Bases	-0.93	-1.48	-0.18	-2.16
Fluphenazine	Bases	-3.35	-4.91	-3.14	-3.44
Galantamine	Bases	-3.21	-4.97	-3.19	-3.46
Guanidine	Bases	-5.60	-9.29	-6.91	-5.08
Haloperidol (+)	Bases	-2.46	-2.87	-1.38	-2.68
Hydroxyzine (+)	Bases	-3.04	-4.39	-2.69	-3.25
Imatinib (+)	Bases	-3.70	-5.43	-3.59	-3.64
Indinavir	Bases	-5.37	-5.59	-3.72	-3.70
Lidocaine (+)	Bases	-3.24	-2.00	-0.63	-2.35
Loperamide (+)	Bases	-2.52	-1.22	0.04	-2.06
Loxapine (+)	Bases	-3.36	-3.37	-1.81	-2.86
Meperidine (+)	Bases	-2.08	-2.03	-0.66	-2.36
Mepyramine (+)	Bases	-2.04	-3.18	-1.65	-2.79
Mesoridazine	Bases	-1.41	-3.63	-2.03	-2.96
Methadone (+)	Bases	-2.02	-0.66	0.52	-1.85
Metoclopramide	Bases	-2.86	-6.70	-4.68	-4.11
Midazolam (+)	Bases	-3.11	-2.68	-1.22	-2.61
Mirtazapine	Bases	-2.75	-1.93	-0.57	-2.32
Misonidazole	Bases	-5.00	-7.93	-5.74	-4.57
Morphine (+)	Bases	-4.86	-5.66	-3.78	-3.72
Naltrindole (+)	Bases	-3.03	-3.82	-2.20	-3.03
Olanzapine	Bases	-2.73	-3.12	-1.60	-2.77
Oxycodone (+)	Bases	-3.48	-6.42	-4.44	-4.01
Pentazocine	Bases	-3.69	-1.23	0.03	-2.06
Pergolide	Bases	-1.14	-1.10	0.14	-2.01
Perphenazine	Bases	-2.61	-4.95	-3.17	-3.46
Pramipexole	Bases	-2.57	-4.90	-3.13	-3.44
Prazosin	Bases	-4.36	-9.71	-7.27	-5.24
Propranolol (+)	Bases	-1.42	-0.23	0.89	-1.69
Pyrimethamine	Bases	-3.57	-6.63	-4.62	-4.09
Quetiapine	Bases	-3.06	-5.26	-3.44	-3.57
Quinidine (+)	Bases	-2.82	-4.57	-2.84	-3.31
Quinine	Bases	-3.45	-4.62	-2.89	-3.33

Rimantadine	Bases	0.13	-1.41	-0.12	-2.13
Risperidone	Bases	-2.94	-2.66	-1.20	-2.60
Rizatriptan (+)	Bases	-4.43	-5.52	-3.66	-3.67
Saquinavir	Bases	-4.63	-7.85	-5.67	-4.54
Selegiline	Bases	-3.12	-1.63	-0.31	-2.21
Sertraline	Bases	-1.99	-0.85	0.36	-1.92
Sufentanil (+)	Bases	-3.87	-1.50	-0.20	-2.16
Sumatriptan (+)	Bases	-5.06	-7.29	-5.19	-4.33
Tacrine	Bases	-1.51	-2.77	-1.29	-2.64
Terfenadine (+)	Bases	-0.92	0.53	1.55	-1.40
Thioridazine (+)	Bases	-1.95	-1.19	0.07	-2.05
Trazodone	Bases	-3.13	-4.36	-2.66	-3.24
Trifluoperazine	Bases	-3.00	-3.24	-1.70	-2.82
U69593 (+)	Bases	-2.10	-1.20	0.06	-2.05
Venlafaxine (+)	Bases	-1.66	-3.45	-1.88	-2.89
Verapamil (+)	Bases	-2.26	-5.88	-3.97	-3.81
Vinblastine	Bases	-4.81	-6.54	-4.54	-4.05
Vincristine (-)	Bases	-5.60	-8.08	-5.87	-4.63
Ziprasidone (+)	Bases	-3.25	-4.99	-3.21	-3.47
1,4-Butanediol	Neutral	-5.03	-7.24	-5.14	-4.32
Aldosterone	Neutral	-5.46	-8.81	-6.50	-4.90
Alfuzosin (-)	Neutral	-4.64	-9.37	-6.98	-5.11
Aminophenazone	Neutral	-3.30	-4.07	-2.41	-3.13
Antipyrine (+)	Neutral	-4.00	-2.74	-1.27	-2.63
Arabinose	Neutral	-6.63	-12.68	-9.83	-6.36
Butanol	Neutral	-2.88	-3.91	-2.28	-3.07
Caffeine (-)	Neutral	-4.00	-7.74	-5.57	-4.50
Carbamazepine	Neutral	-3.26	-2.92	-1.42	-2.70
Colchicine (-)	Neutral	-5.14	-8.53	-6.26	-4.80
Corticosterone	Neutral	-4.29	-6.40	-4.42	-4.00
Creatinine (-)	Neutral	-6.69	-9.72	-7.28	-5.25
Cyclosporine A	Neutral	-4.17	-4.93	-3.15	-3.45
D-Fructose	Neutral	-6.80	-13.29	-10.35	-6.58
Dianhydrogalactitol	Neutral	-5.60	-10.03	-7.55	-5.36
Diazepam (+)	Neutral	-3.01	-3.87	-2.24	-3.05
Digoxin (-)	Neutral	-6.30	-9.60	-7.18	-5.20
Erythritol (-)	Neutral	-6.57	-11.99	-9.24	-6.10
Estradiol (+)	Neutral	-2.83	-2.74	-1.27	-2.63
Ethanol (+)	Neutral	-3.28	-4.68	-2.94	-3.36
Ethosuximide	Neutral	-4.46	-6.39	-4.41	-4.00
Ethylene glycol	Neutral	-4.99	-7.94	-5.75	-4.58
Etoposide	Neutral	-5.91	-13.60	-10.62	-6.70
Formamide	Neutral	-5.72	-7.36	-5.25	-4.36

Galactitol	Neutral	-6.41	-15.48	-12.24	-7.41
Hispidulin	Neutral	-3.11	-7.66	-5.51	-4.47
Hydrocortisone	Neutral	-5.85	-8.24	-6.01	-4.69
Hydroxyurea	Neutral	-6.00	-7.59	-5.45	-4.45
Hypoxanthine (-)	Neutral	-5.49	-9.26	-6.88	-5.07
Iodoacetamide	Neutral	-4.06	-6.52	-4.52	-4.05
Iodoantipyrine	Neutral	-3.07	-2.77	-1.29	-2.64
Isocarboxazid (+)	Neutral	-3.22	-3.06	-1.54	-2.75
Isopropanol	Neutral	-3.66	-3.65	-2.05	-2.97
Lamotrigine	Neutral	-4.67	-8.06	-5.85	-4.62
Loratadine	Neutral	-3.48	-3.07	-1.55	-2.75
Mannitol	Neutral	-6.27	-15.56	-12.31	-7.44
Meprobamate (-)	Neutral	-5.09	-11.04	-8.42	-5.74
Methanol	Neutral	-3.66	-5.87	-3.96	-3.80
Methylurea	Neutral	-5.70	-8.66	-6.37	-4.85
Metronidazole	Neutral	-4.85	-6.97	-4.91	-4.21
Niacinamide	Neutral	-4.88	-7.34	-5.23	-4.35
Pemoline (-)	Neutral	-5.45	-7.64	-5.49	-4.47
Phenytoin	Neutral	-4.15	-5.69	-3.81	-3.73
Procarbazine	Neutral	-4.62	-4.17	-2.50	-3.16
Progesterone	Neutral	-3.74	-1.73	-0.40	-2.25
Propylene glycol	Neutral	-4.49	-6.76	-4.73	-4.14
Ralimetinib dimesylate	Neutral	-2.93	-2.99	-1.48	-2.72
Ritonavir	Neutral	-4.87	-6.15	-4.21	-3.91
Sucrose	Neutral	-7.27	-18.41	-14.76	-8.50
Temazepam	Neutral	-3.35	-5.70	-3.82	-3.74
Testosterone (+)	Neutral	-3.10	-2.72	-1.25	-2.62
Theobromine (-)	Neutral	-5.00	-9.08	-6.73	-5.01
Theophylline	Neutral	-5.24	-8.99	-6.65	-4.97
Thiourea (+)	Neutral	-5.30	-7.29	-5.19	-4.33
Thymidine	Neutral	-5.84	-12.60	-9.76	-6.33
Thymine (-)	Neutral	-3.93	-8.23	-6.00	-4.69
Urea	Neutral	-6.12	-9.62	-7.19	-5.21
Xanthine (-)	Neutral	-5.62	-11.77	-9.05	-6.01
Zaleplon	Neutral	-4.25	-5.45	-3.60	-3.64
Zidovudine (-)	Neutral	-5.99	-9.90	-7.43	-5.31
DPDPE	Zwitterions	-5.97	-14.63	-11.51	-7.09
Gabapentin	Zwitterions	-4.34	-5.41	-3.57	-3.63
Glycine	Zwitterions	-5.50	-8.47	-6.20	-4.78
Grepafloxacin	Zwitterions	-4.86	-6.19	-4.24	-3.92
L-Alanine	Zwitterions	-5.50	-7.28	-5.18	-4.33
L-Arginine	Zwitterions	-4.64	-11.08	-8.45	-5.76
L-Aspartic acid	Zwitterions	-6.66	-10.41	-7.87	-5.50

L-Dopa	Zwitterions	-3.99	-9.60	-7.18	-5.20
L-Glutamic acid	Zwitterions	-6.26	-10.35	-7.82	-5.48
L-Glutamine	Zwitterions	-5.28	-11.45	-8.77	-5.89
L-Histidine	Zwitterions	-4.28	-9.56	-7.14	-5.19
L-Isoleucine	Zwitterions	-4.16	-5.91	-4.00	-3.82
L-Kynurenine	Zwitterions	-6.16	-8.46	-6.19	-4.77
L-Leucine	Zwitterions	-3.63	-5.98	-4.06	-3.84
L-Lysine	Zwitterions	-4.93	-8.68	-6.38	-4.86
L-Methionine	Zwitterions	-4.39	-6.90	-4.85	-4.19
L-Ornithine	Zwitterions	-4.68	-9.53	-7.12	-5.17
L-Phenylalanine	Zwitterions	-4.13	-5.41	-3.57	-3.63
L-Threonine	Zwitterions	-5.21	-9.17	-6.81	-5.04
L-Tryptophan	Zwitterions	-4.22	-6.95	-4.89	-4.21
L-Tyrosine	Zwitterions	-3.90	-8.03	-5.82	-4.61
L-Valine	Zwitterions	-4.68	-6.19	-4.24	-3.92
Melphalan	Zwitterions	-5.27	-6.50	-4.51	-4.04
Tiagabine	Zwitterions	-4.45	-2.78	-1.30	-2.64
Outliers (17 compounds:7 acids, 3 bases, 5 neutrals, 2 zwitterions)					
Ascorbic acid	Acids	-2.54	-13.80	-10.79	-6.78
Chlorambucil	Acids	-0.80	-3.82	-2.20	-3.03
Indomethacin	Acids	-1.06	-5.69	-3.81	-3.73
Methotrexate	Acids	-5.57	-17.84	-14.27	-8.29
Naproxen	Acids	-0.77	-3.78	-2.16	-3.02
Neotrofin	Acids	-3.80	-12.11	-9.34	-6.14
Salicylic acid	Acids	-1.02	-4.99	-3.21	-3.47
Daunorubicin	Bases	-2.40	-13.82	-10.81	-6.78
Doxorubicin	Bases	-3.35	-15.94	-12.64	-7.58
Mitoxantrone	Bases	-3.06	-12.42	-9.61	-6.26
Adenosine	Neutral	-4.42	-15.77	-12.49	-7.51
D-Glucose	Neutral	-4.82	-14.87	-11.72	-7.18
Methylprednisolone	Neutral	-7.00	-8.11	-5.89	-4.64
Paclitaxel	Neutral	-6.63	-7.56	-5.42	-4.44
Phenelzine	Neutral	-4.32	-0.76	0.44	-1.89
Cetirizine	Zwitterions	-5.63	-4.27	-2.59	-3.20
Fexofenadine	Zwitterions	-5.94	-2.63	-1.17	-2.59

*- "efflux minimized" intrinsic BBB permeability coefficients $\log P_{0\ exp}^{\mathrm{BBB}}$, which were obtained by the *in situ* rodent brain perfusion technique and corrected for ionization, were compiled by Avdeef in Table 9.7 [36]. "+" sign indicates BBB-permeable compounds (BBB+), "-" sign indicates BBB-impermeable compounds (BBB-) used in Figure S8.

**** - Calulation of intrinsic permeability coefficients of unionized species through PM was performed using the equation $\log P_{0\ calc}^{\mathrm{PM}} = 0.861 \log P_{\Sigma}^{\mathrm{BLM}} + 1.092$.

***** -** Calulation of intrinsic permeability coefficients of unionized species through BBB was performed using the equation $\log P_{0\ calc}^{\mathrm{BBB}} = 0.375 \log P_{\Sigma}^{\mathrm{BLM}} - 1.600$.

Table S4. Experimental ($\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$) and calculated ($\log P_{0\ calc}^{\mathrm{Caco-2/MDCK}}$) intrinsic permeability coefficients of unionized molecules through Caco-2/MDCK cell membranes.

Compound Name	Group	$\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$ *	$\log P_{\Sigma}^{\mathrm{BLM}}$	$\log P_{0\ \mathrm{calc}}^{\mathrm{PM}}$ **	$\log P_{0\ calc}^{\mathrm{Caco-2/MDCK}}$ ***
Main set (165 compounds: 10 acids, 69 bases, 53 neutrals, 33 zwitterions)					
Flumequine	Acids	-2.47	-5.02	-3.23	-3.91
Acetylsalicylic acid	Acids	-1.53	-3.32	-1.77	-3.44
Ampicillin	Acids	-7.08	-9.37	-6.98	-5.09
Ceftibuten	Acids	-5.32	-13.98	-10.95	-6.34
Cephaloridine	Acids	-6.53	-8.54	-6.26	-4.86
Chlorothiazide	Acids	-6.62	-12.28	-9.48	-5.88
Fluorescein	Acids	-2.29	-6.12	-4.18	-4.20
Furosemide	Acids	-3.50	-8.49	-6.22	-4.85
Losartan	Acids	-3.96	-1.81	-0.47	-3.03
Warfarin	Acids	-1.54	-3.31	-1.76	-3.44
Alfentanil	Bases	-3.54	-4.73	-2.98	-3.83
Amodiaquine	Bases	-2.88	-4.39	-2.69	-3.73
Bremazocine	Bases	-2.86	-2.64	-1.18	-3.26
Brompheniramine	Bases	-2.70	-1.81	-0.47	-3.03
Chlorpheniramine	Bases	-2.72	-2.05	-0.67	-3.10
Clemastine	Bases	-2.50	0.15	1.22	-2.50
Dextromethorphan	Bases	-2.6	-2.00	-0.63	-3.08
Dextrorphan	Bases	-2.53	-2.99	-1.48	-3.35
Diphenhydramine	Bases	-3.12	-0.65	0.53	-2.72
Ephedrine	Bases	-2.91	-3.49	-1.91	-3.49
Hydroxyzine	Bases	-4.13	-4.39	-2.69	-3.73
Lincomycin	Bases	-6.51	-12.13	-9.36	-5.84
Loxapine	Bases	-4.23	-3.37	-1.81	-3.46
Nicotine	Bases	-3.62	-3.55	-1.97	-3.51
Practolol	Bases	-3.43	-3.91	-2.28	-3.60
Pumafentrine	Bases	-3.36	-2.40	-0.98	-3.19
Rizatriptan	Bases	-4.18	-5.52	-3.66	-4.04
Scopolamine	Bases	-4.57	-4.74	-2.99	-3.83
Sulpiride	Bases	-4.16	-8.90	-6.57	-4.96
Tolafentrine	Bases	-4.59	-5.84	-3.94	-4.13
Acebutolol	Bases	-4.19	-5.54	-3.68	-4.05
Alprenolol	Bases	-2.23	-1.40	-0.11	-2.92
Amantadine	Bases	-2.17	-1.99	-0.62	-3.08
Amiloride	Bases	-4.75	-12.19	-9.41	-5.85
Amoxapine	Bases	-3.84	-3.59	-2.00	-3.52
Atenolol	Bases	-4.34	-6.07	-4.14	-4.19

Chloroquine	Bases	-1.18	-1.78	-0.44	-3.02
Cimetidine	Bases	-6.06	-6.89	-4.84	-4.41
Citalopram	Bases	-2.99	-4.57	-2.84	-3.78
Desipramine	Bases	-1.67	-0.98	0.25	-2.81
Diltiazem	Bases	-3.12	-4.46	-2.75	-3.75
Dipyridamole	Bases	-3.86	-10.91	-8.30	-5.51
Domperidone	Bases	-4.46	-6.49	-4.50	-4.30
Erythromycin	Bases	-4.24	-7.94	-5.75	-4.70
Famotidine	Bases	-6.41	-11.50	-8.81	-5.67
Guanabenz	Bases	-2.86	-6.93	-4.88	-4.42
Imipramine	Bases	-1.82	-0.91	0.31	-2.79
Indinavir	Bases	-4.72	-5.59	-3.72	-4.06
Labetalol	Bases	-4.27	-4.91	-3.14	-3.88
Loperamide	Bases	-3.43	-1.22	0.04	-2.87
Mepyramine	Bases	-2.84	-3.18	-1.65	-3.41
Metoclopramide	Bases	-2.54	-6.70	-4.68	-4.36
Metoprolol	Bases	-1.85	-2.24	-0.84	-3.15
Midazolam	Bases	-3.44	-2.68	-1.22	-3.27
Morphine	Bases	-4.55	-5.66	-3.78	-4.08
Nadolol	Bases	-4.47	-5.27	-3.45	-3.97
Nalbuphine	Bases	-3.30	-4.07	-2.41	-3.65
Nelfinavir	Bases	-3.67	-2.39	-0.97	-3.19
Pindolol	Bases	-2.22	-4.26	-2.58	-3.70
Pirenzepine	Bases	-5.11	-7.70	-5.54	-4.63
Prazosin	Bases	-4.54	-9.71	-7.27	-5.18
Propranolol	Bases	-1.54	-0.23	0.89	-2.60
Quinidine	Bases	-3.31	-4.57	-2.84	-3.78
Quinine	Bases	-2.83	-4.62	-2.89	-3.80
Ranitidine	Bases	-5.27	-5.16	-3.35	-3.94
Saquinavir	Bases	-5.35	-7.85	-5.67	-4.67
Sotalol	Bases	-4.60	-5.88	-3.97	-4.14
Sumatriptan	Bases	-4.29	-7.29	-5.19	-4.52
Terbutaline	Bases	-5.23	-6.83	-4.79	-4.40
Terfenadine	Bases	-3.74	0.53	1.55	-2.40
Timolol	Bases	-2.42	-6.63	-4.62	-4.34
Topotecan	Bases	-4.77	-10.37	-7.84	-5.36
Trimethoprim	Bases	-3.95	-10.83	-8.24	-5.48
Venlafaxine	Bases	-2.84	-3.45	-1.88	-3.48
Verapamil	Bases	-2.18	-5.88	-3.97	-4.14
Vinblastine	Bases	-4.50	-6.54	-4.54	-4.32
Vincristine	Bases	-5.54	-8.08	-5.87	-4.74
Ziprasidone	Bases	-4.75	-4.99	-3.21	-3.90
Zolmitriptan	Bases	-4.26	-8.09	-5.88	-4.74

Antipyrine	Neutral	-4.05	-2.74	-1.27	-3.29
Benserazide	Neutral	-5.58	-13.22	-10.29	-6.13
Chloramphenicol	Neutral	-4.47	-8.21	-5.98	-4.77
DMP-450	Neutral	-3.80	-5.09	-3.29	-3.92
Erythritol	Neutral	-6.56	-11.99	-9.24	-5.80
Ethosuximide	Neutral	-4.91	-6.39	-4.41	-4.28
Guanfacine	Neutral	-4.73	-7.23	-5.14	-4.51
Hydrochlorothiazide	Neutral	-6.32	-12.25	-9.46	-5.87
Isocarboxazid	Neutral	-4.54	-3.06	-1.54	-3.37
Meprobamate	Neutral	-4.94	-11.04	-8.42	-5.54
Minoxidil	Neutral	-5.68	-7.25	-5.15	-4.51
Netivudine	Neutral	-6.20	-14.44	-11.35	-6.47
Pemoline	Neutral	-5.30	-7.64	-5.49	-4.62
Praziquantel	Neutral	-3.44	-3.98	-2.34	-3.62
Primidone	Neutral	-5.59	-6.61	-4.60	-4.34
Propylthiouracil	Neutral	-3.76	-5.01	-3.22	-3.90
Ralimetinib dimesylate	Neutral	-3.99	-2.99	-1.48	-3.35
Thiabendazole	Neutral	-3.51	-3.72	-2.11	-3.55
Water	Neutral	-6.00	-7.51	-5.38	-4.58
Acetaminophen	Neutral	-4.34	-5.63	-3.76	-4.07
Aciclovir	Neutral	-5.87	-13.72	-10.73	-6.27
Alfuzosin	Neutral	-4.27	-9.37	-6.98	-5.09
Amprenavir	Neutral	-4.38	-7.33	-5.22	-4.53
Bromocriptine	Neutral	-4.67	-6.54	-4.54	-4.32
Caffeine	Neutral	-4.14	-7.74	-5.57	-4.64
Carbamazepine	Neutral	-3.69	-2.92	-1.42	-3.33
Clonidine	Neutral	-3.91	-5.42	-3.58	-4.01
Creatinine	Neutral	-5.90	-9.72	-7.28	-5.18
Cyclosporine A	Neutral	-5.24	-4.93	-3.15	-3.88
Dexamethasone	Neutral	-4.65	-8.79	-6.48	-4.93
Diazepam	Neutral	-4.20	-3.87	-2.24	-3.59
Digoxin	Neutral	-5.43	-9.60	-7.18	-5.15
Etoposide	Neutral	-6.11	-13.60	-10.62	-6.24
Famciclovir	Neutral	-4.79	-9.07	-6.72	-5.01
Flavone	Neutral	-4.48	-1.18	0.08	-2.86
Ganciclovir	Neutral	-6.99	-15.73	-12.46	-6.82
Genistein	Neutral	-2.59	-7.67	-5.51	-4.63
Hydrocortisone	Neutral	-4.63	-8.24	-6.01	-4.78
Lamivudine	Neutral	-5.79	-11.23	-8.58	-5.59
Lamotrigine	Neutral	-4.45	-8.06	-5.85	-4.73
Lansoprazole	Neutral	-3.76	-8.86	-6.54	-4.95
Loratadine	Neutral	-4.75	-3.07	-1.55	-3.38

Methylprednisolone	Neutral	-4.63	-8.11	-5.89	-4.75
Omeprazole	Neutral	-3.86	-10.60	-8.04	-5.42
Paclitaxel	Neutral	-5.26	-7.56	-5.42	-4.60
Phenol red	Neutral	-6.64	-7.57	-5.43	-4.60
Phenytoin	Neutral	-4.16	-5.69	-3.81	-4.09
Resveratrol	Neutral	-4.82	-6.14	-4.20	-4.21
Ritonavir	Neutral	-4.10	-6.15	-4.21	-4.21
Testosterone	Neutral	-3.58	-2.72	-1.25	-3.28
Theophylline	Neutral	-4.17	-8.99	-6.65	-4.98
Urea	Neutral	-6.00	-9.62	-7.19	-5.16
Zidovudine	Neutral	-4.97	-9.90	-7.43	-5.23
CNV97100	Zwitterions	-5.05	-7.72	-5.56	-4.64
CNV97102	Zwitterions	-4.38	-6.88	-4.83	-4.41
CNV97103	Zwitterions	-4.45	-6.49	-4.50	-4.30
CNV97104	Zwitterions	-4.53	-6.10	-4.16	-4.20
Gly-Pro	Zwitterions	-5.18	-9.72	-7.28	-5.18
Me-ciprofloxacin	Zwitterions	-3.70	-7.42	-5.30	-4.56
Moxifloxacin	Zwitterions	-3.25	-7.70	-5.54	-4.63
Sarafloxacin	Zwitterions	-5.24	-6.79	-4.76	-4.39
5-Aminolevulinic acid	Zwitterions	-4.96	-7.99	-5.79	-4.71
Amoxicillin	Zwitterions	-5.70	-11.97	-9.22	-5.79
Cefaclor	Zwitterions	-6.02	-10.83	-8.24	-5.48
Cefadroxil	Zwitterions	-6.07	-12.75	-9.89	-6.01
Cefatrizine	Zwitterions	-5.57	-12.40	-9.59	-5.91
Cefsulodin	Zwitterions	-6.78	-16.08	-12.76	-6.91
Cephalexin	Zwitterions	-6.03	-10.11	-7.62	-5.29
Cephaloglycin	Zwitterions	-6.33	-11.19	-8.55	-5.58
Cephradine	Zwitterions	-6.11	-9.99	-7.51	-5.26
Cetirizine	Zwitterions	-5.31	-4.27	-2.59	-3.70
Ciprofloxacin	Zwitterions	-5.22	-7.78	-5.61	-4.66
Enalaprilat	Zwitterions	-5.55	-5.39	-3.55	-4.01
Gatifloxacin	Zwitterions	-4.81	-7.62	-5.47	-4.61
Gly-Sar	Zwitterions	-5.54	-10.80	-8.21	-5.48
Grepafloxacin	Zwitterions	-4.23	-6.19	-4.24	-4.22
L-Alanine	Zwitterions	-5.74	-7.28	-5.18	-4.52
L-Dopa	Zwitterions	-6.11	-9.60	-7.18	-5.15
Levofloxacin	Zwitterions	-3.58	-7.83	-5.65	-4.67
Lisinopril	Zwitterions	-5.68	-7.14	-5.06	-4.48
L-Leucine	Zwitterions	-5.45	-5.98	-4.06	-4.17
Lomefloxacin	Zwitterions	-4.54	-7.66	-5.51	-4.62
L-Phenylalanine	Zwitterions	-4.63	-5.41	-3.57	-4.01
Norfloxacin	Zwitterions	-5.54	-8.06	-5.85	-4.73
Ofloxacin	Zwitterions	-4.49	-8.56	-6.28	-4.87

Sparfloxacin	Zwitterions	-4.16	-7.36	-5.25	-4.54
Outliers (20 compounds: 14 acids, 2 bases, 1 neutral, 3 zwitterions)					
Diclofenac	Acids	-1.07	-4.27	-2.59	-3.70
Fluvastatin	Acids	-1.33	-4.85	-3.09	-3.86
Glipizide	Acids	-2.47	-7.90	-5.71	-4.69
Ibuprofen	Acids	-0.53	-1.91	-0.58	-3.06
Indomethacin	Acids	-0.81	-5.69	-3.80	-4.09
Isoxicam	Acids	-1.68	-7.52	-5.36	-4.58
Ketoprofen	Acids	-1.23	-3.48	-1.91	-3.49
L-Lactic acid	Acids	-1.92	-7.54	-5.38	-4.59
Naproxen	Acids	-0.95	-3.78	-2.18	-3.57
Piroxicam	Acids	-2.01	-8.27	-6.00	-4.79
Quercetin	Acids	-3.20	-10.26	-7.75	-5.33
Salicylic acid	Acids	-0.43	-4.99	-3.21	-3.90
Sulfasalazine	Acids	-2.66	-8.41	-6.15	-4.83
Zomepirac	Acids	-1.51	-5.76	-3.86	-4.11
Doxorubicin	Bases	-4.12	-15.94	-12.54	-6.87
Mitoxantrone	Bases	-2.86	-12.42	-9.54	-5.92
Pantoprazole	Neutral	-3.87	-13.27	-10.26	-6.15
Acrivastine	Zwitterions	-5.74	-2.89	-1.42	-3.33
Fexofenadine	Zwitterions	-6.46	-2.63	-1.20	-3.26
Gabapentin	Zwitterions	-6.57	-5.41	-3.56	-4.01

*- experimental intrinsic Caco-2/MDCK permeability coefficients corrected for nontrancellular effects were compiled by Avdeef in Table 8.6.[7] Some of these data were averages of apical-to-basolateral and basolateral-to-apical measurements that may cancel out some of contribution due to efflux/uptake carrier-mediated processes.

**** - Calulation of intrinsic permeability coefficients of unionized species through PM was performed using the equation $\log P_{0\,calc}^{\mathrm{PM}} = 0.861\,\log P_{\Sigma}^{\mathrm{BLM}} + 1.092$.

***** -** Calulation of intrinsic permeability coefficients of unionized species through Caco-2/MDCK cells was performed using the equation: $\log P_{0\,calc}^{\mathrm{Caco-2/MDCK}} = 0.272\,\log P_{\Sigma}^{\mathrm{BLM}} - 2.541$.

Table S5. Experimental ($\log P_{0\ exp}^{\mathrm{PAMPA-DS}}$) and calculated ($\log P_{0\ calc}^{\mathrm{PAMPA-DS}}$) intrinsic permeability coefficients of unionized molecules through double-sink Parallel Artificial Membrane Permeability Assay (PAMPA-DS).

Compound Name	Group	$\log P_{0\ exp}^{\mathrm{PAMPA-DS}*}$	$\log P_{\Sigma}^{\mathrm{BLM}}$	$\log P_{0\ calc}^{\mathrm{PM}}$**	$\log P_{0\ calc}^{\mathrm{PAMPA-DS}***}$
Main set (280 compounds: 50 acids, 122 bases, 72 neutral, 36 zwitterions)					
13-cis-Retinoic acid	Acids	0.37	0.52	2.22	2.67
2-Naphthoic acid	Acids	-2.72	-3.07	-1.37	-0.85
3,4-Dihydroxyphenylacetic acid	Acids	-6.15	-7.73	-6.03	-5.42
3-Hydroxyphenylacetic acid	Acids	-4.25	-6.26	-4.56	-3.98
3-Phenylpropionic acid	Acids	-3.89	-3.33	-1.63	-1.11
4-Methylbenzoic acid	Acids	-3.51	-3.53	-1.83	-1.30
Acetylsalicylic acid	Acids	-4.45	-3.32	-1.62	-1.10
alpha-Carbamoyl-p-Toluic acid	Acids	-5.91	-7.86	-6.16	-5.55
alpha-Carboxy-p-Toluic acid	Acids	-4.51	-6.79	-5.09	-4.50
alpha-Chloro-p-Toluic acid	Acids	-3.03	-4.19	-2.49	-1.95
alpha-Cyano-p-Toluic acid	Acids	-4.33	-6.21	-4.51	-3.93
alpha-Hydroxy-p-Toluic acid	Acids	-5.02	-6.77	-5.07	-4.48
alpha-Methoxy-p-Toluic acid	Acids	-4.13	-5.40	-3.70	-3.14
Ampicillin	Acids	-7.43	-9.37	-7.67	-7.03
Benazepril	Acids	-3.28	-2.31	-0.61	-0.11
Benzoic acid	Acids	-3.94	-3.85	-2.15	-1.62
Benzthiazide	Acids	-6.43	-9.84	-8.14	-7.49
Biochanin A	Acids	-2.58	-6.94	-5.24	-4.65
Cephaloridine	Acids	-7.33	-8.54	-6.84	-6.22
Cerivastatin	Acids	-3.01	-5.30	-3.60	-3.04
Diclofenac	Acids	-1.37	-4.27	-2.57	-2.03
Flufenamic acid	Acids	-1.19	-4.05	-2.35	-1.81
Flumequine	Acids	-3.85	-5.02	-3.32	-2.77
Fluorescein	Acids	-3.01	-6.12	-4.42	-3.84
Flurbiprofen	Acids	-1.78	-2.48	-0.78	-0.27
Fluvastatin	Acids	-2.73	-4.85	-3.15	-2.60
Furosemide	Acids	-4.03	-8.49	-6.79	-6.17
Gemfibrozil	Acids	-1.59	-1.71	-0.01	0.48
Glipizide	Acids	-4.41	-7.90	-6.20	-5.59
Ibuprofen	Acids	-2.11	-1.91	-0.21	0.29
Indomethacin	Acids	-1.65	-5.69	-3.99	-3.42
Isoxicam	Acids	-3.20	-7.52	-5.82	-5.22
Kaempferol	Acids	-5.66	-10.14	-8.44	-7.79
Ketoprofen	Acids	-2.67	-3.48	-1.78	-1.25
L-Lactic acid	Acids	-6.20	-7.54	-5.84	-5.24

Mefenamic acid	Acids	-1.41	-1.36	0.34	0.82
Nalidixic Acid	Acids	-3.88	-6.04	-4.34	-3.77
Naproxen	Acids	-2.30	-3.78	-2.08	-1.55
Naringenin	Acids	-3.71	-8.08	-6.38	-5.77
Oxolinic acid	Acids	-4.66	-8.76	-7.06	-6.43
Phenylbutazone	Acids	-1.96	-1.07	0.63	1.11
Piroxicam	Acids	-3.32	-8.27	-6.57	-5.95
Probenecid	Acids	-1.83	-5.42	-3.72	-3.16
Quercetin	Acids	-4.77	-10.26	-8.56	-7.91
Rosmarinic acid	Acids	-7.39	-10.80	-9.10	-8.44
Salicylic acid	Acids	-2.64	-4.99	-3.29	-2.74
Sulfasalazine	Acids	-4.44	-8.41	-6.71	-6.09
Torasemide	Acids	-4.34	-8.40	-6.70	-6.08
Warfarin	Acids	-2.59	-3.31	-1.61	-1.09
Zomepirac	Acids	-2.61	-5.76	-4.06	-3.49
4-Phenylbutylamine	Bases	-0.59	-2.14	-0.44	0.06
Acebutolol	Bases	-3.39	-5.54	-3.84	-3.28
Albuterol	Bases	-4.92	-6.73	-5.03	-4.44
Alfentanil	Bases	-3.53	-4.73	-3.03	-2.48
Alprenolol	Bases	0.02	-1.40	0.30	0.79
Amantadine	Bases	-1.21	-1.99	-0.29	0.21
Amiloride	Bases	-7.38	-12.19	-10.49	-9.80
Amiodarone	Bases	2.58	-0.36	1.34	1.81
Amitriptyline	Bases	1.30	0.11	1.81	2.27
Amodiaquine	Bases	-0.21	-4.39	-2.69	-2.15
Amoxapine	Bases	-1.66	-3.59	-1.89	-1.36
Astemizole	Bases	1.00	-1.87	-0.17	0.32
Atenolol	Bases	-5.06	-6.07	-4.37	-3.80
Bepridil	Bases	1.63	0.72	2.42	2.87
Bremazocine	Bases	-1.49	-2.64	-0.94	-0.43
Brompheniramine	Bases	-0.35	-1.81	-0.11	0.38
Bupivacaine	Bases	-2.07	-0.95	0.75	1.23
Buspirone	Bases	-2.48	-4.75	-3.05	-2.50
Butacaine	Bases	0.25	-2.22	-0.52	-0.02
Carvedilol	Bases	0.05	-4.30	-2.60	-2.06
Chloroquine	Bases	1.09	-1.78	-0.08	0.41
Chlorpheniramine	Bases	-0.60	-2.05	-0.35	0.15
Chlorpromazine	Bases	1.62	-2.14	-0.44	0.06
Chlorprothixene	Bases	1.44	-1.23	0.47	0.95
Cimetidine	Bases	-6.20	-6.89	-5.19	-4.60
Cinnarizine	Bases	0.64	1.17	2.87	3.31
Citalopram	Bases	-0.95	-4.57	-2.87	-2.32
Clemastine	Bases	1.96	0.15	1.85	2.31

Clofazimine	Bases	2.79	-0.12	1.58	2.04
Clotrimazole	Bases	-1.31	-0.63	1.07	1.54
Clozapine	Bases	-0.39	-3.70	-2.00	-1.47
Cyproheptadine	Bases	0.44	0.20	1.90	2.36
Desipramine	Bases	1.74	-0.98	0.72	1.20
Dextromethorphan	Bases	-0.18	-2.00	-0.30	0.20
Dextrorphan	Bases	-1.34	-2.99	-1.29	-0.77
Diltiazem	Bases	-1.33	-4.46	-2.76	-2.22
Diphenhydramine	Bases	-0.71	-0.65	1.05	1.52
Disopyramide	Bases	-1.14	-2.46	-0.76	-0.25
Domperidone	Bases	-2.78	-6.49	-4.79	-4.21
Doxepin	Bases	0.44	-1.45	0.25	0.74
Ephedrine	Bases	-2.90	-3.49	-1.79	-1.26
Ergonovine	Bases	-4.14	-6.86	-5.16	-4.57
Erythromycin	Bases	-2.40	-7.94	-6.24	-5.63
Famotidine	Bases	-7.75	-11.50	-9.80	-9.12
Fendiline	Bases	1.62	2.18	3.88	4.30
Galantamine	Bases	-3.15	-4.97	-3.27	-2.72
Guanabenz	Bases	-1.34	-6.93	-5.23	-4.64
Haloperidol	Bases	0.05	-2.87	-1.17	-0.66
Hydroxyzine	Bases	-1.50	-4.39	-2.69	-2.15
Imatinib	Bases	-1.40	-5.43	-3.73	-3.17
Imipramine	Bases	0.98	-0.91	0.79	1.27
Indinavir	Bases	-3.57	-5.59	-3.89	-3.32
Ketoconazole	Bases	-1.41	-5.76	-4.06	-3.49
Labetalol	Bases	-4.94	-4.91	-3.21	-2.66
Lidocaine	Bases	-1.42	-2.00	-0.30	0.20
Loperamide	Bases	0.15	-1.22	0.48	0.96
Loxapine	Bases	-1.09	-3.37	-1.67	-1.15
Meperidine	Bases	0.79	-2.03	-0.33	0.17
Mepyramine	Bases	-0.42	-3.18	-1.48	-0.96
Methadone	Bases	0.08	-0.66	1.04	1.51
Metipranolol	Bases	0.30	-3.73	-2.03	-1.50
Metoclopramide	Bases	-1.94	-6.70	-5.00	-4.41
Metoprolol	Bases	-1.17	-2.24	-0.54	-0.04
Mexiletine	Bases	-0.45	-2.37	-0.67	-0.17
Miconazole	Bases	-0.45	-3.03	-1.33	-0.81
Midazolam	Bases	-2.47	-2.68	-0.98	-0.47
Morantel	Bases	-2.05	-2.74	-1.04	-0.53
Morphine	Bases	-3.59	-5.66	-3.96	-3.39
Nadolol	Bases	-4.34	-5.27	-3.57	-3.01
Nalbuphine	Bases	-2.56	-4.07	-2.37	-1.83
Naltrindole	Bases	-0.94	-3.82	-2.12	-1.59

Nelfinavir	Bases	-3.27	-2.39	-0.69	-0.19
Nicardipine	Bases	-0.79	-4.79	-3.09	-2.54
Nicotine	Bases	-3.42	-3.55	-1.85	-1.32
Nortriptyline	Bases	2.02	0.02	1.72	2.18
Ondansetron	Bases	-2.38	-3.48	-1.78	-1.25
Orphenadrine	Bases	0.06	-0.78	0.92	1.39
Oxprenolol	Bases	-0.60	-3.86	-2.16	-1.63
Papaverine	Bases	-2.44	-5.20	-3.50	-2.94
Penbutolol	Bases	1.70	-1.44	0.26	0.75
Phenazopyridine	Bases	-2.66	-6.91	-5.21	-4.62
Pilocarpine	Bases	-4.88	-4.89	-3.19	-2.64
Pindolol	Bases	-1.75	-4.26	-2.56	-2.02
Pirenzepine	Bases	-3.46	-7.70	-6.00	-5.39
Practolol	Bases	-3.40	-3.91	-2.21	-1.68
Pramocaine	Bases	-0.99	-3.00	-1.30	-0.78
Procaine	Bases	-2.46	-4.16	-2.46	-1.92
Procyclidine	Bases	1.70	-0.74	0.96	1.43
Promethazine	Bases	0.96	-1.45	0.25	0.74
Propafenone	Bases	0.72	-3.47	-1.77	-1.25
Propoxyphene	Bases	0.72	-0.19	1.51	1.97
Propranolol	Bases	0.43	-0.23	1.47	1.93
Protriptyline	Bases	2.43	0.01	1.71	2.17
Pumafentrine	Bases	0.59	-2.40	-0.70	-0.20
Pyridoxine	Bases	-6.62	-9.90	-8.20	-7.55
Quetiapine	Bases	-1.85	-5.26	-3.56	-3.00
Quinidine	Bases	-1.56	-4.57	-2.87	-2.32
Quinine	Bases	-1.05	-4.62	-2.92	-2.37
Ranitidine	Bases	-5.14	-5.16	-3.46	-2.90
Risperidone	Bases	-2.01	-2.66	-0.96	-0.45
Rizatriptan	Bases	-2.76	-5.52	-3.82	-3.26
Saquinavir	Bases	-3.69	-7.85	-6.15	-5.54
Scopolamine	Bases	-3.00	-4.74	-3.04	-2.49
Sertraline	Bases	2.10	-0.85	0.85	1.33
Sotalol	Bases	-4.83	-5.88	-4.18	-3.61
Sulpiride	Bases	-4.57	-8.90	-7.20	-6.57
Sumatriptan	Bases	-4.18	-7.29	-5.59	-4.99
Tamoxifen	Bases	1.98	0.75	2.45	2.89
Terbutaline	Bases	-7.25	-6.83	-5.13	-4.54
Terfenadine	Bases	2.63	0.53	2.23	2.68
Thioridazine	Bases	1.81	-1.19	0.51	0.99
Tolafentrine	Bases	-0.17	-5.84	-4.14	-3.57
Topotecan	Bases	-5.12	-10.37	-8.67	-8.01
Trifluprom azine	Bases	1.63	-2.50	-0.80	-0.29

Trihexyphenidyl	Bases	2.09	-0.42	1.28	1.75
Trimipramine	Bases	1.58	-0.46	1.24	1.71
U69593	Bases	0.37	-1.20	0.50	0.98
Venlafaxine	Bases	-1.63	-3.45	-1.75	-1.23
Vincristine	Bases	-2.72	-8.08	-6.38	-5.77
Zimelidine	Bases	-0.43	-2.75	-1.05	-0.54
Ziprasidone	Bases	-0.61	-4.99	-3.29	-2.74
Zolpidem	Bases	-3.06	-2.83	-1.13	-0.62
11beta-Hydroxyprogesterone	Neutral	-3.46	-3.51	-1.81	-1.28
11-Dehydrocorticosterone	Neutral	-4.36	-6.77	-5.07	-4.48
11-Deoxycortisol	Neutral	-3.80	-6.51	-4.81	-4.23
2,4-Dibromoestradiol	Neutral	-3.21	-2.86	-1.16	-0.65
Acetaminophen	Neutral	-5.81	-5.63	-3.93	-3.36
Aciclovir	Neutral	-10.00	-13.72	-12.01	-11.30
Albendazole	Neutral	-3.12	-6.97	-5.27	-4.68
Aldosterone	Neutral	-4.88	-8.81	-7.11	-6.48
Alfuzosin	Neutral	-4.34	-9.37	-7.67	-7.03
Aminoglutethimide	Neutral	-3.76	-7.15	-5.45	-4.86
Amprenavir	Neutral	-3.64	-7.33	-5.63	-5.03
Aniline	Neutral	-3.71	-3.16	-1.46	-0.94
Beclomethasone	Neutral	-3.70	-8.55	-6.85	-6.23
Bendroflumethiazide	Neutral	-5.27	-9.32	-7.62	-6.98
Benserazide	Neutral	-10.70	-13.22	-11.51	-10.81
Bromocriptine	Neutral	-4.04	-6.54	-4.84	-4.26
Budesonide	Neutral	-2.62	-6.61	-4.91	-4.33
Caffeine	Neutral	-5.55	-7.74	-6.04	-5.43
Carbamazepine	Neutral	-3.73	-2.92	-1.22	-0.71
Chloramphenicol	Neutral	-5.30	-8.21	-6.51	-5.90
Chlorthalidone	Neutral	-6.64	-9.95	-8.25	-7.60
Clonidine	Neutral	-3.00	-5.42	-3.72	-3.16
Corticosterone	Neutral	-3.86	-6.40	-4.70	-4.12
Cortisone	Neutral	-4.46	-8.67	-6.97	-6.35
Creatinine	Neutral	-7.52	-9.72	-8.02	-7.38
Cyclosporine A	Neutral	-3.21	-4.93	-3.23	-2.68
Cyclothiazide	Neutral	-5.46	-9.09	-7.39	-6.76
Danazol	Neutral	-1.79	-1.12	0.58	1.06
Deoxycorticosterone	Neutral	-2.85	-4.59	-2.89	-2.34
Dexamethasone	Neutral	-4.05	-8.79	-7.09	-6.46
Diazepam	Neutral	-2.44	-3.87	-2.17	-1.64
Digoxin	Neutral	-5.78	-9.60	-7.90	-7.26
DMP-450	Neutral	-3.61	-5.09	-3.39	-2.83
Erythritol	Neutral	-8.56	-11.99	-10.29	-9.60
Ethosuximide	Neutral	-5.20	-6.39	-4.69	-4.11

Famciclovir	Neutral	-4.59	-9.07	-7.37	-6.74
Felodipine	Neutral	-3.48	-4.52	-2.82	-2.28
Flavone	Neutral	-2.10	-1.18	0.52	1.00
Genistein	Neutral	-4.69	-7.67	-5.97	-5.37
Griseofulvin	Neutral	-3.61	-8.96	-7.26	-6.63
Guanfacine	Neutral	-2.56	-7.23	-5.53	-4.93
Hydrochlorothiazide	Neutral	-8.30	-12.25	-10.55	-9.86
Hydrocortisone	Neutral	-4.32	-8.24	-6.54	-5.92
Itraconazole	Neutral	-0.29	-3.66	-1.96	-1.43
Lamotrigine	Neutral	-5.87	-8.06	-6.36	-5.75
Lansoprazole	Neutral	-3.89	-8.86	-7.16	-6.53
Loratadine	Neutral	-0.66	-3.07	-1.37	-0.85
Meprobamate	Neutral	-5.71	-11.04	-9.34	-8.67
Methylprednisolone	Neutral	-4.38	-8.11	-6.41	-5.80
Metolazone	Neutral	-4.85	-6.84	-5.14	-4.55
Mifepristone	Neutral	-1.37	-2.04	-0.34	0.16
Minoxidil	Neutral	-4.62	-7.25	-5.55	-4.95
Nifedipine	Neutral	-3.35	-5.52	-3.82	-3.26
Nitrendipine	Neutral	-1.80	-4.56	-2.86	-2.31
Pemoline	Neutral	-4.93	-7.64	-5.94	-5.34
Phenol red	Neutral	-3.89	-7.57	-5.87	-5.27
Phenytoin	Neutral	-4.37	-5.69	-3.99	-3.42
Praziquantel	Neutral	-2.78	-3.98	-2.28	-1.75
Prednisolone	Neutral	-4.46	-8.37	-6.67	-6.05
Prednisone	Neutral	-4.33	-8.80	-7.10	-6.47
Primidone	Neutral	-5.44	-6.61	-4.91	-4.33
Progesterone	Neutral	-2.55	-1.73	-0.03	0.46
Propylthiouracil	Neutral	-5.36	-5.01	-3.31	-2.76
Quintozene	Neutral	-2.20	-4.73	-3.03	-2.48
Ralimetinib dimesylate	Neutral	-0.99	-2.99	-1.29	-0.77
Resveratrol	Neutral	-4.38	-6.14	-4.44	-3.86
Ritonavir	Neutral	-1.68	-6.15	-4.45	-3.87
Testosterone	Neutral	-2.83	-2.72	-1.02	-0.51
Theophylline	Neutral	-5.99	-8.99	-7.29	-6.66
Thiabendazole	Neutral	-3.45	-3.72	-2.02	-1.49
Valdecoxib	Neutral	-4.10	-4.14	-2.44	-1.90
Zidovudine	Neutral	-5.79	-9.90	-8.20	-7.55
Acrivastine	Zwitterions	-4.07	-2.89	-1.19	-0.68
Amoxicillin	Zwitterions	-6.80	-11.97	-10.27	-9.58
Cefaclor	Zwitterions	-7.61	-10.83	-9.13	-8.47
Cefadroxil	Zwitterions	-8.87	-12.75	-11.05	-10.35
Cefatrizine	Zwitterions	-9.81	-12.40	-10.70	-10.01
Cefsulodin	Zwitterions	-12.30	-16.08	-14.37	-13.62

Cephalexin	Zwitterions	-7.53	-10.11	-8.41	-7.76
Cephaloglycin	Zwitterions	-7.80	-11.19	-9.49	-8.82
Cephradine	Zwitterions	-7.98	-9.99	-8.29	-7.64
Cetirizine	Zwitterions	-4.13	-4.27	-2.57	-2.03
Ciprofloxacin	Zwitterions	-5.47	-7.78	-6.08	-5.47
CNV97100	Zwitterions	-5.32	-7.72	-6.02	-5.41
CNV97102	Zwitterions	-4.32	-6.88	-5.18	-4.59
CNV97103	Zwitterions	-3.81	-6.49	-4.79	-4.21
CNV97104	Zwitterions	-3.34	-6.10	-4.40	-3.83
Enoxacin	Zwitterions	-4.90	-7.96	-6.26	-5.65
Gabapentin	Zwitterions	-3.36	-5.41	-3.71	-3.15
Gatifloxacin	Zwitterions	-4.50	-7.62	-5.92	-5.32
Gly-Pro	Zwitterions	-10.40	-9.72	-8.02	-7.38
Gly-Sar	Zwitterions	-10.50	-10.80	-9.10	-8.44
Grepafloxacin	Zwitterions	-4.49	-6.19	-4.49	-3.91
L-Alanine	Zwitterions	-8.07	-7.28	-5.58	-4.98
L-Arginine	Zwitterions	-5.82	-11.08	-9.38	-8.71
L-Dopa	Zwitterions	-7.52	-9.60	-7.90	-7.26
Lisinopril	Zwitterions	-6.43	-7.14	-5.44	-4.85
L-Leucine	Zwitterions	-7.19	-5.98	-4.28	-3.71
Lomefloxacin	Zwitterions	-4.73	-7.66	-5.96	-5.36
L-Phenylalanine	Zwitterions	-5.36	-5.41	-3.71	-3.15
L-Tryptophan	Zwitterions	-8.00	-6.95	-5.25	-4.66
Me-ciprofloxacin	Zwitterions	-4.44	-7.42	-5.72	-5.12
Melphalan	Zwitterions	-3.45	-6.50	-4.80	-4.22
Norfloxacin	Zwitterions	-6.16	-8.06	-6.36	-5.75
Ofloxacin	Zwitterions	-5.21	-8.56	-6.86	-6.24
Sarafloxacin	Zwitterions	-4.84	-6.79	-5.09	-4.50
Sparfloxacin	Zwitterions	-4.04	-7.36	-5.66	-5.06
Trovafloxacin	Zwitterions	-3.75	-7.71	-6.01	-5.40
Outliers (42 compounds: 4 acids, 19 bases, 14 neutrals, 5 zwitterions)					
Ceftibuten	Acids	-7.64	-13.98	-12.27	-11.56
Chlorothiazide	Acids	-6.58	-12.28	-10.58	-9.89
Meloxicam	Acids	-2.86	-8.48	-6.78	-6.16
Montelukast	Acids	-6.47	-0.04	1.66	2.12
Amlodipine	Bases	0.62	-7.25	-5.55	-4.95
Azythromycin	Bases	-10.00	-6.47	-4.77	-4.19
Dipyridamole	Bases	-2.84	-10.91	-9.21	-8.54
Doxorubicin	Bases	-3.67	-15.94	-14.23	-13.48
Fentanyl	Bases	-0.95	0.29	1.99	2.44
Fluvoxamine	Bases	0.88	-4.95	-3.25	-2.70
Hydralazine	Bases	-4.53	-1.43	0.27	0.76

Lincomycin	Bases	-5.10	-12.13	-10.43	-9.74
Mitoxantrone	Bases	-3.82	-12.42	-10.72	-10.03
Noscapine	Bases	-2.25	-8.45	-6.75	-6.13
Perphenazine	Bases	0.81	-4.95	-3.25	-2.70
Prazosin	Bases	-2.58	-9.71	-8.01	-7.37
Primaquine	Bases	0.56	-5.24	-3.54	-2.98
Timolol	Bases	-0.97	-6.63	-4.93	-4.35
Triamterene	Bases	-3.58	-11.45	-9.75	-9.07
Trimethoprim	Bases	-3.38	-10.83	-9.13	-8.47
Verapamil	Bases	0.26	-5.88	-4.18	-3.61
Vinblastine	Bases	-0.42	-6.54	-4.84	-4.26
Zolmitriptan	Bases	-1.71	-8.09	-6.39	-5.78
Alprazolam	Neutral	-3.73	-1.38	0.32	0.81
Antipyrine	Neutral	-5.69	-2.74	-1.04	-0.53
Etoposide	Neutral	-5.22	-13.60	-11.89	-11.18
Ganciclovir	Neutral	-8.26	-15.73	-14.02	-13.27
Hesperetin	Neutral	-3.33	-9.42	-7.72	-7.08
Isocarboxazid	Neutral	-4.75	-3.06	-1.36	-0.84
Netivudine	Neutral	-7.26	-14.44	-12.73	-12.01
Omeprazole	Neutral	-3.49	-10.60	-8.90	-8.24
Paclitaxel	Neutral	-1.09	-7.56	-5.86	-5.26
Pantoprazole	Neutral	-3.40	-13.27	-11.56	-10.86
Probucol	Neutral	-3.18	1.78	3.48	3.91
Silibinin	Neutral	-5.07	-13.91	-12.20	-11.49
Triamcinolone	Neutral	-5.22	-10.92	-9.22	-8.55
Trioxsalen	Neutral	-2.89	-1.51	0.19	0.68
5-Aminolevulinic acid	Zwitterions	-9.88	-7.99	-6.29	-5.68
Chlortetracycline	Zwitterions	-5.39	-12.79	-11.09	-10.39
DPDPE	Zwitterions	-7.31	-14.63	-12.92	-12.19
Enalaprilat	Zwitterions	-7.43	-5.39	-3.69	-3.13
Fexofenadine	Zwitterions	-5.17	-2.63	-0.93	-0.42

*- intrinsic permeability coefficients obtained in double-sink PAMPA-DS assay were compiled by Avdeef in Table 7.13.[5]

**** - Calulation of intrinsic permeability coefficients of unionized species through PM was performed using the equation $\log P_{0\,calc}^{\mathrm{PM}} = \log P_{\Sigma}^{\mathrm{BLM}} + 1.699$.

***** - Calulation of intrinsic permeability coefficients of unionized species through PAMPA-DS system was performed using the equation: $\log P_{0\,calc}^{\mathrm{PAMPA-DS}} = 0.981 \log P_{\Sigma}^{\mathrm{BLM}} - 2.159$.

Table S6. Experimental ($\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-pH}\ exp}$) and calculated ($\log P^{\mathrm{PAMPA-DS}}_{\mathrm{m-pH}\ calc}$) membrane permeability coefficients of ionized molecules through double-sink Parallel Artificial Membrane Permeability Assay (PAMPA-DS) at specified pH values.

Compound name	Group	$\log P^{\mathrm{PAMPA-DS}*}_{\mathrm{m-6.5}\ exp}$	$\log P^{\mathrm{PAMPA-DS}*}_{\mathrm{m-7.4}\ exp}$	$\log P^{\mathrm{PAMPA-DS}**}_{\mathrm{m-6.5}\ calc}$	$\log P^{\mathrm{PAMPA-DS}**}_{\mathrm{m-7.4}\ calc}$
133 compounds: 40 acids, 93 bases					
13-cis-Retinoic acid	Acids	-1.47	-2.36	0.91	0.04
2-Naphthoic acid	Acids	-4.92	-5.82	-2.98	-3.85
3,4-Dihydroxyphenylacetic acid	Acids	-8.52	-10.00	-9.06	-9.95
3-Hydroxyphenylacetic acid	Acids	-6.52	-7.40	-6.21	-7.09
3-Phenylpropionic acid	Acids	-5.74	-6.70	-3.21	-4.09
4-Methylbenzoic acid	Acids	-5.64	-6.52	-3.20	-4.07
Acetylsalicylic acid	Acids	-7.46	-8.40	-4.93	-5.81
alpha-Carbamoyl-p-Toluic acid	Acids	-8.40	-9.00	-7.64	-8.52
alpha-Carboxy-p-Toluic acid	Acids	-9.00	-10.00	-8.43	-10.18
alpha-Chloro-p-Toluic acid	Acids	-5.54	-6.40	-4.07	-4.95
alpha-Cyano-p-Toluic acid	Acids	-6.70	-7.70	-5.87	-6.75
alpha-Hydroxy-p-Toluic acid	Acids	-7.30	-8.00	-6.41	-7.29
alpha-Methoxy-p-Toluic acid	Acids	-6.52	-7.40	-5.20	-6.08
Benazepril	Acids	-4.80	-5.68	-3.79	-4.67
Benzoic acid	Acids	-6.22	-7.00	-3.71	-4.58
Benzthiazide	Acids	-6.52	-7.00	-8.23	-9.11
Biochanin A	Acids	-2.68	-3.05	-5.59	-6.53
Cerivastatin	Acids	-4.62	-5.51	-5.46	-6.35
Diclofenac	Acids	-3.73	-4.64	-4.36	-5.25
Flufenamic acid	Acids	-3.45	-4.36	-4.24	-5.12
Flumequine	Acids	-4.10	-4.72	-3.70	-4.58
Flurbiprofen	Acids	-4.10	-5.00	-2.71	-3.58
Furosemide	Acids	-7.00	-7.70	-9.54	-10.43
Gemfibrozil	Acids	-3.39	-4.28	-1.41	-2.28
Ibuprofen	Acids	-4.03	-4.92	-1.74	-2.61
Indomethacin	Acids	-3.59	-4.48	-5.13	-6.01
Isoxicam	Acids	-5.47	-6.40	-8.17	-9.05
Kaempferol	Acids	-6.30	-7.00	-8.30	-8.30
Ketoprofen	Acids	-5.06	-5.96	-3.48	-4.35
Mefenamic acid	Acids	-3.38	-4.28	-2.61	-3.49
Nalidixic Acid	Acids	-4.38	-5.14	-4.07	-4.95

Naproxen	Acids	-4.48	-5.39	-3.59	-4.46
Naringenin	Acids	-3.71	-3.71	-6.39	-6.89
Phenylbutazone	Acids	-3.87	-4.77	-1.17	-2.04
Piroxicam	Acids	-4.62	-5.49	-7.80	-8.68
Probenecid	Acids	-5.17	-6.10	-6.04	-6.93
Salicylic acid	Acids	-6.10	-7.00	-6.99	-7.88
Sulfasalazine	Acids	-8.15	-9.00	-10.55	-11.44
Torasemide	Acids	-4.55	-5.12	-6.22	-7.03
Warfarin	Acids	-4.13	-5.00	-2.40	-3.29
4-Phenylbutylamine	Bases	-4.59	-3.69	-3.81	-2.92
Acebutolol	Bases	-6.40	-5.51	-5.90	-5.02
Albuterol	Bases	-7.70	-6.74	-7.34	-6.45
Alfentanil	Bases	-3.72	-3.56	-2.63	-2.63
Alprenolol	Bases	-2.99	-2.10	-2.11	-1.25
Amiodarone	Bases	0.02	0.91	-1.93	-1.07
Amitriptyline	Bases	-1.69	-0.79	0.63	0.79
Astemizole	Bases	-1.19	-0.24	-1.85	-0.97
Atenolol	Bases	-8.00	-7.22	-7.42	-6.53
Bepridil	Bases	-0.86	0.03	0.50	1.27
Bremazocine	Bases	-3.49	-2.62	-0.41	-0.41
Bupivacaine	Bases	-3.49	-2.69	-0.20	0.68
Buspirone	Bases	-3.61	-2.89	-2.38	-2.44
Butacaine	Bases	-3.34	-2.44	0.45	0.45
Carvedilol	Bases	-1.44	-0.63	-4.54	-3.66
Chloroquine	Bases	-4.32	-3.42	-2.21	-1.37
Chlorpromazine	Bases	-1.11	-0.22	0.08	0.08
Chlorprothixene	Bases	-1.16	-0.27	-0.95	-0.08
Cimetidine	Bases	-6.70	-6.30	-4.65	-4.05
Cinnarizine	Bases	-0.58	0.17	2.56	3.24
Clofazimine	Bases	-0.90	0.00	-0.69	0.19
Clotrimazole	Bases	-1.43	-1.33	1.54	1.54
Clozapine	Bases	-1.80	-1.00	-2.78	-1.89
Cyproheptadine	Bases	-1.66	-0.79	0.85	1.73
Desipramine	Bases	-1.91	-1.01	-2.46	-1.60
Diltiazem	Bases	-2.86	-2.04	-3.71	-2.82
Diphenhydramine	Bases	-3.30	-2.41	-0.93	-0.13
Disopyramide	Bases	-4.96	-4.06	-0.03	-0.03
Domperidone	Bases	-3.80	-3.12	-6.22	-5.34
Doxepin	Bases	-2.51	-1.61	-2.19	-1.34
Ergonovine	Bases	-4.70	-4.26	-4.98	-4.51
Famotidine	Bases	-8.00	-8.00	-10.75	-9.41
Fendiline	Bases	-1.08	-0.19	1.33	2.13
Galantamine	Bases	-5.27	-4.39	-4.79	-3.93

Haloperidol	Bases	-2.11	-1.23	-1.14	-1.10
Hydroxyzine	Bases	-2.56	-1.87	-3.15	-2.27
Imatinib	Bases	-2.53	-1.81	-4.36	-3.48
Imipramine	Bases	-2.03	-1.13	-1.58	-0.74
Indinavir	Bases	-3.78	-3.60	-3.44	-3.44
Ketoconazole	Bases	-1.71	-1.46	-3.08	-2.94
Labetalol	Bases	-5.96	-5.28	-6.96	-6.08
Lidocaine	Bases	-2.89	-2.08	-1.23	-0.35
Loperamide	Bases	-2.05	-1.17	-1.33	-0.45
Meperidine	Bases	-1.29	-0.42	-1.84	-0.99
Methadone	Bases	-2.41	-1.52	1.46	1.46
Metipranolol	Bases	-2.74	-1.84	-4.45	-3.57
Metoprolol	Bases	-4.23	-3.33	-4.76	-3.87
Mexiletine	Bases	-3.09	-2.19	-2.73	-1.84
Miconazole	Bases	-0.59	-0.47	0.01	0.01
Morantel	Bases	-7.40	-6.52	-5.72	-4.86
Morphine	Bases	-5.22	-4.40	-5.99	-5.11
Nadolol	Bases	-7.52	-6.70	-6.29	-5.40
Nalbuphine	Bases	-4.28	-3.42	-6.68	-5.80
Naltrindole	Bases	-2.74	-1.89	-4.28	-3.39
Nicardipine	Bases	-1.54	-0.99	-2.50	-2.50
Nicotine	Bases	-5.04	-4.21	-2.85	-1.97
Nortriptyline	Bases	-1.60	-0.70	-1.29	-0.43
Orphenadrine	Bases	-2.24	-1.36	-0.87	-0.03
Oxprenolol	Bases	-3.67	-2.77	-4.61	-3.73
Papaverine	Bases	-2.69	-2.48	-2.92	-2.92
Penbutolol	Bases	-1.72	-0.82	-2.58	-1.73
Phenazopyridine	Bases	-2.68	-2.67	-3.69	-3.69
Pilocarpine	Bases	-5.57	-5.06	-2.96	-1.85
Pindolol	Bases	-4.80	-3.89	-4.84	-3.95
Pramocaine	Bases	-1.94	-1.29	-1.31	-0.71
Procaine	Bases	-5.00	-4.11	-4.40	-3.56
Procyclidine	Bases	-2.20	-1.30	-1.16	-0.37
Promethazine	Bases	-1.54	-0.65	-1.73	-0.88
Propafenone	Bases	-2.38	-1.48	-4.32	-3.44
Propoxyphene	Bases	-1.84	-0.95	-0.45	0.32
Propranolol	Bases	-2.60	-1.70	-2.87	-2.00
Protriptyline	Bases	-1.43	-0.53	-1.72	-0.84
Pyridoxine	Bases	-6.70	-6.70	-6.95	-6.95
Quetiapine	Bases	-2.71	-2.10	-3.62	-3.01
Quinidine	Bases	-3.61	-2.74	-4.11	-3.23
Quinine	Bases	-3.10	-2.22	-4.11	-3.23
Ranitidine	Bases	-7.00	-6.10	-2.98	-2.80

Risperidone	Bases	-3.43	-2.63	-2.10	-1.22
Saquinavir	Bases	-4.17	-3.79	-6.56	-6.56
Sertraline	Bases	-0.89	0.00	-1.10	-0.26
Sulpiride	Bases	-7.00	-6.30	-9.40	-8.56
Sumatriptan	Bases	-7.30	-6.40	-8.09	-7.24
Tamoxifen	Bases	-0.09	0.78	0.96	1.84
Terbutaline	Bases	-10.00	-8.52	-7.95	-7.06
Terfenadine	Bases	-0.72	0.18	-0.64	0.22
Thioridazine	Bases	-0.51	0.38	-2.11	-1.27
Trifluprom azine	Bases	-1.11	-0.22	-2.99	-2.13
Trihexyphenidyl	Bases	-1.71	-0.81	-0.60	0.12
Trimipramine	Bases	-1.32	-0.42	-1.04	-0.22
U69593	Bases	-2.43	-1.53	0.96	0.96
Vincristine	Bases	-3.70	-3.02	-5.74	-5.74
Zimelidine	Bases	-2.01	-1.18	-2.62	-1.74
Zolpidem	Bases	-3.55	-3.16	-0.07	-0.07

*- membrane permeability coefficients obtained in double-sink PAMPA-DS assay at pH 6.5 and 7.4 were corrected for ABL(aqueous boundary layer)-effect by Avdeef and compiled in Table 7.13.[5]

** - Calulations of membrane permeability coefficients of ionized species through PAMPA-DS system at pH 6.5 and 7.4 were performed using the equation: $\log P_{\mathrm{pH}\,calc}^{\mathrm{PAMPA-DS}} = 0.981 \log P_{\mathrm{pH}\Sigma}^{\mathrm{BLM}} - 2.159$.

Table S7. Data set fot comparison of intrinsic permeability coefficients measured in cell-based assays (Caco-2/MDCK) and by the *in situ* brain perfusion technique (BBB).

Compound Name	Group	$\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$*	$\log P_{0\ exp}^{\mathrm{BBB}}$**
73 compounds: 7 acids, 35 bases, 25 neutral, 6 zwitterions			
Quercetin	Acids	-3.2	-4.03
Warfarin	Acids	-1.54	-1.56
Fluvastatin	Acids	-1.33	-2.28
Naproxen	Acids	-0.95	-0.77
Indomethacin	Acids	-0.81	-1.06
Ibuprofen	Acids	-0.53	-1.22
Salicylic acid	Acids	-0.43	-1.02
Cimetidine	Bases	-6.06	-5.61
Vincristine	Bases	-5.54	-5.6
Saquinavir	Bases	-5.35	-4.63
Ziprasidone	Bases	-4.75	-3.25
Indinavir	Bases	-4.72	-5.37
Morphine	Bases	-4.55	-4.86
Prazosin	Bases	-4.54	-4.36
Vinblastine	Bases	-4.5	-4.81
Domperidone	Bases	-4.46	-4.45
Sumatriptan	Bases	-4.29	-5.06
Loxapine	Bases	-4.23	-3.36
Rizatriptan	Bases	-4.18	-4.43
Hydroxyzine	Bases	-4.13	-3.04
Doxorubicin	Bases	-4.12	-3.35
Dipyridamole	Bases	-3.86	-4.59
Amoxapine	Bases	-3.84	-2.75
Alfentanil	Bases	-3.54	-2.98
Midazolam	Bases	-3.44	-3.11
Loperamide	Bases	-3.43	-2.52
Quinidine	Bases	-3.31	-2.82
Diltiazem	Bases	-3.12	-2.81
Diphenhydramine	Bases	-3.12	-1.90
Citalopram	Bases	-2.99	-2.07
Mitoxantrone	Bases	-2.86	-3.06
Bremazocine	Bases	-2.86	-2.76
Mepyramine	Bases	-2.84	-2.04
Venlafaxine	Bases	-2.84	-1.66
Quinine	Bases	-2.83	-3.45
Chlorpheniramine	Bases	-2.72	-1.84

Brompheniramine	Bases	-2.70	-1.58
Metoclopramide	Bases	-2.54	-2.86
Clemastine	Bases	-2.50	-0.95
Verapamil	Bases	-2.18	-2.26
Amantadine	Bases	-2.17	-0.86
Propranolol	Bases	-1.54	-1.42
Erythritol	Neutral	-6.56	-6.57
Etoposide	Neutral	-6.11	-5.91
Urea	Neutral	-6.00	-6.12
Creatinine	Neutral	-5.90	-6.69
Digoxin	Neutral	-5.43	-6.30
Pemoline	Neutral	-5.3	-5.45
Paclitaxel	Neutral	-5.26	-6.63
Cyclosporine A	Neutral	-5.24	-4.17
Zidovudine	Neutral	-4.97	-5.99
Meprobamate	Neutral	-4.94	-5.09
Ethosuximide	Neutral	-4.91	-4.46
Loratadine	Neutral	-4.75	-3.48
Hydrocortisone	Neutral	-4.63	-5.85
Isocarboxazid	Neutral	-4.54	-3.22
Lamotrigine	Neutral	-4.45	-4.67
Alfuzosin	Neutral	-4.27	-4.64
Diazepam	Neutral	-4.20	-3.01
Theophylline	Neutral	-4.17	-5.24
Phenytoin	Neutral	-4.16	-4.15
Caffeine	Neutral	-4.14	-4.00
Ritonavir	Neutral	-4.10	-4.87
Antipyrine	Neutral	-4.05	-4.00
Ralimetinib dimesylate	Neutral	-3.99	-2.93
Carbamazepine	Neutral	-3.69	-3.26
Testosterone	Neutral	-3.58	-3.10
Fexofenadine	Zwitterions	-6.46	-5.94
L-Alanine	Zwitterions	-5.74	-5.50
L-Leucine	Zwitterions	-5.45	-3.63
Cetirizine	Zwitterions	-5.31	-5.63
L-Phenylalanine	Zwitterions	-4.63	-4.13
Grepafloxacin	Zwitterions	-4.23	-4.86

* – experimental intrinsic Caco-2/MDCK permeability coefficients corrected for non-trancellular effects ($\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$) were compiled by Avdeef in Table 8.6.[7]

**- "efflux minimized" intrinsic BBB permeability coefficients corrected for ionization, which were obtained by the *in situ* rodent brain perfusion technique ($\log P_{0\ exp}^{\mathrm{BBB}}$), were compiled by Avdeef in Table 9.7.[36]

Table S8. Data set for comparison of intrinsic permeability coefficients measured in artificial membranes (BLM), cell-based assays (Caco-2/MDCK) and by the *in situ* brain perfusion technique (BBB).

Name (experimental)	Group	$\log P_{0\ exp}^{\mathrm{BLM}}$ *	$\log P_{0\ exp}^{\mathrm{BBB}}$ **	$\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$ ***
23 compounds: 5 acids, 7 bases, 11 neutral				
Acetylsalicylic acid	Acids	-0.82		-1.53
Butyric acid	Acids	-1.02	-2.15	
Hexanoic acid	Acids	0.04	-1.31	
Octanoic acid	Acids	-0.76	-1.14	
Salicylic acid	Acids	-0.11	-1.02	-0.43
Chlorpromazine	Bases	0.59	-1.23	
Codeine	Bases	-0.85	-3.80	
Domperidone	Bases	-2.60	-4.45	-4.46
Labetalol	Bases	-2.10		-4.27
Loperamide	Bases	-0.42	-2.52	-3.43
Propranolol	Bases	0.19	-1.42	-1.54
Verapamil	Bases	0.01	-2.60	-2.18
1,4-Butanediol	Neutral	-3.57	-5.03	
Acetamide	Neutral	-3.54	-4.98	
Erythritol	Neutral	-6.40	-6.57	-6.56
Ethylene glycol	Neutral	-4.06	-4.39	
Formamide	Neutral	-4.00	-5.72	
Glycerol	Neutral	-5.27	-5.25	
Hydrocortisone	Neutral	-3.25	-5.85	-4.63
Propylene glycol	Neutral	-3.55	-4.49	
Theophylline	Neutral	-3.53	-5.24	-4.17
Urea	Neutral	-5.40	-6.12	-6.00
Water	Neutral	-2.72		-6.00

* – experimental intrinsic BLM permeability coefficients ($\log P_{0\ exp}^{\mathrm{BLM}}$) for unionized molecules were compiled in Table S1.

** – "efflux minimized" intrinsic BBB permeability coefficients, which were obtained by the *in situ* rodent brain perfusion technique and corrected for ionization ($\log P_{0\ exp}^{\mathrm{BBB}}$), were compiled by Avdeef in Table 9.7.[36]

*** – experimental intrinsic Caco-2/MDCK permeability coefficients corrected for nontrancellular effects ($\log P_{0\ exp}^{\mathrm{Caco-2/MDCK}}$)were compiled by Avdeef in Table 8.6.[7] Some of these data were averages of apical-to-basolateral and basolateral-to-apical measurements that may cancel out some of contribution due to efflux/uptake carrier-mediated processes.

Table S9. Data set for comparison of intrinsic permeability coefficients measured in unilamellar lipid bilayers (BLM) and double-sink Parallel Artificial Membrane Permeability Assay (PAMPA-DS).

Compound Name	Group	$\log P_{0\,exp}^{\mathrm{BLM}}$ *	$\log P_{0\,exp}^{\mathrm{PAMPA-DS}}$ **
24 compounds: 12 acids, 7 bases, 4 neutral, 1 zwitterions			
2-Naphthoic acid	Acids	1.23	-2.72
4-Methylbenzoic acid	Acids	0.04	-3.51
Acetylsalicylic acid	Acids	-0.82	-4.45
alpha-Carbamoyl-p-Toluic acid	Acids	-4.39	-5.91
alpha-Chloro-p-Toluic acid	Acids	-0.19	-3.03
alpha-Hydroxy-p-Toluic acid	Acids	-2.80	-5.02
alpha-Carboxy-p-Toluic acid	Acids	-3.74	-4.51
alpha-Methoxy-p-Toluic acid	Acids	-0.46	-4.13
alpha-Cyano-p-Toluic acid	Acids	-1.57	-4.33
Benzoic acid	Acids	-0.24	-3.94
L-Lactic acid	Acids	-4.30	-6.20
Salicylic acid	Acids	-0.11	-2.64
Labetalol	Bases	-2.10	-4.94
Domperidone	Bases	-2.60	-2.78
Loperamide	Bases	-0.42	0.15
Propranolol	Bases	0.19	0.43
Chlorpromazine	Bases	0.59	1.62
Desipramine	Bases	0.65	1.74
Verapamil	Bases	0.01	0.26
Erythritol	Neutral	-6.40	-8.56
Theophylline	Neutral	-3.53	-5.99
Prednisolone	Neutral	-3.82	-4.46
Hydrocortisone	Neutral	-3.25	-4.32
Norfloxacin	Zwitterions	-6.23	-6.16

* – experimental intrinsic BLM permeability coefficients for unionized molecules ($\log P_{0\,exp}^{\mathrm{BLM}}$) were compiled in Table S1.

** - experimental intrinsic permeability coefficients obtained in double-sink PAMPA-DS assay ($\log P_{0\,exp}^{\mathrm{PAMPA-DS}}$) were compiled by Avdeef in Table 7.13.[5]

REFERENCES

1. Kučerka, N.; Nagle, J. F.; Sachs, J. N.; Feller, S. E.; Pencer, J.; Jackson, A.; Katsaras, J. Lipid Bilayer Structure Determined by the Simultaneous Analysis of Neutron and X-Ray Scattering Data. *Biophys. J.* **2008**, *95*, 2356-2367.
2. Lomize, A. L.; Pogozheva, I. D.; Mosberg, H. I. Anisotropic Solvent Model of the Lipid Bilayer. 2. Energetics of Insertion of Small Molecules, Peptides, and Proteins In Membranes. *J. Chem. Inf. Model.* **2011**, *51*, 930-946.
3. Finkelstein, A. Water and Nonelectrolyte Permeability of Lipid Bilayer Membranes. *J. Gen. Physiol.* **1976**, *68*, 127-135.
4. Xiang, T. X.; Chen, J.; Anderson, B. D. A Quantitative Model for the Dependence of Solute Permeability on Peptide and Cholesterol Content in Biomembranes. *J. Membr. Biol.* **2000**, *177*, 137-148.
5. Avdeef, A. Permeability—PAMPA. In *Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 319-498.
6. Brocke, S. A.; Degen, A.; MacKerell, A. D.; Dutagaci, B.; Feig, M. Prediction of Membrane Permeation of Drug Molecules by Combining an Implicit Membrane Model with Machine Learning. *J. Chem. Inf. Model.* **2018**, *59*, 1147-1162.
7. Avdeef, A. Permeability: Caco-2/MDCK. In *Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 499-574.
8. Leung, S. S.; Mijalkovic, J.; Borrelli, K.; Jacobson, M. P. Testing Physical Models of Passive Membrane Permeation. *J. Chem. Inf. Model.* **2012**, *52*, 1621-1636.
9. Xiang, T. X.; Anderson, B. D. The Relationship Between Permeant Size and Permeability in Lipid Bilayer Membranes. *J. Membr. Biol.* **1994**, *140*, 111-122.
10. Cao, Y.; Xiang, T. X.; Anderson, B. D. Development of Structure-Lipid Bilayer Permeability Relationships for Peptide-Like Small Organic Molecules. *Mol. Pharm.* **2008**, *5*, 371-388.
11. Wolosin, J. M.; Ginsburg, H. The Permeation of Organic Acids Through Lecithin Bilayers. Resemblance to Diffusion in Polymers. *Biochim. Biophys. Acta* **1975**, *389*, 20-33.
12. Xiang, T. X.; Xu, Y. H.; Anderson, B. D. The Barrier Domain for Solute Permeation Varies with Lipid Bilayer Phase Structure. *J. Membr. Biol.* **1998**, *165*, 77-90.
13. Walter, A.; Gutknecht, J. Permeability of Small Nonelectrolytes Through Lipid Bilayer-Membranes. *J. Membr. Biol.* **1986**, *90*, 207-217.
14. Orbach, E.; Finkelstein, A. The Nonelectrolyte Permeability of Planar Lipid Bilayer Membranes. *J. Gen. Physiol.* **1980**, *75*, 427-436.
15. Gutknecht, J. Aspirin, Acetaminophen and Proton Transport Through Phospholipid Bilayers and Mitochondrial Membranes. *Mol. Cell. Biochem.* **1992**, *114*, 3-8.
16. Akeson, M. A.; Munns, D. N. Lipid Bilayer Permeation by Neutral Aluminum Citrate and by Three Alpha-Hydroxy Carboxylic Acids. *Biochim. Biophys. Acta* **1989**, *984*, 200-206.

17. Bochain, A.; Estey, L.; Haronian, G.; Reale, M.; Rojas, C.; Cramer, J. Determination of Catecholamine Permeability Coefficients for Passive Diffusion Across Phospholipid Vesicle Membranes. *J. Membr. Biol.* **1981**, *60*, 73-76.

18. Evtodienko, V. Y.; Bondarenko, D. I.; Antonenko, Y. N. Permeation of Dicarboxylic Acids with Different Terminal Position of Two Carboxylic Groups Through Planar Bilayer Lipid Membranes. *Biochim. Biophys. Acta* **1999**, *1420*, 95-103.

19. Li, S.; Hu, P. C.; Malmstadt, N. Imaging Molecular Transport Across Lipid Bilayers. *Biophys. J.* **2011**, *101*, 700-708.

20. Pohl, P.; Rokitskaya, T. I.; Pohl, E. E.; Saparov, S. M. Permeation of Phloretin Across Bilayer Lipid Membranes Monitored by Dipole Potential and Microelectrode Measurements. *Biochim. Biophys. Acta* **1997**, *1323*, 163-172.

21. Antonenko, Y. N.; Pohl, P.; Denisov, G. A. Permeation of Ammonia Across Bilayer Lipid Membranes Studied by Ammonium Ion Selective Microelectrodes. *Biophys. J.* **1997**, *72*, 2187-2195.

22. Eyer, K.; Paech, F.; Schuler, F.; Kuhn, P.; Kissner, R.; Belli, S.; Dittrich, P. S.; Kramer, S. D. A Liposomal Fluorescence Assay to Study Permeation Kinetics of Drug-Like Weak Bases Across the Lipid Bilayer. *J. Control. Release* **2014**, *173*, 102-109.

23. Piqueras, A. I.; Somers, M.; Hammond, T. G.; Strange, K.; Harris, H. W., Jr.; Gawryl, M.; Zeidel, M. L. Permeability Properties of Rat Renal Lysosomes. *Am. J. Physiol.* **1994**, *266*, C121-C133.

24. Gutknecht, J.; Walter, A. Histamine, Theophylline and Tryptamine Transport Through Lipid Bilayer Membranes. *Biochim. Biophys. Acta* **1981**, 649, 149-154.

25. Brunner, J.; Graham, D. E.; Hauser, H.; Semenza, G. Ion And Sugar Permeabilities of Lecithin Bilayers: Comparison of Curved and Planar Bilayers. *J. Membr. Biol* **1980**, *57*, 133-141.

26. Ly, H. V.; Longo, M. L. The Influence of Short-Chain Alcohols on Interfacial Tension, Mechanical Properties, Area/Molecule, and Permeability of Fluid Lipid Bilayers. *Biophys. J.* **2004**, 87, 1013-1033.

27. Poznansky, M.; Tong, S.; White, P. C.; Milgram, J. M.; Solomon, A. K. Nonelectrolyte Diffusion Across Lipid Bilayer Systems. *J. Gen. Physiol.* **1976**, *67*, 45-66.

28. Sacerdote, M. G.; Szostak, J. W. Semipermeable Lipid Bilayers Exhibit Diastereoselectivity Favoring Ribose. *Proc. Natl. Acad. Sci. U. S. A.* **2005**, *102*, 6004-6008.

29. Cama, J.; Schaich, M.; Al Nahas, K.; Hernandez-Ainsa, S.; Pagliara, S.; Keyser, U. F. Direct Optofluidic Measurement of The Lipid Permeability of Fluoroquinolones. *Sci Rep* **2016**, *6*, 32824.

30. Pohl, E. E.; Voltchenko, A. M.; Rupprecht, A. Flip-Flop of Hydroxy Fatty Acids Across the Membrane as Monitored by Proton-Sensitive Microelectrodes. *Biochim. Biophys. Acta* **2008**, *1778*, 1292-1297.

31. Thomae, A. V.; Koch, T.; Panse, C.; Wunderli-Allenspach, H.; Kramer, S. D. Comparing the Lipid Membrane Affinity and Permeation of Drug-Like Acids: the Intriguing Effects of Cholesterol and Charged Lipids. *Pharm. Res.* **2007**, *24*, 1457-1472.

32. Xiang, T.; Anderson, B. D. Influence of a Transmembrane Protein on the Permeability of Small Molecules Across Lipid Membranes. *J. Membr. Biol.* **2000**, *173*, 187-201.

33. Bar-On, Z.; Degani, H., Permeability of Alkylamines Across Phosphatidylcholine Vesicles as Studied by 1H-NMR. *Biochim. Biophys. Acta* **1985**, *813*, 207-212.

34. Chakrabarti, A. C.; Deamer, D. W. Permeability of Lipid Bilayers to Amino Acids and Phosphate. *Biochim. Biophys. Acta* **1992**, *1111*, 171-177.

35. Missner, A.; Pohl, P. 110 Years of the Meyer-Overton Rule: Predicting Membrane Permeability of Gases and Other Small Compounds. *Chemphyschem.* **2009**, *10*, 1405-1414.

36. Avdeef, A. Permeability: Blood–Brain Barrier. In *Absorption and Drug Development*; John Wiley & Sons, Inc.: Hoboken, NJ, 2012; pp 575-680.